"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","biomaterial_provider_ch1","treatment_protocol_ch1","growth_protocol_ch1","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","data_processing","platform_id","contact_name","contact_email","contact_phone","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","fixative:ch1","gender:ch1","tissue type:ch1","IDFILE"
"GSM1934697","LGWU101986-1036378WU","GSM1934697","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101986","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934697/suppl/GSM1934697_20111102_20111102-9741-1_LGWU101986-1036378WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934697_20111102_20111102-9741-1_LGWU101986-1036378WU_02.RCC.gz"
"GSM1934698","LGWU102547-1036381WU","GSM1934698","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102547","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934698/suppl/GSM1934698_20111102_20111102-9741-1_LGWU102547-1036381WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934698_20111102_20111102-9741-1_LGWU102547-1036381WU_05.RCC.gz"
"GSM1934699","LGWU102569-1036382WU","GSM1934699","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102569","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934699/suppl/GSM1934699_20111102_20111102-9741-1_LGWU102569-1036382WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934699_20111102_20111102-9741-1_LGWU102569-1036382WU_06.RCC.gz"
"GSM1934700","LGWU102614-1036385WU","GSM1934700","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102614","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934700/suppl/GSM1934700_20111102_20111102-9741-1_LGWU102614-1036385WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934700_20111102_20111102-9741-1_LGWU102614-1036385WU_09.RCC.gz"
"GSM1934701","LGWU102680-1036384WU","GSM1934701","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102680","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934701/suppl/GSM1934701_20111102_20111102-9741-1_LGWU102680-1036384WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934701_20111102_20111102-9741-1_LGWU102680-1036384WU_08.RCC.gz"
"GSM1934702","LGWU102731-1036388WU","GSM1934702","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102731","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934702/suppl/GSM1934702_20111102_20111102-9741-1_LGWU102731-1036388WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934702_20111102_20111102-9741-1_LGWU102731-1036388WU_12.RCC.gz"
"GSM1934703","LGWU107295-1036383WU","GSM1934703","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107295","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934703/suppl/GSM1934703_20111102_20111102-9741-1_LGWU107295-1036383WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934703_20111102_20111102-9741-1_LGWU107295-1036383WU_07.RCC.gz"
"GSM1934704","LGWU201357-1036377WU","GSM1934704","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 201357","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934704/suppl/GSM1934704_20111102_20111102-9741-1_LGWU201357-1036377WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934704_20111102_20111102-9741-1_LGWU201357-1036377WU_01.RCC.gz"
"GSM1934705","LGWU702410-1036379WU","GSM1934705","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702410","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934705/suppl/GSM1934705_20111102_20111102-9741-1_LGWU702410-1036379WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934705_20111102_20111102-9741-1_LGWU702410-1036379WU_03.RCC.gz"
"GSM1934706","LGWU702420-1036380WU","GSM1934706","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702420","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934706/suppl/GSM1934706_20111102_20111102-9741-1_LGWU702420-1036380WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934706_20111102_20111102-9741-1_LGWU702420-1036380WU_04.RCC.gz"
"GSM1934707","LGWU702568-1036386WU","GSM1934707","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702568","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934707/suppl/GSM1934707_20111102_20111102-9741-1_LGWU702568-1036386WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934707_20111102_20111102-9741-1_LGWU702568-1036386WU_10.RCC.gz"
"GSM1934708","LGWU702589-1036387WU","GSM1934708","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702589","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934708/suppl/GSM1934708_20111102_20111102-9741-1_LGWU702589-1036387WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934708_20111102_20111102-9741-1_LGWU702589-1036387WU_11.RCC.gz"
"GSM1934709","LGWU102776-1036390WU","GSM1934709","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102776","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934709/suppl/GSM1934709_20111102_20111102-9741-2_LGWU102776-1036390WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934709_20111102_20111102-9741-2_LGWU102776-1036390WU_02.RCC.gz"
"GSM1934710","LGWU109257-1036400WU","GSM1934710","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109257","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934710/suppl/GSM1934710_20111102_20111102-9741-2_LGWU109257-1036400WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934710_20111102_20111102-9741-2_LGWU109257-1036400WU_12.RCC.gz"
"GSM1934711","LGWU109355-1036389WU","GSM1934711","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109355","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934711/suppl/GSM1934711_20111102_20111102-9741-2_LGWU109355-1036389WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934711_20111102_20111102-9741-2_LGWU109355-1036389WU_01.RCC.gz"
"GSM1934712","LGWU702272-1036391WU","GSM1934712","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702272","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934712/suppl/GSM1934712_20111102_20111102-9741-2_LGWU702272-1036391WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934712_20111102_20111102-9741-2_LGWU702272-1036391WU_03.RCC.gz"
"GSM1934713","LGWU702707-1036392WU","GSM1934713","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702707","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934713/suppl/GSM1934713_20111102_20111102-9741-2_LGWU702707-1036392WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934713_20111102_20111102-9741-2_LGWU702707-1036392WU_04.RCC.gz"
"GSM1934714","LGWU702741-1036395WU","GSM1934714","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702741","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934714/suppl/GSM1934714_20111102_20111102-9741-2_LGWU702741-1036395WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934714_20111102_20111102-9741-2_LGWU702741-1036395WU_07.RCC.gz"
"GSM1934715","LGWU703193-1036393WU","GSM1934715","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703193","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934715/suppl/GSM1934715_20111102_20111102-9741-2_LGWU703193-1036393WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934715_20111102_20111102-9741-2_LGWU703193-1036393WU_05.RCC.gz"
"GSM1934716","LGWU703194-1036394WU","GSM1934716","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703194","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934716/suppl/GSM1934716_20111102_20111102-9741-2_LGWU703194-1036394WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934716_20111102_20111102-9741-2_LGWU703194-1036394WU_06.RCC.gz"
"GSM1934717","LGWU703229-1036396WU","GSM1934717","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703229","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934717/suppl/GSM1934717_20111102_20111102-9741-2_LGWU703229-1036396WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934717_20111102_20111102-9741-2_LGWU703229-1036396WU_08.RCC.gz"
"GSM1934718","LGWU703282-1036397WU","GSM1934718","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703282","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934718/suppl/GSM1934718_20111102_20111102-9741-2_LGWU703282-1036397WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934718_20111102_20111102-9741-2_LGWU703282-1036397WU_09.RCC.gz"
"GSM1934719","LGWU703286-1036398WU","GSM1934719","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703286","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934719/suppl/GSM1934719_20111102_20111102-9741-2_LGWU703286-1036398WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934719_20111102_20111102-9741-2_LGWU703286-1036398WU_10.RCC.gz"
"GSM1934720","LGWU703330-1036399WU","GSM1934720","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703330","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934720/suppl/GSM1934720_20111102_20111102-9741-2_LGWU703330-1036399WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934720_20111102_20111102-9741-2_LGWU703330-1036399WU_11.RCC.gz"
"GSM1934721","LGWU102517-1036404WU","GSM1934721","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102517","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934721/suppl/GSM1934721_20111103_20111103-9741-1_LGWU102517-1036404WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934721_20111103_20111103-9741-1_LGWU102517-1036404WU_04.RCC.gz"
"GSM1934722","LGWU107382-1036415WU","GSM1934722","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107382","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934722/suppl/GSM1934722_20111103_20111103-9741-1_LGWU107382-1036415WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934722_20111103_20111103-9741-1_LGWU107382-1036415WU_12.RCC.gz"
"GSM1934723","LGWU109080-1036414WU","GSM1934723","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109080","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934723/suppl/GSM1934723_20111103_20111103-9741-1_LGWU109080-1036414WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934723_20111103_20111103-9741-1_LGWU109080-1036414WU_11.RCC.gz"
"GSM1934724","LGWU200852-1036410WU","GSM1934724","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200852","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934724/suppl/GSM1934724_20111103_20111103-9741-1_LGWU200852-1036410WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934724_20111103_20111103-9741-1_LGWU200852-1036410WU_07.RCC.gz"
"GSM1934725","LGWU209165-1036408WU","GSM1934725","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 209165","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934725/suppl/GSM1934725_20111103_20111103-9741-1_LGWU209165-1036408WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934725_20111103_20111103-9741-1_LGWU209165-1036408WU_06.RCC.gz"
"GSM1934726","LGWU702166-1036402WU","GSM1934726","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702166","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934726/suppl/GSM1934726_20111103_20111103-9741-1_LGWU702166-1036402WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934726_20111103_20111103-9741-1_LGWU702166-1036402WU_02.RCC.gz"
"GSM1934727","LGWU702424-1036403WU","GSM1934727","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702424","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934727/suppl/GSM1934727_20111103_20111103-9741-1_LGWU702424-1036403WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934727_20111103_20111103-9741-1_LGWU702424-1036403WU_03.RCC.gz"
"GSM1934728","LGWU702464-1036407WU","GSM1934728","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702464","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934728/suppl/GSM1934728_20111103_20111103-9741-1_LGWU702464-1036407WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934728_20111103_20111103-9741-1_LGWU702464-1036407WU_05.RCC.gz"
"GSM1934729","LGWU702611-1036412WU","GSM1934729","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702611","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934729/suppl/GSM1934729_20111103_20111103-9741-1_LGWU702611-1036412WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934729_20111103_20111103-9741-1_LGWU702611-1036412WU_09.RCC.gz"
"GSM1934730","LGWU702630-1036413WU","GSM1934730","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702630","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934730/suppl/GSM1934730_20111103_20111103-9741-1_LGWU702630-1036413WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934730_20111103_20111103-9741-1_LGWU702630-1036413WU_10.RCC.gz"
"GSM1934731","LGWU702839-1036401WU","GSM1934731","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702839","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934731/suppl/GSM1934731_20111103_20111103-9741-1_LGWU702839-1036401WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934731_20111103_20111103-9741-1_LGWU702839-1036401WU_01.RCC.gz"
"GSM1934732","LGWU109057-1036432WU","GSM1934732","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109057","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934732/suppl/GSM1934732_20111103_20111103-9741-2_LGWU109057-1036432WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934732_20111103_20111103-9741-2_LGWU109057-1036432WU_10.RCC.gz"
"GSM1934733","LGWU205467-1036425WU","GSM1934733","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 205467","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934733/suppl/GSM1934733_20111103_20111103-9741-2_LGWU205467-1036425WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934733_20111103_20111103-9741-2_LGWU205467-1036425WU_07.RCC.gz"
"GSM1934734","LGWU209166-1036430WU","GSM1934734","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 209166","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934734/suppl/GSM1934734_20111103_20111103-9741-2_LGWU209166-1036430WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934734_20111103_20111103-9741-2_LGWU209166-1036430WU_09.RCC.gz"
"GSM1934735","LGWU702315-1036416WU","GSM1934735","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702315","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934735/suppl/GSM1934735_20111103_20111103-9741-2_LGWU702315-1036416WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934735_20111103_20111103-9741-2_LGWU702315-1036416WU_01.RCC.gz"
"GSM1934736","LGWU702440-1036426WU","GSM1934736","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702440","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934736/suppl/GSM1934736_20111103_20111103-9741-2_LGWU702440-1036426WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934736_20111103_20111103-9741-2_LGWU702440-1036426WU_08.RCC.gz"
"GSM1934737","LGWU702772-1036421WU","GSM1934737","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702772","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934737/suppl/GSM1934737_20111103_20111103-9741-2_LGWU702772-1036421WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934737_20111103_20111103-9741-2_LGWU702772-1036421WU_05.RCC.gz"
"GSM1934738","LGWU703210-1036417WU","GSM1934738","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703210","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934738/suppl/GSM1934738_20111103_20111103-9741-2_LGWU703210-1036417WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934738_20111103_20111103-9741-2_LGWU703210-1036417WU_02.RCC.gz"
"GSM1934739","LGWU703228-1036433WU","GSM1934739","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703228","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934739/suppl/GSM1934739_20111103_20111103-9741-2_LGWU703228-1036433WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934739_20111103_20111103-9741-2_LGWU703228-1036433WU_11.RCC.gz"
"GSM1934740","LGWU703250-1036419WU","GSM1934740","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703250","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934740/suppl/GSM1934740_20111103_20111103-9741-2_LGWU703250-1036419WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934740_20111103_20111103-9741-2_LGWU703250-1036419WU_03.RCC.gz"
"GSM1934741","LGWU703254-1036434WU","GSM1934741","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703254","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934741/suppl/GSM1934741_20111103_20111103-9741-2_LGWU703254-1036434WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934741_20111103_20111103-9741-2_LGWU703254-1036434WU_12.RCC.gz"
"GSM1934742","LGWU703267-1036420WU","GSM1934742","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703267","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934742/suppl/GSM1934742_20111103_20111103-9741-2_LGWU703267-1036420WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934742_20111103_20111103-9741-2_LGWU703267-1036420WU_04.RCC.gz"
"GSM1934743","LGWU703407-1036423WU","GSM1934743","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703407","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934743/suppl/GSM1934743_20111103_20111103-9741-2_LGWU703407-1036423WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934743_20111103_20111103-9741-2_LGWU703407-1036423WU_06.RCC.gz"
"GSM1934744","LGWU102677-1036444WU","GSM1934744","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102677","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934744/suppl/GSM1934744_20111104_20111104-9741-1_LGWU102677-1036444WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934744_20111104_20111104-9741-1_LGWU102677-1036444WU_09.RCC.gz"
"GSM1934745","LGWU102773-1036447WU","GSM1934745","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102773","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934745/suppl/GSM1934745_20111104_20111104-9741-1_LGWU102773-1036447WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934745_20111104_20111104-9741-1_LGWU102773-1036447WU_12.RCC.gz"
"GSM1934746","LGWU702222-1036443WU","GSM1934746","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702222","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934746/suppl/GSM1934746_20111104_20111104-9741-1_LGWU702222-1036443WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934746_20111104_20111104-9741-1_LGWU702222-1036443WU_08.RCC.gz"
"GSM1934747","LGWU702445-1036440WU","GSM1934747","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702445","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934747/suppl/GSM1934747_20111104_20111104-9741-1_LGWU702445-1036440WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934747_20111104_20111104-9741-1_LGWU702445-1036440WU_05.RCC.gz"
"GSM1934748","LGWU702527-1036442WU","GSM1934748","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702527","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934748/suppl/GSM1934748_20111104_20111104-9741-1_LGWU702527-1036442WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934748_20111104_20111104-9741-1_LGWU702527-1036442WU_07.RCC.gz"
"GSM1934749","LGWU702574-1036445WU","GSM1934749","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702574","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934749/suppl/GSM1934749_20111104_20111104-9741-1_LGWU702574-1036445WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934749_20111104_20111104-9741-1_LGWU702574-1036445WU_10.RCC.gz"
"GSM1934750","LGWU702588-1036446WU","GSM1934750","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702588","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934750/suppl/GSM1934750_20111104_20111104-9741-1_LGWU702588-1036446WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934750_20111104_20111104-9741-1_LGWU702588-1036446WU_11.RCC.gz"
"GSM1934751","LGWU702780-1036436WU","GSM1934751","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702780","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934751/suppl/GSM1934751_20111104_20111104-9741-1_LGWU702780-1036436WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934751_20111104_20111104-9741-1_LGWU702780-1036436WU_02.RCC.gz"
"GSM1934752","LGWU703355-1036438WU","GSM1934752","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703355","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934752/suppl/GSM1934752_20111104_20111104-9741-1_LGWU703355-1036438WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934752_20111104_20111104-9741-1_LGWU703355-1036438WU_03.RCC.gz"
"GSM1934753","LGWU703357-1036439WU","GSM1934753","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703357","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934753/suppl/GSM1934753_20111104_20111104-9741-1_LGWU703357-1036439WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934753_20111104_20111104-9741-1_LGWU703357-1036439WU_04.RCC.gz"
"GSM1934754","LGWU107364-1036451WU","GSM1934754","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107364","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934754/suppl/GSM1934754_20111104_20111104-9741-2_LGWU107364-1036451WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934754_20111104_20111104-9741-2_LGWU107364-1036451WU_04.RCC.gz"
"GSM1934755","LGWU200443-1036460WU","GSM1934755","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200443","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934755/suppl/GSM1934755_20111104_20111104-9741-2_LGWU200443-1036460WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934755_20111104_20111104-9741-2_LGWU200443-1036460WU_12.RCC.gz"
"GSM1934756","LGWU702276-1036450WU","GSM1934756","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702276","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934756/suppl/GSM1934756_20111104_20111104-9741-2_LGWU702276-1036450WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934756_20111104_20111104-9741-2_LGWU702276-1036450WU_03.RCC.gz"
"GSM1934757","LGWU702301-1036453WU","GSM1934757","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702301","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934757/suppl/GSM1934757_20111104_20111104-9741-2_LGWU702301-1036453WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934757_20111104_20111104-9741-2_LGWU702301-1036453WU_06.RCC.gz"
"GSM1934758","LGWU702313-1036457WU","GSM1934758","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702313","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934758/suppl/GSM1934758_20111104_20111104-9741-2_LGWU702313-1036457WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934758_20111104_20111104-9741-2_LGWU702313-1036457WU_09.RCC.gz"
"GSM1934759","LGWU702667-1036449WU","GSM1934759","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702667","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934759/suppl/GSM1934759_20111104_20111104-9741-2_LGWU702667-1036449WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934759_20111104_20111104-9741-2_LGWU702667-1036449WU_02.RCC.gz"
"GSM1934760","LGWU702709-1036452WU","GSM1934760","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702709","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934760/suppl/GSM1934760_20111104_20111104-9741-2_LGWU702709-1036452WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934760_20111104_20111104-9741-2_LGWU702709-1036452WU_05.RCC.gz"
"GSM1934761","LGWU702721-1036454WU","GSM1934761","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702721","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934761/suppl/GSM1934761_20111104_20111104-9741-2_LGWU702721-1036454WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934761_20111104_20111104-9741-2_LGWU702721-1036454WU_07.RCC.gz"
"GSM1934762","LGWU702731-1036456WU","GSM1934762","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702731","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934762/suppl/GSM1934762_20111104_20111104-9741-2_LGWU702731-1036456WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934762_20111104_20111104-9741-2_LGWU702731-1036456WU_08.RCC.gz"
"GSM1934763","LGWU702766-1036459WU","GSM1934763","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702766","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934763/suppl/GSM1934763_20111104_20111104-9741-2_LGWU702766-1036459WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934763_20111104_20111104-9741-2_LGWU702766-1036459WU_11.RCC.gz"
"GSM1934764","LGWU703118-1036448WU","GSM1934764","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703118","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934764/suppl/GSM1934764_20111104_20111104-9741-2_LGWU703118-1036448WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934764_20111104_20111104-9741-2_LGWU703118-1036448WU_01.RCC.gz"
"GSM1934765","LGWU703240-1036458WU","GSM1934765","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703240","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934765/suppl/GSM1934765_20111104_20111104-9741-2_LGWU703240-1036458WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934765_20111104_20111104-9741-2_LGWU703240-1036458WU_10.RCC.gz"
"GSM1934766","LGWU102600-1036473WU","GSM1934766","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102600","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934766/suppl/GSM1934766_20111104_20111104-9741-3_LGWU102600-1036473WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934766_20111104_20111104-9741-3_LGWU102600-1036473WU_12.RCC.gz"
"GSM1934767","LGWU109284-1036464WU","GSM1934767","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109284","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934767/suppl/GSM1934767_20111104_20111104-9741-3_LGWU109284-1036464WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934767_20111104_20111104-9741-3_LGWU109284-1036464WU_03.RCC.gz"
"GSM1934768","LGWU112099-1036471WU","GSM1934768","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 112099","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934768/suppl/GSM1934768_20111104_20111104-9741-3_LGWU112099-1036471WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934768_20111104_20111104-9741-3_LGWU112099-1036471WU_10.RCC.gz"
"GSM1934769","LGWU209164-1036468WU","GSM1934769","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 209164","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934769/suppl/GSM1934769_20111104_20111104-9741-3_LGWU209164-1036468WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934769_20111104_20111104-9741-3_LGWU209164-1036468WU_07.RCC.gz"
"GSM1934770","LGWU702391-1036469WU","GSM1934770","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702391","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934770/suppl/GSM1934770_20111104_20111104-9741-3_LGWU702391-1036469WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934770_20111104_20111104-9741-3_LGWU702391-1036469WU_08.RCC.gz"
"GSM1934771","LGWU702405-1036470WU","GSM1934771","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702405","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934771/suppl/GSM1934771_20111104_20111104-9741-3_LGWU702405-1036470WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934771_20111104_20111104-9741-3_LGWU702405-1036470WU_09.RCC.gz"
"GSM1934772","LGWU702457-1036472WU","GSM1934772","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702457","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934772/suppl/GSM1934772_20111104_20111104-9741-3_LGWU702457-1036472WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934772_20111104_20111104-9741-3_LGWU702457-1036472WU_11.RCC.gz"
"GSM1934773","LGWU702825-1036465WU","GSM1934773","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702825","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934773/suppl/GSM1934773_20111104_20111104-9741-3_LGWU702825-1036465WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934773_20111104_20111104-9741-3_LGWU702825-1036465WU_04.RCC.gz"
"GSM1934774","LGWU703327-1036461WU","GSM1934774","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703327","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934774/suppl/GSM1934774_20111104_20111104-9741-3_LGWU703327-1036461WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934774_20111104_20111104-9741-3_LGWU703327-1036461WU_01.RCC.gz"
"GSM1934775","LGWU703333-1036462WU","GSM1934775","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703333","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934775/suppl/GSM1934775_20111104_20111104-9741-3_LGWU703333-1036462WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934775_20111104_20111104-9741-3_LGWU703333-1036462WU_02.RCC.gz"
"GSM1934776","LGWU703387-1036466WU","GSM1934776","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703387","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934776/suppl/GSM1934776_20111104_20111104-9741-3_LGWU703387-1036466WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934776_20111104_20111104-9741-3_LGWU703387-1036466WU_05.RCC.gz"
"GSM1934777","LGWU703433-1036467WU","GSM1934777","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703433","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934777/suppl/GSM1934777_20111104_20111104-9741-3_LGWU703433-1036467WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934777_20111104_20111104-9741-3_LGWU703433-1036467WU_06.RCC.gz"
"GSM1934778","LGWU102712-1036476WU","GSM1934778","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102712","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934778/suppl/GSM1934778_20111104_20111104-9741-4_LGWU102712-1036476WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934778_20111104_20111104-9741-4_LGWU102712-1036476WU_02.RCC.gz"
"GSM1934779","LGWU107371-1036480WU","GSM1934779","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107371","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934779/suppl/GSM1934779_20111104_20111104-9741-4_LGWU107371-1036480WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934779_20111104_20111104-9741-4_LGWU107371-1036480WU_06.RCC.gz"
"GSM1934780","LGWU203348-1036478WU","GSM1934780","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203348","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934780/suppl/GSM1934780_20111104_20111104-9741-4_LGWU203348-1036478WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934780_20111104_20111104-9741-4_LGWU203348-1036478WU_04.RCC.gz"
"GSM1934781","LGWU702284-1036479WU","GSM1934781","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702284","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934781/suppl/GSM1934781_20111104_20111104-9741-4_LGWU702284-1036479WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934781_20111104_20111104-9741-4_LGWU702284-1036479WU_05.RCC.gz"
"GSM1934782","LGWU702311-1036481WU","GSM1934782","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702311","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934782/suppl/GSM1934782_20111104_20111104-9741-4_LGWU702311-1036481WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934782_20111104_20111104-9741-4_LGWU702311-1036481WU_07.RCC.gz"
"GSM1934783","LGWU702338-1036485WU","GSM1934783","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702338","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934783/suppl/GSM1934783_20111104_20111104-9741-4_LGWU702338-1036485WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934783_20111104_20111104-9741-4_LGWU702338-1036485WU_10.RCC.gz"
"GSM1934784","LGWU702526-1036477WU","GSM1934784","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702526","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934784/suppl/GSM1934784_20111104_20111104-9741-4_LGWU702526-1036477WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934784_20111104_20111104-9741-4_LGWU702526-1036477WU_03.RCC.gz"
"GSM1934785","LGWU702575-1036474WU","GSM1934785","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702575","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934785/suppl/GSM1934785_20111104_20111104-9741-4_LGWU702575-1036474WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934785_20111104_20111104-9741-4_LGWU702575-1036474WU_01.RCC.gz"
"GSM1934786","LGWU703188-1036482WU","GSM1934786","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703188","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934786/suppl/GSM1934786_20111104_20111104-9741-4_LGWU703188-1036482WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934786_20111104_20111104-9741-4_LGWU703188-1036482WU_08.RCC.gz"
"GSM1934787","LGWU703237-1036484WU","GSM1934787","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703237","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934787/suppl/GSM1934787_20111104_20111104-9741-4_LGWU703237-1036484WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934787_20111104_20111104-9741-4_LGWU703237-1036484WU_09.RCC.gz"
"GSM1934788","LGWU703329-1036487WU","GSM1934788","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703329","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934788/suppl/GSM1934788_20111104_20111104-9741-4_LGWU703329-1036487WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934788_20111104_20111104-9741-4_LGWU703329-1036487WU_11.RCC.gz"
"GSM1934789","LGWU703392-1036489WU","GSM1934789","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703392","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934789/suppl/GSM1934789_20111104_20111104-9741-4_LGWU703392-1036489WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934789_20111104_20111104-9741-4_LGWU703392-1036489WU_12.RCC.gz"
"GSM1934790","LGWU072195-1036496WU","GSM1934790","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 072195","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934790/suppl/GSM1934790_20111108_20111108-9741-1_LGWU072195-1036496WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934790_20111108_20111108-9741-1_LGWU072195-1036496WU_03.RCC.gz"
"GSM1934791","LGWU073196-1036499WU","GSM1934791","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 073196","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934791/suppl/GSM1934791_20111108_20111108-9741-1_LGWU073196-1036499WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934791_20111108_20111108-9741-1_LGWU073196-1036499WU_04.RCC.gz"
"GSM1934792","LGWU073531-1036501WU","GSM1934792","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 073531","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934792/suppl/GSM1934792_20111108_20111108-9741-1_LGWU073531-1036501WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934792_20111108_20111108-9741-1_LGWU073531-1036501WU_05.RCC.gz"
"GSM1934793","LGWU102596-1036508WU","GSM1934793","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102596","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934793/suppl/GSM1934793_20111108_20111108-9741-1_LGWU102596-1036508WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934793_20111108_20111108-9741-1_LGWU102596-1036508WU_09.RCC.gz"
"GSM1934794","LGWU102690-1036512WU","GSM1934794","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102690","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934794/suppl/GSM1934794_20111108_20111108-9741-1_LGWU102690-1036512WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934794_20111108_20111108-9741-1_LGWU102690-1036512WU_12.RCC.gz"
"GSM1934795","LGWU107286-1036505WU","GSM1934795","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107286","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934795/suppl/GSM1934795_20111108_20111108-9741-1_LGWU107286-1036505WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934795_20111108_20111108-9741-1_LGWU107286-1036505WU_07.RCC.gz"
"GSM1934796","LGWU107316-1036494WU","GSM1934796","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107316","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934796/suppl/GSM1934796_20111108_20111108-9741-1_LGWU107316-1036494WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934796_20111108_20111108-9741-1_LGWU107316-1036494WU_02.RCC.gz"
"GSM1934797","LGWU107337-1036506WU","GSM1934797","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107337","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934797/suppl/GSM1934797_20111108_20111108-9741-1_LGWU107337-1036506WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934797_20111108_20111108-9741-1_LGWU107337-1036506WU_08.RCC.gz"
"GSM1934798","LGWU108958-1036510WU","GSM1934798","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108958","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934798/suppl/GSM1934798_20111108_20111108-9741-1_LGWU108958-1036510WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934798_20111108_20111108-9741-1_LGWU108958-1036510WU_10.RCC.gz"
"GSM1934799","LGWU109033-1036511WU","GSM1934799","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109033","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934799/suppl/GSM1934799_20111108_20111108-9741-1_LGWU109033-1036511WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934799_20111108_20111108-9741-1_LGWU109033-1036511WU_11.RCC.gz"
"GSM1934800","LGWU109151-1036504WU","GSM1934800","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109151","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934800/suppl/GSM1934800_20111108_20111108-9741-1_LGWU109151-1036504WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934800_20111108_20111108-9741-1_LGWU109151-1036504WU_06.RCC.gz"
"GSM1934801","LGWU202109-1036491WU","GSM1934801","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 202109","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934801/suppl/GSM1934801_20111108_20111108-9741-1_LGWU202109-1036491WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934801_20111108_20111108-9741-1_LGWU202109-1036491WU_01.RCC.gz"
"GSM1934802","LGWU072137-1036528WU","GSM1934802","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 072137","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934802/suppl/GSM1934802_20111108_20111108-9741-2_LGWU072137-1036528WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934802_20111108_20111108-9741-2_LGWU072137-1036528WU_09.RCC.gz"
"GSM1934803","LGWU072934-1036515WU","GSM1934803","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 072934","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934803/suppl/GSM1934803_20111108_20111108-9741-2_LGWU072934-1036515WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934803_20111108_20111108-9741-2_LGWU072934-1036515WU_02.RCC.gz"
"GSM1934804","LGWU073150-1036518WU","GSM1934804","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 073150","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934804/suppl/GSM1934804_20111108_20111108-9741-2_LGWU073150-1036518WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934804_20111108_20111108-9741-2_LGWU073150-1036518WU_03.RCC.gz"
"GSM1934805","LGWU073456-1036519WU","GSM1934805","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 073456","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934805/suppl/GSM1934805_20111108_20111108-9741-2_LGWU073456-1036519WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934805_20111108_20111108-9741-2_LGWU073456-1036519WU_04.RCC.gz"
"GSM1934806","LGWU102474-1036533WU","GSM1934806","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102474","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934806/suppl/GSM1934806_20111108_20111108-9741-2_LGWU102474-1036533WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934806_20111108_20111108-9741-2_LGWU102474-1036533WU_12.RCC.gz"
"GSM1934807","LGWU102736-1036513WU","GSM1934807","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102736","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934807/suppl/GSM1934807_20111108_20111108-9741-2_LGWU102736-1036513WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934807_20111108_20111108-9741-2_LGWU102736-1036513WU_01.RCC.gz"
"GSM1934808","LGWU102762-1036524WU","GSM1934808","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102762","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934808/suppl/GSM1934808_20111108_20111108-9741-2_LGWU102762-1036524WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934808_20111108_20111108-9741-2_LGWU102762-1036524WU_07.RCC.gz"
"GSM1934809","LGWU103574-1036521WU","GSM1934809","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 103574","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934809/suppl/GSM1934809_20111108_20111108-9741-2_LGWU103574-1036521WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934809_20111108_20111108-9741-2_LGWU103574-1036521WU_06.RCC.gz"
"GSM1934810","LGWU107284-1036531WU","GSM1934810","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107284","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934810/suppl/GSM1934810_20111108_20111108-9741-2_LGWU107284-1036531WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934810_20111108_20111108-9741-2_LGWU107284-1036531WU_11.RCC.gz"
"GSM1934811","LGWU107317-1036520WU","GSM1934811","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107317","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934811/suppl/GSM1934811_20111108_20111108-9741-2_LGWU107317-1036520WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934811_20111108_20111108-9741-2_LGWU107317-1036520WU_05.RCC.gz"
"GSM1934812","LGWU109248-1036527WU","GSM1934812","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109248","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934812/suppl/GSM1934812_20111108_20111108-9741-2_LGWU109248-1036527WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934812_20111108_20111108-9741-2_LGWU109248-1036527WU_08.RCC.gz"
"GSM1934813","LGWU102491-1036534WU","GSM1934813","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102491","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934813/suppl/GSM1934813_20111108_20111108-9741-3_LGWU102491-1036534WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934813_20111108_20111108-9741-3_LGWU102491-1036534WU_01.RCC.gz"
"GSM1934814","LGWU102511-1036539WU","GSM1934814","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102511","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934814/suppl/GSM1934814_20111108_20111108-9741-3_LGWU102511-1036539WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934814_20111108_20111108-9741-3_LGWU102511-1036539WU_05.RCC.gz"
"GSM1934815","LGWU102513-1036537WU","GSM1934815","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102513","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934815/suppl/GSM1934815_20111108_20111108-9741-3_LGWU102513-1036537WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934815_20111108_20111108-9741-3_LGWU102513-1036537WU_04.RCC.gz"
"GSM1934816","LGWU107270-1036542WU","GSM1934816","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107270","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934816/suppl/GSM1934816_20111108_20111108-9741-3_LGWU107270-1036542WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934816_20111108_20111108-9741-3_LGWU107270-1036542WU_08.RCC.gz"
"GSM1934817","LGWU107272-1036540WU","GSM1934817","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107272","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934817/suppl/GSM1934817_20111108_20111108-9741-3_LGWU107272-1036540WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934817_20111108_20111108-9741-3_LGWU107272-1036540WU_06.RCC.gz"
"GSM1934818","LGWU109346-1036535WU","GSM1934818","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109346","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934818/suppl/GSM1934818_20111108_20111108-9741-3_LGWU109346-1036535WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934818_20111108_20111108-9741-3_LGWU109346-1036535WU_02.RCC.gz"
"GSM1934819","LGWU702175-1036541WU","GSM1934819","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702175","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934819/suppl/GSM1934819_20111108_20111108-9741-3_LGWU702175-1036541WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934819_20111108_20111108-9741-3_LGWU702175-1036541WU_07.RCC.gz"
"GSM1934820","LGWU702193-1036544WU","GSM1934820","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702193","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934820/suppl/GSM1934820_20111108_20111108-9741-3_LGWU702193-1036544WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934820_20111108_20111108-9741-3_LGWU702193-1036544WU_10.RCC.gz"
"GSM1934821","LGWU702382-1036536WU","GSM1934821","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702382","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934821/suppl/GSM1934821_20111108_20111108-9741-3_LGWU702382-1036536WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934821_20111108_20111108-9741-3_LGWU702382-1036536WU_03.RCC.gz"
"GSM1934822","LGWU702463-1036543WU","GSM1934822","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702463","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934822/suppl/GSM1934822_20111108_20111108-9741-3_LGWU702463-1036543WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934822_20111108_20111108-9741-3_LGWU702463-1036543WU_09.RCC.gz"
"GSM1934823","LGWU702479-1036545WU","GSM1934823","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702479","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934823/suppl/GSM1934823_20111108_20111108-9741-3_LGWU702479-1036545WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934823_20111108_20111108-9741-3_LGWU702479-1036545WU_11.RCC.gz"
"GSM1934824","LGWU702481-1036546WU","GSM1934824","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702481","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934824/suppl/GSM1934824_20111108_20111108-9741-3_LGWU702481-1036546WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934824_20111108_20111108-9741-3_LGWU702481-1036546WU_12.RCC.gz"
"GSM1934825","LGWU102605-1036552WU","GSM1934825","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102605","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934825/suppl/GSM1934825_20111108_20111108-9741-4_LGWU102605-1036552WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934825_20111108_20111108-9741-4_LGWU102605-1036552WU_05.RCC.gz"
"GSM1934826","LGWU102633-1036553WU","GSM1934826","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102633","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934826/suppl/GSM1934826_20111108_20111108-9741-4_LGWU102633-1036553WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934826_20111108_20111108-9741-4_LGWU102633-1036553WU_06.RCC.gz"
"GSM1934827","LGWU702214-1036550WU","GSM1934827","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702214","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934827/suppl/GSM1934827_20111108_20111108-9741-4_LGWU702214-1036550WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934827_20111108_20111108-9741-4_LGWU702214-1036550WU_03.RCC.gz"
"GSM1934828","LGWU702229-1036555WU","GSM1934828","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702229","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934828/suppl/GSM1934828_20111108_20111108-9741-4_LGWU702229-1036555WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934828_20111108_20111108-9741-4_LGWU702229-1036555WU_08.RCC.gz"
"GSM1934829","LGWU702230-1036556WU","GSM1934829","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702230","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934829/suppl/GSM1934829_20111108_20111108-9741-4_LGWU702230-1036556WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934829_20111108_20111108-9741-4_LGWU702230-1036556WU_09.RCC.gz"
"GSM1934830","LGWU702231-1036557WU","GSM1934830","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702231","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934830/suppl/GSM1934830_20111108_20111108-9741-4_LGWU702231-1036557WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934830_20111108_20111108-9741-4_LGWU702231-1036557WU_10.RCC.gz"
"GSM1934831","LGWU702482-1036547WU","GSM1934831","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702482","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934831/suppl/GSM1934831_20111108_20111108-9741-4_LGWU702482-1036547WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934831_20111108_20111108-9741-4_LGWU702482-1036547WU_01.RCC.gz"
"GSM1934832","LGWU702516-1036549WU","GSM1934832","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702516","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934832/suppl/GSM1934832_20111108_20111108-9741-4_LGWU702516-1036549WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934832_20111108_20111108-9741-4_LGWU702516-1036549WU_02.RCC.gz"
"GSM1934833","LGWU702525-1036551WU","GSM1934833","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702525","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934833/suppl/GSM1934833_20111108_20111108-9741-4_LGWU702525-1036551WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934833_20111108_20111108-9741-4_LGWU702525-1036551WU_04.RCC.gz"
"GSM1934834","LGWU702549-1036554WU","GSM1934834","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702549","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934834/suppl/GSM1934834_20111108_20111108-9741-4_LGWU702549-1036554WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934834_20111108_20111108-9741-4_LGWU702549-1036554WU_07.RCC.gz"
"GSM1934835","LGWU702571-1036558WU","GSM1934835","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702571","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934835/suppl/GSM1934835_20111108_20111108-9741-4_LGWU702571-1036558WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934835_20111108_20111108-9741-4_LGWU702571-1036558WU_11.RCC.gz"
"GSM1934836","LGWU702581-1036559WU","GSM1934836","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702581","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934836/suppl/GSM1934836_20111108_20111108-9741-4_LGWU702581-1036559WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934836_20111108_20111108-9741-4_LGWU702581-1036559WU_12.RCC.gz"
"GSM1934837","LGWU101103-1036563WU","GSM1934837","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101103","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934837/suppl/GSM1934837_20111110_20111109-9741-1_LGWU101103-1036563WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934837_20111110_20111109-9741-1_LGWU101103-1036563WU_04.RCC.gz"
"GSM1934838","LGWU102689-1036560WU","GSM1934838","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102689","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934838/suppl/GSM1934838_20111110_20111109-9741-1_LGWU102689-1036560WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934838_20111110_20111109-9741-1_LGWU102689-1036560WU_01.RCC.gz"
"GSM1934839","LGWU102693-1036561WU","GSM1934839","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102693","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934839/suppl/GSM1934839_20111110_20111109-9741-1_LGWU102693-1036561WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934839_20111110_20111109-9741-1_LGWU102693-1036561WU_02.RCC.gz"
"GSM1934840","LGWU107331-1036567WU","GSM1934840","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107331","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934840/suppl/GSM1934840_20111110_20111109-9741-1_LGWU107331-1036567WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934840_20111110_20111109-9741-1_LGWU107331-1036567WU_08.RCC.gz"
"GSM1934841","LGWU203343-1036571WU","GSM1934841","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203343","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934841/suppl/GSM1934841_20111110_20111109-9741-1_LGWU203343-1036571WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934841_20111110_20111109-9741-1_LGWU203343-1036571WU_12.RCC.gz"
"GSM1934842","LGWU702621-1036562WU","GSM1934842","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702621","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934842/suppl/GSM1934842_20111110_20111109-9741-1_LGWU702621-1036562WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934842_20111110_20111109-9741-1_LGWU702621-1036562WU_03.RCC.gz"
"GSM1934843","LGWU702656-1036565WU","GSM1934843","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702656","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934843/suppl/GSM1934843_20111110_20111109-9741-1_LGWU702656-1036565WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934843_20111110_20111109-9741-1_LGWU702656-1036565WU_06.RCC.gz"
"GSM1934844","LGWU702658-1036568WU","GSM1934844","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702658","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934844/suppl/GSM1934844_20111110_20111109-9741-1_LGWU702658-1036568WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934844_20111110_20111109-9741-1_LGWU702658-1036568WU_09.RCC.gz"
"GSM1934845","LGWU702663-1036569WU","GSM1934845","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702663","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934845/suppl/GSM1934845_20111110_20111109-9741-1_LGWU702663-1036569WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934845_20111110_20111109-9741-1_LGWU702663-1036569WU_10.RCC.gz"
"GSM1934846","LGWU702676-1036570WU","GSM1934846","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702676","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934846/suppl/GSM1934846_20111110_20111109-9741-1_LGWU702676-1036570WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934846_20111110_20111109-9741-1_LGWU702676-1036570WU_11.RCC.gz"
"GSM1934847","LGWU703124-1036564WU","GSM1934847","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703124","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934847/suppl/GSM1934847_20111110_20111109-9741-1_LGWU703124-1036564WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934847_20111110_20111109-9741-1_LGWU703124-1036564WU_05.RCC.gz"
"GSM1934848","LGWU703126-1036566WU","GSM1934848","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703126","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934848/suppl/GSM1934848_20111110_20111109-9741-1_LGWU703126-1036566WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934848_20111110_20111109-9741-1_LGWU703126-1036566WU_07.RCC.gz"
"GSM1934849","LGWU102768-1036572WU","GSM1934849","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102768","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934849/suppl/GSM1934849_20111110_20111109-9741-2_LGWU102768-1036572WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934849_20111110_20111109-9741-2_LGWU102768-1036572WU_01.RCC.gz"
"GSM1934850","LGWU107362-1036573WU","GSM1934850","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107362","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934850/suppl/GSM1934850_20111110_20111109-9741-2_LGWU107362-1036573WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934850_20111110_20111109-9741-2_LGWU107362-1036573WU_02.RCC.gz"
"GSM1934851","LGWU108968-1036576WU","GSM1934851","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108968","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934851/suppl/GSM1934851_20111110_20111109-9741-2_LGWU108968-1036576WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934851_20111110_20111109-9741-2_LGWU108968-1036576WU_05.RCC.gz"
"GSM1934852","LGWU109181-1036581WU","GSM1934852","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109181","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934852/suppl/GSM1934852_20111110_20111109-9741-2_LGWU109181-1036581WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934852_20111110_20111109-9741-2_LGWU109181-1036581WU_10.RCC.gz"
"GSM1934853","LGWU109254-1036578WU","GSM1934853","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109254","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934853/suppl/GSM1934853_20111110_20111109-9741-2_LGWU109254-1036578WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934853_20111110_20111109-9741-2_LGWU109254-1036578WU_07.RCC.gz"
"GSM1934854","LGWU702296-1036574WU","GSM1934854","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702296","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934854/suppl/GSM1934854_20111110_20111109-9741-2_LGWU702296-1036574WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934854_20111110_20111109-9741-2_LGWU702296-1036574WU_03.RCC.gz"
"GSM1934855","LGWU702300-1036575WU","GSM1934855","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702300","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934855/suppl/GSM1934855_20111110_20111109-9741-2_LGWU702300-1036575WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934855_20111110_20111109-9741-2_LGWU702300-1036575WU_04.RCC.gz"
"GSM1934856","LGWU702729-1036577WU","GSM1934856","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702729","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934856/suppl/GSM1934856_20111110_20111109-9741-2_LGWU702729-1036577WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934856_20111110_20111109-9741-2_LGWU702729-1036577WU_06.RCC.gz"
"GSM1934857","LGWU703187-1036579WU","GSM1934857","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703187","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934857/suppl/GSM1934857_20111110_20111109-9741-2_LGWU703187-1036579WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934857_20111110_20111109-9741-2_LGWU703187-1036579WU_08.RCC.gz"
"GSM1934858","LGWU703203-1036580WU","GSM1934858","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703203","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934858/suppl/GSM1934858_20111110_20111109-9741-2_LGWU703203-1036580WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934858_20111110_20111109-9741-2_LGWU703203-1036580WU_09.RCC.gz"
"GSM1934859","LGWU703233-1036582WU","GSM1934859","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703233","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934859/suppl/GSM1934859_20111110_20111109-9741-2_LGWU703233-1036582WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934859_20111110_20111109-9741-2_LGWU703233-1036582WU_11.RCC.gz"
"GSM1934860","LGWU703238-1036583WU","GSM1934860","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703238","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934860/suppl/GSM1934860_20111110_20111109-9741-2_LGWU703238-1036583WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934860_20111110_20111109-9741-2_LGWU703238-1036583WU_12.RCC.gz"
"GSM1934861","LGWU109139-1036585WU","GSM1934861","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109139","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934861/suppl/GSM1934861_20111111_20111109-9741-3_LGWU109139-1036585WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934861_20111111_20111109-9741-3_LGWU109139-1036585WU_02.RCC.gz"
"GSM1934862","LGWU109288-1036595WU","GSM1934862","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109288","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934862/suppl/GSM1934862_20111111_20111109-9741-3_LGWU109288-1036595WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934862_20111111_20111109-9741-3_LGWU109288-1036595WU_12.RCC.gz"
"GSM1934863","LGWU109399-1036592WU","GSM1934863","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109399","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934863/suppl/GSM1934863_20111111_20111109-9741-3_LGWU109399-1036592WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934863_20111111_20111109-9741-3_LGWU109399-1036592WU_09.RCC.gz"
"GSM1934864","LGWU702335-1036584WU","GSM1934864","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702335","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934864/suppl/GSM1934864_20111111_20111109-9741-3_LGWU702335-1036584WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934864_20111111_20111109-9741-3_LGWU702335-1036584WU_01.RCC.gz"
"GSM1934865","LGWU702776-1036586WU","GSM1934865","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702776","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934865/suppl/GSM1934865_20111111_20111109-9741-3_LGWU702776-1036586WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934865_20111111_20111109-9741-3_LGWU702776-1036586WU_03.RCC.gz"
"GSM1934866","LGWU702777-1036588WU","GSM1934866","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702777","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934866/suppl/GSM1934866_20111111_20111109-9741-3_LGWU702777-1036588WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934866_20111111_20111109-9741-3_LGWU702777-1036588WU_05.RCC.gz"
"GSM1934867","LGWU702806-1036593WU","GSM1934867","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702806","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934867/suppl/GSM1934867_20111111_20111109-9741-3_LGWU702806-1036593WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934867_20111111_20111109-9741-3_LGWU702806-1036593WU_10.RCC.gz"
"GSM1934868","LGWU703289-1036587WU","GSM1934868","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703289","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934868/suppl/GSM1934868_20111111_20111109-9741-3_LGWU703289-1036587WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934868_20111111_20111109-9741-3_LGWU703289-1036587WU_04.RCC.gz"
"GSM1934869","LGWU703295-1036589WU","GSM1934869","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703295","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934869/suppl/GSM1934869_20111111_20111109-9741-3_LGWU703295-1036589WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934869_20111111_20111109-9741-3_LGWU703295-1036589WU_06.RCC.gz"
"GSM1934870","LGWU703299-1036590WU","GSM1934870","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703299","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934870/suppl/GSM1934870_20111111_20111109-9741-3_LGWU703299-1036590WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934870_20111111_20111109-9741-3_LGWU703299-1036590WU_07.RCC.gz"
"GSM1934871","LGWU703316-1036591WU","GSM1934871","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703316","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934871/suppl/GSM1934871_20111111_20111109-9741-3_LGWU703316-1036591WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934871_20111111_20111109-9741-3_LGWU703316-1036591WU_08.RCC.gz"
"GSM1934872","LGWU101091-1036602WU","GSM1934872","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101091","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934872/suppl/GSM1934872_20111111_20111109-9741-4_LGWU101091-1036602WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934872_20111111_20111109-9741-4_LGWU101091-1036602WU_07.RCC.gz"
"GSM1934873","LGWU101998-1036600WU","GSM1934873","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101998","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934873/suppl/GSM1934873_20111111_20111109-9741-4_LGWU101998-1036600WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934873_20111111_20111109-9741-4_LGWU101998-1036600WU_05.RCC.gz"
"GSM1934874","LGWU102501-1036607WU","GSM1934874","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102501","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934874/suppl/GSM1934874_20111111_20111109-9741-4_LGWU102501-1036607WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934874_20111111_20111109-9741-4_LGWU102501-1036607WU_12.RCC.gz"
"GSM1934875","LGWU109061-1036598WU","GSM1934875","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109061","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934875/suppl/GSM1934875_20111111_20111109-9741-4_LGWU109061-1036598WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934875_20111111_20111109-9741-4_LGWU109061-1036598WU_03.RCC.gz"
"GSM1934876","LGWU109394-1036605WU","GSM1934876","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109394","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934876/suppl/GSM1934876_20111111_20111109-9741-4_LGWU109394-1036605WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934876_20111111_20111109-9741-4_LGWU109394-1036605WU_10.RCC.gz"
"GSM1934877","LGWU200387-1036606WU","GSM1934877","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200387","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934877/suppl/GSM1934877_20111111_20111109-9741-4_LGWU200387-1036606WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934877_20111111_20111109-9741-4_LGWU200387-1036606WU_11.RCC.gz"
"GSM1934878","LGWU702446-1036599WU","GSM1934878","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702446","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934878/suppl/GSM1934878_20111111_20111109-9741-4_LGWU702446-1036599WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934878_20111111_20111109-9741-4_LGWU702446-1036599WU_04.RCC.gz"
"GSM1934879","LGWU702835-1036597WU","GSM1934879","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702835","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934879/suppl/GSM1934879_20111111_20111109-9741-4_LGWU702835-1036597WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934879_20111111_20111109-9741-4_LGWU702835-1036597WU_02.RCC.gz"
"GSM1934880","LGWU703121-1036601WU","GSM1934880","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703121","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934880/suppl/GSM1934880_20111111_20111109-9741-4_LGWU703121-1036601WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934880_20111111_20111109-9741-4_LGWU703121-1036601WU_06.RCC.gz"
"GSM1934881","LGWU703243-1036603WU","GSM1934881","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703243","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934881/suppl/GSM1934881_20111111_20111109-9741-4_LGWU703243-1036603WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934881_20111111_20111109-9741-4_LGWU703243-1036603WU_08.RCC.gz"
"GSM1934882","LGWU703361-1036604WU","GSM1934882","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703361","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934882/suppl/GSM1934882_20111111_20111109-9741-4_LGWU703361-1036604WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934882_20111111_20111109-9741-4_LGWU703361-1036604WU_09.RCC.gz"
"GSM1934883","LGWU703379-1036596WU","GSM1934883","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703379","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934883/suppl/GSM1934883_20111111_20111109-9741-4_LGWU703379-1036596WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934883_20111111_20111109-9741-4_LGWU703379-1036596WU_01.RCC.gz"
"GSM1934884","LGWU102004-1036611WU","GSM1934884","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102004","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934884/suppl/GSM1934884_20111111_20111110-9741-1_LGWU102004-1036611WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934884_20111111_20111110-9741-1_LGWU102004-1036611WU_04.RCC.gz"
"GSM1934885","LGWU102013-1036612WU","GSM1934885","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102013","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934885/suppl/GSM1934885_20111111_20111110-9741-1_LGWU102013-1036612WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934885_20111111_20111110-9741-1_LGWU102013-1036612WU_05.RCC.gz"
"GSM1934886","LGWU102485-1036613WU","GSM1934886","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102485","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934886/suppl/GSM1934886_20111111_20111110-9741-1_LGWU102485-1036613WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934886_20111111_20111110-9741-1_LGWU102485-1036613WU_06.RCC.gz"
"GSM1934887","LGWU102514-1036614WU","GSM1934887","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102514","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934887/suppl/GSM1934887_20111111_20111110-9741-1_LGWU102514-1036614WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934887_20111111_20111110-9741-1_LGWU102514-1036614WU_07.RCC.gz"
"GSM1934888","LGWU102612-1036617WU","GSM1934888","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102612","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934888/suppl/GSM1934888_20111111_20111110-9741-1_LGWU102612-1036617WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934888_20111111_20111110-9741-1_LGWU102612-1036617WU_09.RCC.gz"
"GSM1934889","LGWU102703-1036618WU","GSM1934889","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102703","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934889/suppl/GSM1934889_20111111_20111110-9741-1_LGWU102703-1036618WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934889_20111111_20111110-9741-1_LGWU102703-1036618WU_10.RCC.gz"
"GSM1934890","LGWU107294-1036615WU","GSM1934890","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107294","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934890/suppl/GSM1934890_20111111_20111110-9741-1_LGWU107294-1036615WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934890_20111111_20111110-9741-1_LGWU107294-1036615WU_08.RCC.gz"
"GSM1934891","LGWU109100-1036622WU","GSM1934891","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109100","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934891/suppl/GSM1934891_20111111_20111110-9741-1_LGWU109100-1036622WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934891_20111111_20111110-9741-1_LGWU109100-1036622WU_11.RCC.gz"
"GSM1934892","LGWU109185-1036623WU","GSM1934892","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109185","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934892/suppl/GSM1934892_20111111_20111110-9741-1_LGWU109185-1036623WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934892_20111111_20111110-9741-1_LGWU109185-1036623WU_12.RCC.gz"
"GSM1934893","LGWU109364-1036608WU","GSM1934893","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109364","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934893/suppl/GSM1934893_20111111_20111110-9741-1_LGWU109364-1036608WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934893_20111111_20111110-9741-1_LGWU109364-1036608WU_01.RCC.gz"
"GSM1934894","LGWU703260-1036609WU","GSM1934894","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703260","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934894/suppl/GSM1934894_20111111_20111110-9741-1_LGWU703260-1036609WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934894_20111111_20111110-9741-1_LGWU703260-1036609WU_02.RCC.gz"
"GSM1934895","LGWU703344-1036610WU","GSM1934895","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703344","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934895/suppl/GSM1934895_20111111_20111110-9741-1_LGWU703344-1036610WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934895_20111111_20111110-9741-1_LGWU703344-1036610WU_03.RCC.gz"
"GSM1934896","LGWU102473-1036625WU","GSM1934896","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102473","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934896/suppl/GSM1934896_20111111_20111110-9741-2_LGWU102473-1036625WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934896_20111111_20111110-9741-2_LGWU102473-1036625WU_02.RCC.gz"
"GSM1934897","LGWU102492-1036628WU","GSM1934897","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102492","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934897/suppl/GSM1934897_20111111_20111110-9741-2_LGWU102492-1036628WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934897_20111111_20111110-9741-2_LGWU102492-1036628WU_05.RCC.gz"
"GSM1934898","LGWU102522-1036631WU","GSM1934898","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102522","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934898/suppl/GSM1934898_20111111_20111110-9741-2_LGWU102522-1036631WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934898_20111111_20111110-9741-2_LGWU102522-1036631WU_08.RCC.gz"
"GSM1934899","LGWU102525-1036633WU","GSM1934899","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102525","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934899/suppl/GSM1934899_20111111_20111110-9741-2_LGWU102525-1036633WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934899_20111111_20111110-9741-2_LGWU102525-1036633WU_10.RCC.gz"
"GSM1934900","LGWU102566-1036634WU","GSM1934900","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102566","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934900/suppl/GSM1934900_20111111_20111110-9741-2_LGWU102566-1036634WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934900_20111111_20111110-9741-2_LGWU102566-1036634WU_11.RCC.gz"
"GSM1934901","LGWU107250-1036626WU","GSM1934901","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107250","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934901/suppl/GSM1934901_20111111_20111110-9741-2_LGWU107250-1036626WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934901_20111111_20111110-9741-2_LGWU107250-1036626WU_03.RCC.gz"
"GSM1934902","LGWU107304-1036630WU","GSM1934902","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107304","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934902/suppl/GSM1934902_20111111_20111110-9741-2_LGWU107304-1036630WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934902_20111111_20111110-9741-2_LGWU107304-1036630WU_07.RCC.gz"
"GSM1934903","LGWU109191-1036624WU","GSM1934903","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109191","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934903/suppl/GSM1934903_20111111_20111110-9741-2_LGWU109191-1036624WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934903_20111111_20111110-9741-2_LGWU109191-1036624WU_01.RCC.gz"
"GSM1934904","LGWU206755-1036629WU","GSM1934904","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 206755","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934904/suppl/GSM1934904_20111111_20111110-9741-2_LGWU206755-1036629WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934904_20111111_20111110-9741-2_LGWU206755-1036629WU_06.RCC.gz"
"GSM1934905","LGWU702379-1036627WU","GSM1934905","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702379","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934905/suppl/GSM1934905_20111111_20111110-9741-2_LGWU702379-1036627WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934905_20111111_20111110-9741-2_LGWU702379-1036627WU_04.RCC.gz"
"GSM1934906","LGWU702435-1036632WU","GSM1934906","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702435","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934906/suppl/GSM1934906_20111111_20111110-9741-2_LGWU702435-1036632WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934906_20111111_20111110-9741-2_LGWU702435-1036632WU_09.RCC.gz"
"GSM1934907","LGWU702458-1036635WU","GSM1934907","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702458","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934907/suppl/GSM1934907_20111111_20111110-9741-2_LGWU702458-1036635WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934907_20111111_20111110-9741-2_LGWU702458-1036635WU_12.RCC.gz"
"GSM1934908","LGWU102592-1036638WU","GSM1934908","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102592","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934908/suppl/GSM1934908_20111111_20111110-9741-3_LGWU102592-1036638WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934908_20111111_20111110-9741-3_LGWU102592-1036638WU_03.RCC.gz"
"GSM1934909","LGWU102607-1036642WU","GSM1934909","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102607","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934909/suppl/GSM1934909_20111111_20111110-9741-3_LGWU102607-1036642WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934909_20111111_20111110-9741-3_LGWU102607-1036642WU_07.RCC.gz"
"GSM1934910","LGWU102674-1036647WU","GSM1934910","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102674","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934910/suppl/GSM1934910_20111111_20111110-9741-3_LGWU102674-1036647WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934910_20111111_20111110-9741-3_LGWU102674-1036647WU_12.RCC.gz"
"GSM1934911","LGWU107298-1036641WU","GSM1934911","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107298","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934911/suppl/GSM1934911_20111111_20111110-9741-3_LGWU107298-1036641WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934911_20111111_20111110-9741-3_LGWU107298-1036641WU_06.RCC.gz"
"GSM1934912","LGWU107312-1036637WU","GSM1934912","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107312","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934912/suppl/GSM1934912_20111111_20111110-9741-3_LGWU107312-1036637WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934912_20111111_20111110-9741-3_LGWU107312-1036637WU_02.RCC.gz"
"GSM1934913","LGWU702215-1036639WU","GSM1934913","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702215","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934913/suppl/GSM1934913_20111111_20111110-9741-3_LGWU702215-1036639WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934913_20111111_20111110-9741-3_LGWU702215-1036639WU_04.RCC.gz"
"GSM1934914","LGWU702216-1036640WU","GSM1934914","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702216","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934914/suppl/GSM1934914_20111111_20111110-9741-3_LGWU702216-1036640WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934914_20111111_20111110-9741-3_LGWU702216-1036640WU_05.RCC.gz"
"GSM1934915","LGWU702224-1036643WU","GSM1934915","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702224","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934915/suppl/GSM1934915_20111111_20111110-9741-3_LGWU702224-1036643WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934915_20111111_20111110-9741-3_LGWU702224-1036643WU_08.RCC.gz"
"GSM1934916","LGWU702232-1036645WU","GSM1934916","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702232","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934916/suppl/GSM1934916_20111111_20111110-9741-3_LGWU702232-1036645WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934916_20111111_20111110-9741-3_LGWU702232-1036645WU_10.RCC.gz"
"GSM1934917","LGWU702470-1036636WU","GSM1934917","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702470","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934917/suppl/GSM1934917_20111111_20111110-9741-3_LGWU702470-1036636WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934917_20111111_20111110-9741-3_LGWU702470-1036636WU_01.RCC.gz"
"GSM1934918","LGWU702560-1036644WU","GSM1934918","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702560","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934918/suppl/GSM1934918_20111111_20111110-9741-3_LGWU702560-1036644WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934918_20111111_20111110-9741-3_LGWU702560-1036644WU_09.RCC.gz"
"GSM1934919","LGWU702572-1036646WU","GSM1934919","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702572","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934919/suppl/GSM1934919_20111111_20111110-9741-3_LGWU702572-1036646WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934919_20111111_20111110-9741-3_LGWU702572-1036646WU_11.RCC.gz"
"GSM1934920","LGWU102675-1036649WU","GSM1934920","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102675","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934920/suppl/GSM1934920_20111111_20111110-9741-4_LGWU102675-1036649WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934920_20111111_20111110-9741-4_LGWU102675-1036649WU_02.RCC.gz"
"GSM1934921","LGWU102711-1036657WU","GSM1934921","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102711","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934921/suppl/GSM1934921_20111111_20111110-9741-4_LGWU102711-1036657WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934921_20111111_20111110-9741-4_LGWU102711-1036657WU_10.RCC.gz"
"GSM1934922","LGWU202583-1036652WU","GSM1934922","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 202583","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934922/suppl/GSM1934922_20111111_20111110-9741-4_LGWU202583-1036652WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934922_20111111_20111110-9741-4_LGWU202583-1036652WU_05.RCC.gz"
"GSM1934923","LGWU209114-1036655WU","GSM1934923","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 209114","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934923/suppl/GSM1934923_20111111_20111110-9741-4_LGWU209114-1036655WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934923_20111111_20111110-9741-4_LGWU209114-1036655WU_08.RCC.gz"
"GSM1934924","LGWU215591-1036651WU","GSM1934924","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 215591","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934924/suppl/GSM1934924_20111111_20111110-9741-4_LGWU215591-1036651WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934924_20111111_20111110-9741-4_LGWU215591-1036651WU_04.RCC.gz"
"GSM1934925","LGWU702237-1036648WU","GSM1934925","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702237","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934925/suppl/GSM1934925_20111111_20111110-9741-4_LGWU702237-1036648WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934925_20111111_20111110-9741-4_LGWU702237-1036648WU_01.RCC.gz"
"GSM1934926","LGWU702251-1036653WU","GSM1934926","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702251","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934926/suppl/GSM1934926_20111111_20111110-9741-4_LGWU702251-1036653WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934926_20111111_20111110-9741-4_LGWU702251-1036653WU_06.RCC.gz"
"GSM1934927","LGWU702254-1036654WU","GSM1934927","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702254","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934927/suppl/GSM1934927_20111111_20111110-9741-4_LGWU702254-1036654WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934927_20111111_20111110-9741-4_LGWU702254-1036654WU_07.RCC.gz"
"GSM1934928","LGWU702599-1036650WU","GSM1934928","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702599","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934928/suppl/GSM1934928_20111111_20111110-9741-4_LGWU702599-1036650WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934928_20111111_20111110-9741-4_LGWU702599-1036650WU_03.RCC.gz"
"GSM1934929","LGWU702635-1036656WU","GSM1934929","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702635","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934929/suppl/GSM1934929_20111111_20111110-9741-4_LGWU702635-1036656WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934929_20111111_20111110-9741-4_LGWU702635-1036656WU_09.RCC.gz"
"GSM1934930","LGWU702639-1036658WU","GSM1934930","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702639","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934930/suppl/GSM1934930_20111111_20111110-9741-4_LGWU702639-1036658WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934930_20111111_20111110-9741-4_LGWU702639-1036658WU_11.RCC.gz"
"GSM1934931","LGWU703120-1036659WU","GSM1934931","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703120","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934931/suppl/GSM1934931_20111111_20111110-9741-4_LGWU703120-1036659WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934931_20111111_20111110-9741-4_LGWU703120-1036659WU_12.RCC.gz"
"GSM1934932","LGWU101199-1036660WU","GSM1934932","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101199","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934932/suppl/GSM1934932_20111114_20111111-9741-1_LGWU101199-1036660WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934932_20111114_20111111-9741-1_LGWU101199-1036660WU_01.RCC.gz"
"GSM1934933","LGWU200735-1036662WU","GSM1934933","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200735","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934933/suppl/GSM1934933_20111114_20111111-9741-1_LGWU200735-1036662WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934933_20111114_20111111-9741-1_LGWU200735-1036662WU_03.RCC.gz"
"GSM1934934","LGWU702285-1036664WU","GSM1934934","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702285","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934934/suppl/GSM1934934_20111114_20111111-9741-1_LGWU702285-1036664WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934934_20111114_20111111-9741-1_LGWU702285-1036664WU_05.RCC.gz"
"GSM1934935","LGWU702657-1036661WU","GSM1934935","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702657","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934935/suppl/GSM1934935_20111114_20111111-9741-1_LGWU702657-1036661WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934935_20111114_20111111-9741-1_LGWU702657-1036661WU_02.RCC.gz"
"GSM1934936","LGWU702677-1036663WU","GSM1934936","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702677","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934936/suppl/GSM1934936_20111114_20111111-9741-1_LGWU702677-1036663WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934936_20111114_20111111-9741-1_LGWU702677-1036663WU_04.RCC.gz"
"GSM1934937","LGWU702703-1036668WU","GSM1934937","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702703","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934937/suppl/GSM1934937_20111114_20111111-9741-1_LGWU702703-1036668WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934937_20111114_20111111-9741-1_LGWU702703-1036668WU_09.RCC.gz"
"GSM1934938","LGWU702704-1036669WU","GSM1934938","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702704","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934938/suppl/GSM1934938_20111114_20111111-9741-1_LGWU702704-1036669WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934938_20111114_20111111-9741-1_LGWU702704-1036669WU_10.RCC.gz"
"GSM1934939","LGWU702725-1036671WU","GSM1934939","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702725","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934939/suppl/GSM1934939_20111114_20111111-9741-1_LGWU702725-1036671WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934939_20111114_20111111-9741-1_LGWU702725-1036671WU_12.RCC.gz"
"GSM1934940","LGWU703143-1036665WU","GSM1934940","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703143","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934940/suppl/GSM1934940_20111114_20111111-9741-1_LGWU703143-1036665WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934940_20111114_20111111-9741-1_LGWU703143-1036665WU_06.RCC.gz"
"GSM1934941","LGWU703150-1036666WU","GSM1934941","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703150","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934941/suppl/GSM1934941_20111114_20111111-9741-1_LGWU703150-1036666WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934941_20111114_20111111-9741-1_LGWU703150-1036666WU_07.RCC.gz"
"GSM1934942","LGWU703153-1036667WU","GSM1934942","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703153","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934942/suppl/GSM1934942_20111114_20111111-9741-1_LGWU703153-1036667WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934942_20111114_20111111-9741-1_LGWU703153-1036667WU_08.RCC.gz"
"GSM1934943","LGWU703174-1036670WU","GSM1934943","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703174","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934943/suppl/GSM1934943_20111114_20111111-9741-1_LGWU703174-1036670WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934943_20111114_20111111-9741-1_LGWU703174-1036670WU_11.RCC.gz"
"GSM1934944","LGWU109086-1036678WU","GSM1934944","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109086","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934944/suppl/GSM1934944_20111114_20111111-9741-2_LGWU109086-1036678WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934944_20111114_20111111-9741-2_LGWU109086-1036678WU_07.RCC.gz"
"GSM1934945","LGWU109206-1036684WU","GSM1934945","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109206","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934945/suppl/GSM1934945_20111114_20111111-9741-2_LGWU109206-1036684WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934945_20111114_20111111-9741-2_LGWU109206-1036684WU_12.RCC.gz"
"GSM1934946","LGWU207405-1036675WU","GSM1934946","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 207405","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934946/suppl/GSM1934946_20111114_20111111-9741-2_LGWU207405-1036675WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934946_20111114_20111111-9741-2_LGWU207405-1036675WU_04.RCC.gz"
"GSM1934947","LGWU702728-1036672WU","GSM1934947","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702728","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934947/suppl/GSM1934947_20111114_20111111-9741-2_LGWU702728-1036672WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934947_20111114_20111111-9741-2_LGWU702728-1036672WU_01.RCC.gz"
"GSM1934948","LGWU702744-1036673WU","GSM1934948","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702744","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934948/suppl/GSM1934948_20111114_20111111-9741-2_LGWU702744-1036673WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934948_20111114_20111111-9741-2_LGWU702744-1036673WU_02.RCC.gz"
"GSM1934949","LGWU702755-1036676WU","GSM1934949","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702755","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934949/suppl/GSM1934949_20111114_20111111-9741-2_LGWU702755-1036676WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934949_20111114_20111111-9741-2_LGWU702755-1036676WU_05.RCC.gz"
"GSM1934950","LGWU702782-1036681WU","GSM1934950","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702782","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934950/suppl/GSM1934950_20111114_20111111-9741-2_LGWU702782-1036681WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934950_20111114_20111111-9741-2_LGWU702782-1036681WU_10.RCC.gz"
"GSM1934951","LGWU702798-1036683WU","GSM1934951","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702798","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934951/suppl/GSM1934951_20111114_20111111-9741-2_LGWU702798-1036683WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934951_20111114_20111111-9741-2_LGWU702798-1036683WU_11.RCC.gz"
"GSM1934952","LGWU703217-1036674WU","GSM1934952","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703217","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934952/suppl/GSM1934952_20111114_20111111-9741-2_LGWU703217-1036674WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934952_20111114_20111111-9741-2_LGWU703217-1036674WU_03.RCC.gz"
"GSM1934953","LGWU703253-1036677WU","GSM1934953","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703253","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934953/suppl/GSM1934953_20111114_20111111-9741-2_LGWU703253-1036677WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934953_20111114_20111111-9741-2_LGWU703253-1036677WU_06.RCC.gz"
"GSM1934954","LGWU703288-1036679WU","GSM1934954","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703288","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934954/suppl/GSM1934954_20111114_20111111-9741-2_LGWU703288-1036679WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934954_20111114_20111111-9741-2_LGWU703288-1036679WU_08.RCC.gz"
"GSM1934955","LGWU703300-1036680WU","GSM1934955","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703300","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934955/suppl/GSM1934955_20111114_20111111-9741-2_LGWU703300-1036680WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934955_20111114_20111111-9741-2_LGWU703300-1036680WU_09.RCC.gz"
"GSM1934956","LGWU102470-1036693WU","GSM1934956","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102470","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934956/suppl/GSM1934956_20111114_20111111-9741-3_LGWU102470-1036693WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934956_20111114_20111111-9741-3_LGWU102470-1036693WU_09.RCC.gz"
"GSM1934957","LGWU702185-1036694WU","GSM1934957","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702185","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934957/suppl/GSM1934957_20111114_20111111-9741-3_LGWU702185-1036694WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934957_20111114_20111111-9741-3_LGWU702185-1036694WU_10.RCC.gz"
"GSM1934958","LGWU702361-1036687WU","GSM1934958","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702361","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934958/suppl/GSM1934958_20111114_20111111-9741-3_LGWU702361-1036687WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934958_20111114_20111111-9741-3_LGWU702361-1036687WU_03.RCC.gz"
"GSM1934959","LGWU702690-1036695WU","GSM1934959","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702690","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934959/suppl/GSM1934959_20111114_20111111-9741-3_LGWU702690-1036695WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934959_20111114_20111111-9741-3_LGWU702690-1036695WU_11.RCC.gz"
"GSM1934960","LGWU702805-1036685WU","GSM1934960","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702805","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934960/suppl/GSM1934960_20111114_20111111-9741-3_LGWU702805-1036685WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934960_20111114_20111111-9741-3_LGWU702805-1036685WU_01.RCC.gz"
"GSM1934961","LGWU702819-1036688WU","GSM1934961","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702819","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934961/suppl/GSM1934961_20111114_20111111-9741-3_LGWU702819-1036688WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934961_20111114_20111111-9741-3_LGWU702819-1036688WU_04.RCC.gz"
"GSM1934962","LGWU702828-1036690WU","GSM1934962","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702828","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934962/suppl/GSM1934962_20111114_20111111-9741-3_LGWU702828-1036690WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934962_20111114_20111111-9741-3_LGWU702828-1036690WU_06.RCC.gz"
"GSM1934963","LGWU702830-1036691WU","GSM1934963","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702830","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934963/suppl/GSM1934963_20111114_20111111-9741-3_LGWU702830-1036691WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934963_20111114_20111111-9741-3_LGWU702830-1036691WU_07.RCC.gz"
"GSM1934964","LGWU703163-1036696WU","GSM1934964","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703163","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934964/suppl/GSM1934964_20111114_20111111-9741-3_LGWU703163-1036696WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934964_20111114_20111111-9741-3_LGWU703163-1036696WU_12.RCC.gz"
"GSM1934965","LGWU703343-1036686WU","GSM1934965","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703343","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934965/suppl/GSM1934965_20111114_20111111-9741-3_LGWU703343-1036686WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934965_20111114_20111111-9741-3_LGWU703343-1036686WU_02.RCC.gz"
"GSM1934966","LGWU703378-1036689WU","GSM1934966","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703378","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934966/suppl/GSM1934966_20111114_20111111-9741-3_LGWU703378-1036689WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934966_20111114_20111111-9741-3_LGWU703378-1036689WU_05.RCC.gz"
"GSM1934967","LGWU703391-1036692WU","GSM1934967","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703391","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934967/suppl/GSM1934967_20111114_20111111-9741-3_LGWU703391-1036692WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934967_20111114_20111111-9741-3_LGWU703391-1036692WU_08.RCC.gz"
"GSM1934968","LGWU101087-1036699WU","GSM1934968","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101087","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934968/suppl/GSM1934968_20111115_20111115-9741-1_LGWU101087-1036699WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934968_20111115_20111115-9741-1_LGWU101087-1036699WU_03.RCC.gz"
"GSM1934969","LGWU102515-1036705WU","GSM1934969","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102515","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934969/suppl/GSM1934969_20111115_20111115-9741-1_LGWU102515-1036705WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934969_20111115_20111115-9741-1_LGWU102515-1036705WU_08.RCC.gz"
"GSM1934970","LGWU102575-1036707WU","GSM1934970","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102575","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934970/suppl/GSM1934970_20111115_20111115-9741-1_LGWU102575-1036707WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934970_20111115_20111115-9741-1_LGWU102575-1036707WU_10.RCC.gz"
"GSM1934971","LGWU1045023-1036706WU","GSM1934971","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 104502","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934971/suppl/GSM1934971_20111115_20111115-9741-1_LGWU1045023-1036706WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934971_20111115_20111115-9741-1_LGWU1045023-1036706WU_09.RCC.gz"
"GSM1934972","LGWU107320-1036704WU","GSM1934972","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107320","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934972/suppl/GSM1934972_20111115_20111115-9741-1_LGWU107320-1036704WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934972_20111115_20111115-9741-1_LGWU107320-1036704WU_07.RCC.gz"
"GSM1934973","LGWU109078-1036697WU","GSM1934973","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109078","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934973/suppl/GSM1934973_20111115_20111115-9741-1_LGWU109078-1036697WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934973_20111115_20111115-9741-1_LGWU109078-1036697WU_01.RCC.gz"
"GSM1934974","LGWU216781-1036710WU","GSM1934974","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 216781","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934974/suppl/GSM1934974_20111115_20111115-9741-1_LGWU216781-1036710WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934974_20111115_20111115-9741-1_LGWU216781-1036710WU_12.RCC.gz"
"GSM1934975","LGWU702827-1036700WU","GSM1934975","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702827","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934975/suppl/GSM1934975_20111115_20111115-9741-1_LGWU702827-1036700WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934975_20111115_20111115-9741-1_LGWU702827-1036700WU_04.RCC.gz"
"GSM1934976","LGWU703274-1036698WU","GSM1934976","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703274","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934976/suppl/GSM1934976_20111115_20111115-9741-1_LGWU703274-1036698WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934976_20111115_20111115-9741-1_LGWU703274-1036698WU_02.RCC.gz"
"GSM1934977","LGWU703394-1036701WU","GSM1934977","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703394","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934977/suppl/GSM1934977_20111115_20111115-9741-1_LGWU703394-1036701WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934977_20111115_20111115-9741-1_LGWU703394-1036701WU_05.RCC.gz"
"GSM1934978","LGWU101093-1036722WU","GSM1934978","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101093","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934978/suppl/GSM1934978_20111115_20111115-9741-2_LGWU101093-1036722WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934978_20111115_20111115-9741-2_LGWU101093-1036722WU_08.RCC.gz"
"GSM1934979","LGWU102621-1036721WU","GSM1934979","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102621","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934979/suppl/GSM1934979_20111115_20111115-9741-2_LGWU102621-1036721WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934979_20111115_20111115-9741-2_LGWU102621-1036721WU_07.RCC.gz"
"GSM1934980","LGWU1045029-1036717WU","GSM1934980","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 104502","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934980/suppl/GSM1934980_20111115_20111115-9741-2_LGWU1045029-1036717WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934980_20111115_20111115-9741-2_LGWU1045029-1036717WU_04.RCC.gz"
"GSM1934981","LGWU107259-1036731WU","GSM1934981","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107259","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934981/suppl/GSM1934981_20111115_20111115-9741-2_LGWU107259-1036731WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934981_20111115_20111115-9741-2_LGWU107259-1036731WU_09.RCC.gz"
"GSM1934982","LGWU109016-1036712WU","GSM1934982","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109016","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934982/suppl/GSM1934982_20111115_20111115-9741-2_LGWU109016-1036712WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934982_20111115_20111115-9741-2_LGWU109016-1036712WU_02.RCC.gz"
"GSM1934983","LGWU109291-1036713WU","GSM1934983","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109291","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934983/suppl/GSM1934983_20111115_20111115-9741-2_LGWU109291-1036713WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934983_20111115_20111115-9741-2_LGWU109291-1036713WU_03.RCC.gz"
"GSM1934984","LGWU202632-1036711WU","GSM1934984","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 202632","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934984/suppl/GSM1934984_20111115_20111115-9741-2_LGWU202632-1036711WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934984_20111115_20111115-9741-2_LGWU202632-1036711WU_01.RCC.gz"
"GSM1934985","LGWU702167-1036732WU","GSM1934985","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702167","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934985/suppl/GSM1934985_20111115_20111115-9741-2_LGWU702167-1036732WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934985_20111115_20111115-9741-2_LGWU702167-1036732WU_10.RCC.gz"
"GSM1934986","LGWU702172-1036734WU","GSM1934986","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702172","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934986/suppl/GSM1934986_20111115_20111115-9741-2_LGWU702172-1036734WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934986_20111115_20111115-9741-2_LGWU702172-1036734WU_12.RCC.gz"
"GSM1934987","LGWU702383-1036733WU","GSM1934987","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702383","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934987/suppl/GSM1934987_20111115_20111115-9741-2_LGWU702383-1036733WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934987_20111115_20111115-9741-2_LGWU702383-1036733WU_11.RCC.gz"
"GSM1934988","LGWU702386-1036720WU","GSM1934988","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702386","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934988/suppl/GSM1934988_20111115_20111115-9741-2_LGWU702386-1036720WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934988_20111115_20111115-9741-2_LGWU702386-1036720WU_06.RCC.gz"
"GSM1934989","LGWU102562-1036743WU","GSM1934989","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102562","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934989/suppl/GSM1934989_20111115_20111115-9741-3_LGWU102562-1036743WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934989_20111115_20111115-9741-3_LGWU102562-1036743WU_09.RCC.gz"
"GSM1934990","LGWU102588-1036739WU","GSM1934990","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102588","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934990/suppl/GSM1934990_20111115_20111115-9741-3_LGWU102588-1036739WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934990_20111115_20111115-9741-3_LGWU102588-1036739WU_05.RCC.gz"
"GSM1934991","LGWU107275-1036738WU","GSM1934991","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107275","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934991/suppl/GSM1934991_20111115_20111115-9741-3_LGWU107275-1036738WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934991_20111115_20111115-9741-3_LGWU107275-1036738WU_04.RCC.gz"
"GSM1934992","LGWU107306-1036737WU","GSM1934992","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107306","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934992/suppl/GSM1934992_20111115_20111115-9741-3_LGWU107306-1036737WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934992_20111115_20111115-9741-3_LGWU107306-1036737WU_03.RCC.gz"
"GSM1934993","LGWU203408-1036745WU","GSM1934993","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203408","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934993/suppl/GSM1934993_20111115_20111115-9741-3_LGWU203408-1036745WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934993_20111115_20111115-9741-3_LGWU203408-1036745WU_11.RCC.gz"
"GSM1934994","LGWU702187-1036741WU","GSM1934994","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702187","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934994/suppl/GSM1934994_20111115_20111115-9741-3_LGWU702187-1036741WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934994_20111115_20111115-9741-3_LGWU702187-1036741WU_07.RCC.gz"
"GSM1934995","LGWU702402-1036735WU","GSM1934995","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702402","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934995/suppl/GSM1934995_20111115_20111115-9741-3_LGWU702402-1036735WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934995_20111115_20111115-9741-3_LGWU702402-1036735WU_01.RCC.gz"
"GSM1934996","LGWU702406-1036736WU","GSM1934996","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702406","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934996/suppl/GSM1934996_20111115_20111115-9741-3_LGWU702406-1036736WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934996_20111115_20111115-9741-3_LGWU702406-1036736WU_02.RCC.gz"
"GSM1934997","LGWU702443-1036740WU","GSM1934997","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702443","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934997/suppl/GSM1934997_20111115_20111115-9741-3_LGWU702443-1036740WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934997_20111115_20111115-9741-3_LGWU702443-1036740WU_06.RCC.gz"
"GSM1934998","LGWU702452-1036742WU","GSM1934998","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702452","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934998/suppl/GSM1934998_20111115_20111115-9741-3_LGWU702452-1036742WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934998_20111115_20111115-9741-3_LGWU702452-1036742WU_08.RCC.gz"
"GSM1934999","LGWU702459-1036744WU","GSM1934999","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702459","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1934nnn/GSM1934999/suppl/GSM1934999_20111115_20111115-9741-3_LGWU702459-1036744WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1934999_20111115_20111115-9741-3_LGWU702459-1036744WU_10.RCC.gz"
"GSM1935000","LGWU702489-1036746WU","GSM1935000","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702489","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935000/suppl/GSM1935000_20111115_20111115-9741-3_LGWU702489-1036746WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935000_20111115_20111115-9741-3_LGWU702489-1036746WU_12.RCC.gz"
"GSM1935001","LGWU102685-1036755WU","GSM1935001","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102685","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935001/suppl/GSM1935001_20111115_20111115-9741-4_LGWU102685-1036755WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935001_20111115_20111115-9741-4_LGWU102685-1036755WU_09.RCC.gz"
"GSM1935002","LGWU107301-1036749WU","GSM1935002","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107301","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935002/suppl/GSM1935002_20111115_20111115-9741-4_LGWU107301-1036749WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935002_20111115_20111115-9741-4_LGWU107301-1036749WU_03.RCC.gz"
"GSM1935003","LGWU107305-1036748WU","GSM1935003","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107305","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935003/suppl/GSM1935003_20111115_20111115-9741-4_LGWU107305-1036748WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935003_20111115_20111115-9741-4_LGWU107305-1036748WU_02.RCC.gz"
"GSM1935004","LGWU108978-1036753WU","GSM1935004","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108978","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935004/suppl/GSM1935004_20111115_20111115-9741-4_LGWU108978-1036753WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935004_20111115_20111115-9741-4_LGWU108978-1036753WU_07.RCC.gz"
"GSM1935005","LGWU702207-1036747WU","GSM1935005","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702207","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935005/suppl/GSM1935005_20111115_20111115-9741-4_LGWU702207-1036747WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935005_20111115_20111115-9741-4_LGWU702207-1036747WU_01.RCC.gz"
"GSM1935006","LGWU702245-1036758WU","GSM1935006","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702245","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935006/suppl/GSM1935006_20111115_20111115-9741-4_LGWU702245-1036758WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935006_20111115_20111115-9741-4_LGWU702245-1036758WU_11.RCC.gz"
"GSM1935007","LGWU702249-1036759WU","GSM1935007","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702249","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935007/suppl/GSM1935007_20111115_20111115-9741-4_LGWU702249-1036759WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935007_20111115_20111115-9741-4_LGWU702249-1036759WU_12.RCC.gz"
"GSM1935008","LGWU702548-1036751WU","GSM1935008","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702548","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935008/suppl/GSM1935008_20111115_20111115-9741-4_LGWU702548-1036751WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935008_20111115_20111115-9741-4_LGWU702548-1036751WU_05.RCC.gz"
"GSM1935009","LGWU702559-1036752WU","GSM1935009","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702559","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935009/suppl/GSM1935009_20111115_20111115-9741-4_LGWU702559-1036752WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935009_20111115_20111115-9741-4_LGWU702559-1036752WU_06.RCC.gz"
"GSM1935010","LGWU702586-1036754WU","GSM1935010","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702586","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935010/suppl/GSM1935010_20111115_20111115-9741-4_LGWU702586-1036754WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935010_20111115_20111115-9741-4_LGWU702586-1036754WU_08.RCC.gz"
"GSM1935011","LGWU702604-1036757WU","GSM1935011","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702604","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935011/suppl/GSM1935011_20111115_20111115-9741-4_LGWU702604-1036757WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935011_20111115_20111115-9741-4_LGWU702604-1036757WU_10.RCC.gz"
"GSM1935012","LGWU102787-1036772WU","GSM1935012","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102787","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935012/suppl/GSM1935012_20111117_20111116-9741-1_LGWU102787-1036772WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935012_20111117_20111116-9741-1_LGWU102787-1036772WU_11.RCC.gz"
"GSM1935013","LGWU702260-1036760WU","GSM1935013","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702260","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935013/suppl/GSM1935013_20111117_20111116-9741-1_LGWU702260-1036760WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935013_20111117_20111116-9741-1_LGWU702260-1036760WU_01.RCC.gz"
"GSM1935014","LGWU702314-1036771WU","GSM1935014","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702314","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935014/suppl/GSM1935014_20111117_20111116-9741-1_LGWU702314-1036771WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935014_20111117_20111116-9741-1_LGWU702314-1036771WU_10.RCC.gz"
"GSM1935015","LGWU702650-1036761WU","GSM1935015","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702650","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935015/suppl/GSM1935015_20111117_20111116-9741-1_LGWU702650-1036761WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935015_20111117_20111116-9741-1_LGWU702650-1036761WU_02.RCC.gz"
"GSM1935016","LGWU702666-1036762WU","GSM1935016","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702666","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935016/suppl/GSM1935016_20111117_20111116-9741-1_LGWU702666-1036762WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935016_20111117_20111116-9741-1_LGWU702666-1036762WU_03.RCC.gz"
"GSM1935017","LGWU702678-1036764WU","GSM1935017","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702678","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935017/suppl/GSM1935017_20111117_20111116-9741-1_LGWU702678-1036764WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935017_20111117_20111116-9741-1_LGWU702678-1036764WU_04.RCC.gz"
"GSM1935018","LGWU702695-1036768WU","GSM1935018","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702695","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935018/suppl/GSM1935018_20111117_20111116-9741-1_LGWU702695-1036768WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935018_20111117_20111116-9741-1_LGWU702695-1036768WU_07.RCC.gz"
"GSM1935019","LGWU702699-1036769WU","GSM1935019","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702699","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935019/suppl/GSM1935019_20111117_20111116-9741-1_LGWU702699-1036769WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935019_20111117_20111116-9741-1_LGWU702699-1036769WU_08.RCC.gz"
"GSM1935020","LGWU702717-1036770WU","GSM1935020","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702717","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935020/suppl/GSM1935020_20111117_20111116-9741-1_LGWU702717-1036770WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935020_20111117_20111116-9741-1_LGWU702717-1036770WU_09.RCC.gz"
"GSM1935021","LGWU702739-1036773WU","GSM1935021","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702739","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935021/suppl/GSM1935021_20111117_20111116-9741-1_LGWU702739-1036773WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935021_20111117_20111116-9741-1_LGWU702739-1036773WU_12.RCC.gz"
"GSM1935022","LGWU703145-1036766WU","GSM1935022","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703145","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935022/suppl/GSM1935022_20111117_20111116-9741-1_LGWU703145-1036766WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935022_20111117_20111116-9741-1_LGWU703145-1036766WU_06.RCC.gz"
"GSM1935023","LGWU101702-1036774WU","GSM1935023","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101702","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935023/suppl/GSM1935023_20111117_20111116-9741-2_LGWU101702-1036774WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935023_20111117_20111116-9741-2_LGWU101702-1036774WU_01.RCC.gz"
"GSM1935024","LGWU107386-1036778WU","GSM1935024","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107386","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935024/suppl/GSM1935024_20111117_20111116-9741-2_LGWU107386-1036778WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935024_20111117_20111116-9741-2_LGWU107386-1036778WU_05.RCC.gz"
"GSM1935025","LGWU109040-1036775WU","GSM1935025","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109040","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935025/suppl/GSM1935025_20111117_20111116-9741-2_LGWU109040-1036775WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935025_20111117_20111116-9741-2_LGWU109040-1036775WU_02.RCC.gz"
"GSM1935026","LGWU207687-1036780WU","GSM1935026","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 207687","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935026/suppl/GSM1935026_20111117_20111116-9741-2_LGWU207687-1036780WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935026_20111117_20111116-9741-2_LGWU207687-1036780WU_07.RCC.gz"
"GSM1935027","LGWU702327-1036777WU","GSM1935027","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702327","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935027/suppl/GSM1935027_20111117_20111116-9741-2_LGWU702327-1036777WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935027_20111117_20111116-9741-2_LGWU702327-1036777WU_04.RCC.gz"
"GSM1935028","LGWU702775-1036782WU","GSM1935028","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702775","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935028/suppl/GSM1935028_20111117_20111116-9741-2_LGWU702775-1036782WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935028_20111117_20111116-9741-2_LGWU702775-1036782WU_08.RCC.gz"
"GSM1935029","LGWU702788-1036786WU","GSM1935029","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702788","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935029/suppl/GSM1935029_20111117_20111116-9741-2_LGWU702788-1036786WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935029_20111117_20111116-9741-2_LGWU702788-1036786WU_12.RCC.gz"
"GSM1935030","LGWU703252-1036776WU","GSM1935030","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703252","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935030/suppl/GSM1935030_20111117_20111116-9741-2_LGWU703252-1036776WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935030_20111117_20111116-9741-2_LGWU703252-1036776WU_03.RCC.gz"
"GSM1935031","LGWU703265-1036779WU","GSM1935031","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703265","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935031/suppl/GSM1935031_20111117_20111116-9741-2_LGWU703265-1036779WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935031_20111117_20111116-9741-2_LGWU703265-1036779WU_06.RCC.gz"
"GSM1935032","LGWU703294-1036783WU","GSM1935032","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703294","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935032/suppl/GSM1935032_20111117_20111116-9741-2_LGWU703294-1036783WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935032_20111117_20111116-9741-2_LGWU703294-1036783WU_09.RCC.gz"
"GSM1935033","LGWU703296-1036784WU","GSM1935033","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703296","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935033/suppl/GSM1935033_20111117_20111116-9741-2_LGWU703296-1036784WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935033_20111117_20111116-9741-2_LGWU703296-1036784WU_10.RCC.gz"
"GSM1935034","LGWU703307-1036785WU","GSM1935034","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703307","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935034/suppl/GSM1935034_20111117_20111116-9741-2_LGWU703307-1036785WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935034_20111117_20111116-9741-2_LGWU703307-1036785WU_11.RCC.gz"
"GSM1935035","LGWU101090-1036788WU","GSM1935035","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101090","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935035/suppl/GSM1935035_20111118_20111116-9741-3_LGWU101090-1036788WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935035_20111118_20111116-9741-3_LGWU101090-1036788WU_02.RCC.gz"
"GSM1935036","LGWU102531-1036795WU","GSM1935036","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102531","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935036/suppl/GSM1935036_20111118_20111116-9741-3_LGWU102531-1036795WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935036_20111118_20111116-9741-3_LGWU102531-1036795WU_09.RCC.gz"
"GSM1935037","LGWU109203-1036787WU","GSM1935037","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109203","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935037/suppl/GSM1935037_20111118_20111116-9741-3_LGWU109203-1036787WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935037_20111118_20111116-9741-3_LGWU109203-1036787WU_01.RCC.gz"
"GSM1935038","LGWU109264-1036798WU","GSM1935038","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109264","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935038/suppl/GSM1935038_20111118_20111116-9741-3_LGWU109264-1036798WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935038_20111118_20111116-9741-3_LGWU109264-1036798WU_12.RCC.gz"
"GSM1935039","LGWU702220-1036796WU","GSM1935039","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702220","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935039/suppl/GSM1935039_20111118_20111116-9741-3_LGWU702220-1036796WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935039_20111118_20111116-9741-3_LGWU702220-1036796WU_10.RCC.gz"
"GSM1935040","LGWU702524-1036797WU","GSM1935040","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702524","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935040/suppl/GSM1935040_20111118_20111116-9741-3_LGWU702524-1036797WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935040_20111118_20111116-9741-3_LGWU702524-1036797WU_11.RCC.gz"
"GSM1935041","LGWU702794-1036789WU","GSM1935041","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702794","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935041/suppl/GSM1935041_20111118_20111116-9741-3_LGWU702794-1036789WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935041_20111118_20111116-9741-3_LGWU702794-1036789WU_03.RCC.gz"
"GSM1935042","LGWU702815-1036790WU","GSM1935042","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702815","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935042/suppl/GSM1935042_20111118_20111116-9741-3_LGWU702815-1036790WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935042_20111118_20111116-9741-3_LGWU702815-1036790WU_04.RCC.gz"
"GSM1935043","LGWU702816-1036791WU","GSM1935043","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702816","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935043/suppl/GSM1935043_20111118_20111116-9741-3_LGWU702816-1036791WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935043_20111118_20111116-9741-3_LGWU702816-1036791WU_05.RCC.gz"
"GSM1935044","LGWU702837-1036793WU","GSM1935044","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702837","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935044/suppl/GSM1935044_20111118_20111116-9741-3_LGWU702837-1036793WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935044_20111118_20111116-9741-3_LGWU702837-1036793WU_07.RCC.gz"
"GSM1935045","LGWU703380-1036792WU","GSM1935045","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703380","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935045/suppl/GSM1935045_20111118_20111116-9741-3_LGWU703380-1036792WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935045_20111118_20111116-9741-3_LGWU703380-1036792WU_06.RCC.gz"
"GSM1935046","LGWU101092-1036808WU","GSM1935046","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101092","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935046/suppl/GSM1935046_20111118_20111116-9741-4_LGWU101092-1036808WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935046_20111118_20111116-9741-4_LGWU101092-1036808WU_10.RCC.gz"
"GSM1935047","LGWU102627-1036799WU","GSM1935047","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102627","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935047/suppl/GSM1935047_20111118_20111116-9741-4_LGWU102627-1036799WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935047_20111118_20111116-9741-4_LGWU102627-1036799WU_01.RCC.gz"
"GSM1935048","LGWU102741-1036800WU","GSM1935048","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102741","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935048/suppl/GSM1935048_20111118_20111116-9741-4_LGWU102741-1036800WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935048_20111118_20111116-9741-4_LGWU102741-1036800WU_02.RCC.gz"
"GSM1935049","LGWU109055-1036810WU","GSM1935049","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109055","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935049/suppl/GSM1935049_20111118_20111116-9741-4_LGWU109055-1036810WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935049_20111118_20111116-9741-4_LGWU109055-1036810WU_12.RCC.gz"
"GSM1935050","LGWU109107-1036806WU","GSM1935050","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109107","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935050/suppl/GSM1935050_20111118_20111116-9741-4_LGWU109107-1036806WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935050_20111118_20111116-9741-4_LGWU109107-1036806WU_08.RCC.gz"
"GSM1935051","LGWU109348-1036801WU","GSM1935051","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109348","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935051/suppl/GSM1935051_20111118_20111116-9741-4_LGWU109348-1036801WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935051_20111118_20111116-9741-4_LGWU109348-1036801WU_03.RCC.gz"
"GSM1935052","LGWU201355-1036807WU","GSM1935052","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 201355","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935052/suppl/GSM1935052_20111118_20111116-9741-4_LGWU201355-1036807WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935052_20111118_20111116-9741-4_LGWU201355-1036807WU_09.RCC.gz"
"GSM1935053","LGWU203490-1036803WU","GSM1935053","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203490","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935053/suppl/GSM1935053_20111118_20111116-9741-4_LGWU203490-1036803WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935053_20111118_20111116-9741-4_LGWU203490-1036803WU_05.RCC.gz"
"GSM1935054","LGWU702697-1036802WU","GSM1935054","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702697","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935054/suppl/GSM1935054_20111118_20111116-9741-4_LGWU702697-1036802WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935054_20111118_20111116-9741-4_LGWU702697-1036802WU_04.RCC.gz"
"GSM1935055","LGWU703221-1036804WU","GSM1935055","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703221","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935055/suppl/GSM1935055_20111118_20111116-9741-4_LGWU703221-1036804WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935055_20111118_20111116-9741-4_LGWU703221-1036804WU_06.RCC.gz"
"GSM1935056","LGWU703235-1036805WU","GSM1935056","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703235","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935056/suppl/GSM1935056_20111118_20111116-9741-4_LGWU703235-1036805WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935056_20111118_20111116-9741-4_LGWU703235-1036805WU_07.RCC.gz"
"GSM1935057","LGWU703431-1036809WU","GSM1935057","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703431","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935057/suppl/GSM1935057_20111118_20111116-9741-4_LGWU703431-1036809WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935057_20111118_20111116-9741-4_LGWU703431-1036809WU_11.RCC.gz"
"GSM1935058","LGWU102480-1036813WU","GSM1935058","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102480","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935058/suppl/GSM1935058_20111118_20111117-9741-1_LGWU102480-1036813WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935058_20111118_20111117-9741-1_LGWU102480-1036813WU_02.RCC.gz"
"GSM1935059","LGWU102500-1036817WU","GSM1935059","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102500","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935059/suppl/GSM1935059_20111118_20111117-9741-1_LGWU102500-1036817WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935059_20111118_20111117-9741-1_LGWU102500-1036817WU_06.RCC.gz"
"GSM1935060","LGWU102540-1036814WU","GSM1935060","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102540","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935060/suppl/GSM1935060_20111118_20111117-9741-1_LGWU102540-1036814WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935060_20111118_20111117-9741-1_LGWU102540-1036814WU_03.RCC.gz"
"GSM1935061","LGWU107261-1036815WU","GSM1935061","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107261","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935061/suppl/GSM1935061_20111118_20111117-9741-1_LGWU107261-1036815WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935061_20111118_20111117-9741-1_LGWU107261-1036815WU_04.RCC.gz"
"GSM1935062","LGWU109336-1036812WU","GSM1935062","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109336","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935062/suppl/GSM1935062_20111118_20111117-9741-1_LGWU109336-1036812WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935062_20111118_20111117-9741-1_LGWU109336-1036812WU_01.RCC.gz"
"GSM1935063","LGWU112100-1036816WU","GSM1935063","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 112100","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935063/suppl/GSM1935063_20111118_20111117-9741-1_LGWU112100-1036816WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935063_20111118_20111117-9741-1_LGWU112100-1036816WU_05.RCC.gz"
"GSM1935064","LGWU200761-1036819WU","GSM1935064","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200761","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935064/suppl/GSM1935064_20111118_20111117-9741-1_LGWU200761-1036819WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935064_20111118_20111117-9741-1_LGWU200761-1036819WU_08.RCC.gz"
"GSM1935065","LGWU702196-1036822WU","GSM1935065","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702196","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935065/suppl/GSM1935065_20111118_20111117-9741-1_LGWU702196-1036822WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935065_20111118_20111117-9741-1_LGWU702196-1036822WU_11.RCC.gz"
"GSM1935066","LGWU702387-1036818WU","GSM1935066","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702387","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935066/suppl/GSM1935066_20111118_20111117-9741-1_LGWU702387-1036818WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935066_20111118_20111117-9741-1_LGWU702387-1036818WU_07.RCC.gz"
"GSM1935067","LGWU702465-1036820WU","GSM1935067","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702465","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935067/suppl/GSM1935067_20111118_20111117-9741-1_LGWU702465-1036820WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935067_20111118_20111117-9741-1_LGWU702465-1036820WU_09.RCC.gz"
"GSM1935068","LGWU702475-1036821WU","GSM1935068","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702475","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935068/suppl/GSM1935068_20111118_20111117-9741-1_LGWU702475-1036821WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935068_20111118_20111117-9741-1_LGWU702475-1036821WU_10.RCC.gz"
"GSM1935069","LGWU702507-1036823WU","GSM1935069","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702507","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935069/suppl/GSM1935069_20111118_20111117-9741-1_LGWU702507-1036823WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935069_20111118_20111117-9741-1_LGWU702507-1036823WU_12.RCC.gz"
"GSM1935070","LGWU102682-1036827WU","GSM1935070","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102682","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935070/suppl/GSM1935070_20111118_20111117-9741-2_LGWU102682-1036827WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935070_20111118_20111117-9741-2_LGWU102682-1036827WU_04.RCC.gz"
"GSM1935071","LGWU107365-1036834WU","GSM1935071","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107365","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935071/suppl/GSM1935071_20111118_20111117-9741-2_LGWU107365-1036834WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935071_20111118_20111117-9741-2_LGWU107365-1036834WU_11.RCC.gz"
"GSM1935072","LGWU107368-1036833WU","GSM1935072","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107368","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935072/suppl/GSM1935072_20111118_20111117-9741-2_LGWU107368-1036833WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935072_20111118_20111117-9741-2_LGWU107368-1036833WU_10.RCC.gz"
"GSM1935073","LGWU109355-1036831WU","GSM1935073","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109355","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935073/suppl/GSM1935073_20111118_20111117-9741-2_LGWU109355-1036831WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935073_20111118_20111117-9741-2_LGWU109355-1036831WU_08.RCC.gz"
"GSM1935074","LGWU702238-1036826WU","GSM1935074","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702238","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935074/suppl/GSM1935074_20111118_20111117-9741-2_LGWU702238-1036826WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935074_20111118_20111117-9741-2_LGWU702238-1036826WU_03.RCC.gz"
"GSM1935075","LGWU702255-1036829WU","GSM1935075","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702255","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935075/suppl/GSM1935075_20111118_20111117-9741-2_LGWU702255-1036829WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935075_20111118_20111117-9741-2_LGWU702255-1036829WU_06.RCC.gz"
"GSM1935076","LGWU702569-1036824WU","GSM1935076","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702569","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935076/suppl/GSM1935076_20111118_20111117-9741-2_LGWU702569-1036824WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935076_20111118_20111117-9741-2_LGWU702569-1036824WU_01.RCC.gz"
"GSM1935077","LGWU702583-1036825WU","GSM1935077","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702583","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935077/suppl/GSM1935077_20111118_20111117-9741-2_LGWU702583-1036825WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935077_20111118_20111117-9741-2_LGWU702583-1036825WU_02.RCC.gz"
"GSM1935078","LGWU702613-1036828WU","GSM1935078","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702613","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935078/suppl/GSM1935078_20111118_20111117-9741-2_LGWU702613-1036828WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935078_20111118_20111117-9741-2_LGWU702613-1036828WU_05.RCC.gz"
"GSM1935079","LGWU702623-1036830WU","GSM1935079","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702623","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935079/suppl/GSM1935079_20111118_20111117-9741-2_LGWU702623-1036830WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935079_20111118_20111117-9741-2_LGWU702623-1036830WU_07.RCC.gz"
"GSM1935080","LGWU703115-1036832WU","GSM1935080","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703115","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935080/suppl/GSM1935080_20111118_20111117-9741-2_LGWU703115-1036832WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935080_20111118_20111117-9741-2_LGWU703115-1036832WU_09.RCC.gz"
"GSM1935081","LGWU703122-1036835WU","GSM1935081","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703122","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935081/suppl/GSM1935081_20111118_20111117-9741-2_LGWU703122-1036835WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935081_20111118_20111117-9741-2_LGWU703122-1036835WU_12.RCC.gz"
"GSM1935082","LGWU102780-1036837WU","GSM1935082","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102780","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935082/suppl/GSM1935082_20111118_20111117-9741-3_LGWU102780-1036837WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935082_20111118_20111117-9741-3_LGWU102780-1036837WU_02.RCC.gz"
"GSM1935083","LGWU107358-1036840WU","GSM1935083","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107358","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935083/suppl/GSM1935083_20111118_20111117-9741-3_LGWU107358-1036840WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935083_20111118_20111117-9741-3_LGWU107358-1036840WU_05.RCC.gz"
"GSM1935084","LGWU109024-1036847WU","GSM1935084","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109024","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935084/suppl/GSM1935084_20111118_20111117-9741-3_LGWU109024-1036847WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935084_20111118_20111117-9741-3_LGWU109024-1036847WU_12.RCC.gz"
"GSM1935085","LGWU702277-1036838WU","GSM1935085","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702277","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935085/suppl/GSM1935085_20111118_20111117-9741-3_LGWU702277-1036838WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935085_20111118_20111117-9741-3_LGWU702277-1036838WU_03.RCC.gz"
"GSM1935086","LGWU702297-1036842WU","GSM1935086","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702297","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935086/suppl/GSM1935086_20111118_20111117-9741-3_LGWU702297-1036842WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935086_20111118_20111117-9741-3_LGWU702297-1036842WU_07.RCC.gz"
"GSM1935087","LGWU702714-1036843WU","GSM1935087","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702714","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935087/suppl/GSM1935087_20111118_20111117-9741-3_LGWU702714-1036843WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935087_20111118_20111117-9741-3_LGWU702714-1036843WU_08.RCC.gz"
"GSM1935088","LGWU703125-1036836WU","GSM1935088","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703125","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935088/suppl/GSM1935088_20111118_20111117-9741-3_LGWU703125-1036836WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935088_20111118_20111117-9741-3_LGWU703125-1036836WU_01.RCC.gz"
"GSM1935089","LGWU703149-1036839WU","GSM1935089","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703149","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935089/suppl/GSM1935089_20111118_20111117-9741-3_LGWU703149-1036839WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935089_20111118_20111117-9741-3_LGWU703149-1036839WU_04.RCC.gz"
"GSM1935090","LGWU703159-1036841WU","GSM1935090","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703159","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935090/suppl/GSM1935090_20111118_20111117-9741-3_LGWU703159-1036841WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935090_20111118_20111117-9741-3_LGWU703159-1036841WU_06.RCC.gz"
"GSM1935091","LGWU703180-1036844WU","GSM1935091","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703180","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935091/suppl/GSM1935091_20111118_20111117-9741-3_LGWU703180-1036844WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935091_20111118_20111117-9741-3_LGWU703180-1036844WU_09.RCC.gz"
"GSM1935092","LGWU703189-1036845WU","GSM1935092","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703189","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935092/suppl/GSM1935092_20111118_20111117-9741-3_LGWU703189-1036845WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935092_20111118_20111117-9741-3_LGWU703189-1036845WU_10.RCC.gz"
"GSM1935093","LGWU703202-1036846WU","GSM1935093","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703202","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935093/suppl/GSM1935093_20111118_20111117-9741-3_LGWU703202-1036846WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935093_20111118_20111117-9741-3_LGWU703202-1036846WU_11.RCC.gz"
"GSM1935094","LGWU107389-1036854WU","GSM1935094","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107389","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935094/suppl/GSM1935094_20111118_20111117-9741-4_LGWU107389-1036854WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935094_20111118_20111117-9741-4_LGWU107389-1036854WU_06.RCC.gz"
"GSM1935095","LGWU109123-1036848WU","GSM1935095","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109123","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935095/suppl/GSM1935095_20111118_20111117-9741-4_LGWU109123-1036848WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935095_20111118_20111117-9741-4_LGWU109123-1036848WU_01.RCC.gz"
"GSM1935096","LGWU109204-1036858WU","GSM1935096","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109204","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935096/suppl/GSM1935096_20111118_20111117-9741-4_LGWU109204-1036858WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935096_20111118_20111117-9741-4_LGWU109204-1036858WU_10.RCC.gz"
"GSM1935097","LGWU202587-1036850WU","GSM1935097","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 202587","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935097/suppl/GSM1935097_20111118_20111117-9741-4_LGWU202587-1036850WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935097_20111118_20111117-9741-4_LGWU202587-1036850WU_03.RCC.gz"
"GSM1935098","LGWU203757-1036851WU","GSM1935098","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203757","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935098/suppl/GSM1935098_20111118_20111117-9741-4_LGWU203757-1036851WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935098_20111118_20111117-9741-4_LGWU203757-1036851WU_04.RCC.gz"
"GSM1935099","LGWU702320-1036849WU","GSM1935099","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702320","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935099/suppl/GSM1935099_20111118_20111117-9741-4_LGWU702320-1036849WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935099_20111118_20111117-9741-4_LGWU702320-1036849WU_02.RCC.gz"
"GSM1935100","LGWU702330-1036853WU","GSM1935100","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702330","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935100/suppl/GSM1935100_20111118_20111117-9741-4_LGWU702330-1036853WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935100_20111118_20111117-9741-4_LGWU702330-1036853WU_05.RCC.gz"
"GSM1935101","LGWU702341-1036855WU","GSM1935101","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702341","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935101/suppl/GSM1935101_20111118_20111117-9741-4_LGWU702341-1036855WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935101_20111118_20111117-9741-4_LGWU702341-1036855WU_07.RCC.gz"
"GSM1935102","LGWU702351-1036859WU","GSM1935102","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702351","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935102/suppl/GSM1935102_20111118_20111117-9741-4_LGWU702351-1036859WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935102_20111118_20111117-9741-4_LGWU702351-1036859WU_11.RCC.gz"
"GSM1935103","LGWU702790-1036857WU","GSM1935103","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702790","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935103/suppl/GSM1935103_20111118_20111117-9741-4_LGWU702790-1036857WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935103_20111118_20111117-9741-4_LGWU702790-1036857WU_09.RCC.gz"
"GSM1935104","LGWU703283-1036856WU","GSM1935104","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703283","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935104/suppl/GSM1935104_20111118_20111117-9741-4_LGWU703283-1036856WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935104_20111118_20111117-9741-4_LGWU703283-1036856WU_08.RCC.gz"
"GSM1935105","LGWU703326-1036860WU","GSM1935105","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703326","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935105/suppl/GSM1935105_20111118_20111117-9741-4_LGWU703326-1036860WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935105_20111118_20111117-9741-4_LGWU703326-1036860WU_12.RCC.gz"
"GSM1935106","LGWU101100-1036871WU","GSM1935106","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101100","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935106/suppl/GSM1935106_20111122_20111118-9741-1_LGWU101100-1036871WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935106_20111122_20111118-9741-1_LGWU101100-1036871WU_10.RCC.gz"
"GSM1935107","LGWU101106-1036870WU","GSM1935107","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101106","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935107/suppl/GSM1935107_20111122_20111118-9741-1_LGWU101106-1036870WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935107_20111122_20111118-9741-1_LGWU101106-1036870WU_09.RCC.gz"
"GSM1935108","LGWU102018-1036869WU","GSM1935108","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102018","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935108/suppl/GSM1935108_20111122_20111118-9741-1_LGWU102018-1036869WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935108_20111122_20111118-9741-1_LGWU102018-1036869WU_08.RCC.gz"
"GSM1935109","LGWU200377-1036872WU","GSM1935109","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200377","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935109/suppl/GSM1935109_20111122_20111118-9741-1_LGWU200377-1036872WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935109_20111122_20111118-9741-1_LGWU200377-1036872WU_11.RCC.gz"
"GSM1935110","LGWU207210-1036863WU","GSM1935110","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 207210","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935110/suppl/GSM1935110_20111122_20111118-9741-1_LGWU207210-1036863WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935110_20111122_20111118-9741-1_LGWU207210-1036863WU_03.RCC.gz"
"GSM1935111","LGWU702804-1036862WU","GSM1935111","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702804","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935111/suppl/GSM1935111_20111122_20111118-9741-1_LGWU702804-1036862WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935111_20111122_20111118-9741-1_LGWU702804-1036862WU_02.RCC.gz"
"GSM1935112","LGWU702817-1036864WU","GSM1935112","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702817","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935112/suppl/GSM1935112_20111122_20111118-9741-1_LGWU702817-1036864WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935112_20111122_20111118-9741-1_LGWU702817-1036864WU_04.RCC.gz"
"GSM1935113","LGWU702820-1036867WU","GSM1935113","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702820","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935113/suppl/GSM1935113_20111122_20111118-9741-1_LGWU702820-1036867WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935113_20111122_20111118-9741-1_LGWU702820-1036867WU_06.RCC.gz"
"GSM1935114","LGWU702821-1036868WU","GSM1935114","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702821","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935114/suppl/GSM1935114_20111122_20111118-9741-1_LGWU702821-1036868WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935114_20111122_20111118-9741-1_LGWU702821-1036868WU_07.RCC.gz"
"GSM1935115","LGWU703335-1036861WU","GSM1935115","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703335","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935115/suppl/GSM1935115_20111122_20111118-9741-1_LGWU703335-1036861WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935115_20111122_20111118-9741-1_LGWU703335-1036861WU_01.RCC.gz"
"GSM1935116","LGWU703363-1036866WU","GSM1935116","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703363","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935116/suppl/GSM1935116_20111122_20111118-9741-1_LGWU703363-1036866WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935116_20111122_20111118-9741-1_LGWU703363-1036866WU_05.RCC.gz"
"GSM1935117","LGWU703432-1036873WU","GSM1935117","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703432","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935117/suppl/GSM1935117_20111122_20111118-9741-1_LGWU703432-1036873WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935117_20111122_20111118-9741-1_LGWU703432-1036873WU_12.RCC.gz"
"GSM1935118","LGWU109341-1036876WU","GSM1935118","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109341","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935118/suppl/GSM1935118_20111122_20111118-9741-2_LGWU109341-1036876WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935118_20111122_20111118-9741-2_LGWU109341-1036876WU_03.RCC.gz"
"GSM1935119","LGWU112081-1036880WU","GSM1935119","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 112081","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935119/suppl/GSM1935119_20111122_20111118-9741-2_LGWU112081-1036880WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935119_20111122_20111118-9741-2_LGWU112081-1036880WU_06.RCC.gz"
"GSM1935120","LGWU702164-1036875WU","GSM1935120","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702164","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935120/suppl/GSM1935120_20111122_20111118-9741-2_LGWU702164-1036875WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935120_20111122_20111118-9741-2_LGWU702164-1036875WU_02.RCC.gz"
"GSM1935121","LGWU702173-1036877WU","GSM1935121","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702173","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935121/suppl/GSM1935121_20111122_20111118-9741-2_LGWU702173-1036877WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935121_20111122_20111118-9741-2_LGWU702173-1036877WU_04.RCC.gz"
"GSM1935122","LGWU702252-1036882WU","GSM1935122","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702252","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935122/suppl/GSM1935122_20111122_20111118-9741-2_LGWU702252-1036882WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935122_20111122_20111118-9741-2_LGWU702252-1036882WU_08.RCC.gz"
"GSM1935123","LGWU702257-1036883WU","GSM1935123","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702257","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935123/suppl/GSM1935123_20111122_20111118-9741-2_LGWU702257-1036883WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935123_20111122_20111118-9741-2_LGWU702257-1036883WU_09.RCC.gz"
"GSM1935124","LGWU702307-1036886WU","GSM1935124","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702307","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935124/suppl/GSM1935124_20111122_20111118-9741-2_LGWU702307-1036886WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935124_20111122_20111118-9741-2_LGWU702307-1036886WU_11.RCC.gz"
"GSM1935125","LGWU702371-1036874WU","GSM1935125","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702371","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935125/suppl/GSM1935125_20111122_20111118-9741-2_LGWU702371-1036874WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935125_20111122_20111118-9741-2_LGWU702371-1036874WU_01.RCC.gz"
"GSM1935126","LGWU702408-1036878WU","GSM1935126","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702408","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935126/suppl/GSM1935126_20111122_20111118-9741-2_LGWU702408-1036878WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935126_20111122_20111118-9741-2_LGWU702408-1036878WU_05.RCC.gz"
"GSM1935127","LGWU702551-1036881WU","GSM1935127","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702551","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935127/suppl/GSM1935127_20111122_20111118-9741-2_LGWU702551-1036881WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935127_20111122_20111118-9741-2_LGWU702551-1036881WU_07.RCC.gz"
"GSM1935128","LGWU703166-1036884WU","GSM1935128","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703166","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935128/suppl/GSM1935128_20111122_20111118-9741-2_LGWU703166-1036884WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935128_20111122_20111118-9741-2_LGWU703166-1036884WU_10.RCC.gz"
"GSM1935129","LGWU703199-1036887WU","GSM1935129","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703199","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935129/suppl/GSM1935129_20111122_20111118-9741-2_LGWU703199-1036887WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935129_20111122_20111118-9741-2_LGWU703199-1036887WU_12.RCC.gz"
"GSM1935130","LGWU102507-1036907WU","GSM1935130","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102507","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935130/suppl/GSM1935130_20111122_20111122-9741-2_LGWU102507-1036907WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935130_20111122_20111122-9741-2_LGWU102507-1036907WU_05.RCC.gz"
"GSM1935131","LGWU102556-1036909WU","GSM1935131","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102556","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935131/suppl/GSM1935131_20111122_20111122-9741-2_LGWU102556-1036909WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935131_20111122_20111122-9741-2_LGWU102556-1036909WU_07.RCC.gz"
"GSM1935132","LGWU102558-1036910WU","GSM1935132","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102558","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935132/suppl/GSM1935132_20111122_20111122-9741-2_LGWU102558-1036910WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935132_20111122_20111122-9741-2_LGWU102558-1036910WU_08.RCC.gz"
"GSM1935133","LGWU102571-1036912WU","GSM1935133","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102571","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935133/suppl/GSM1935133_20111122_20111122-9741-2_LGWU102571-1036912WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935133_20111122_20111122-9741-2_LGWU102571-1036912WU_10.RCC.gz"
"GSM1935134","LGWU102608-1036908WU","GSM1935134","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102608","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935134/suppl/GSM1935134_20111122_20111122-9741-2_LGWU102608-1036908WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935134_20111122_20111122-9741-2_LGWU102608-1036908WU_06.RCC.gz"
"GSM1935135","LGWU103905-1036906WU","GSM1935135","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 103905","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935135/suppl/GSM1935135_20111122_20111122-9741-2_LGWU103905-1036906WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935135_20111122_20111122-9741-2_LGWU103905-1036906WU_04.RCC.gz"
"GSM1935136","LGWU1053341-1036913WU","GSM1935136","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 105334","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935136/suppl/GSM1935136_20111122_20111122-9741-2_LGWU1053341-1036913WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935136_20111122_20111122-9741-2_LGWU1053341-1036913WU_11.RCC.gz"
"GSM1935137","LGWU107329-1036914WU","GSM1935137","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107329","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935137/suppl/GSM1935137_20111122_20111122-9741-2_LGWU107329-1036914WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935137_20111122_20111122-9741-2_LGWU107329-1036914WU_12.RCC.gz"
"GSM1935138","LGWU109187-1036904WU","GSM1935138","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109187","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935138/suppl/GSM1935138_20111122_20111122-9741-2_LGWU109187-1036904WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935138_20111122_20111122-9741-2_LGWU109187-1036904WU_02.RCC.gz"
"GSM1935139","LGWU109385-1036905WU","GSM1935139","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109385","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935139/suppl/GSM1935139_20111122_20111122-9741-2_LGWU109385-1036905WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935139_20111122_20111122-9741-2_LGWU109385-1036905WU_03.RCC.gz"
"GSM1935140","LGWU102486-1036922WU","GSM1935140","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102486","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935140/suppl/GSM1935140_20111122_20111122-9741-3_LGWU102486-1036922WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935140_20111122_20111122-9741-3_LGWU102486-1036922WU_07.RCC.gz"
"GSM1935141","LGWU102520-1036923WU","GSM1935141","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102520","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935141/suppl/GSM1935141_20111122_20111122-9741-3_LGWU102520-1036923WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935141_20111122_20111122-9741-3_LGWU102520-1036923WU_08.RCC.gz"
"GSM1935142","LGWU102521-1036924WU","GSM1935142","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102521","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935142/suppl/GSM1935142_20111122_20111122-9741-3_LGWU102521-1036924WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935142_20111122_20111122-9741-3_LGWU102521-1036924WU_09.RCC.gz"
"GSM1935143","LGWU102534-1036925WU","GSM1935143","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102534","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935143/suppl/GSM1935143_20111122_20111122-9741-3_LGWU102534-1036925WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935143_20111122_20111122-9741-3_LGWU102534-1036925WU_10.RCC.gz"
"GSM1935144","LGWU102696-1036926WU","GSM1935144","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102696","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935144/suppl/GSM1935144_20111122_20111122-9741-3_LGWU102696-1036926WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935144_20111122_20111122-9741-3_LGWU102696-1036926WU_11.RCC.gz"
"GSM1935145","LGWU103909-1036918WU","GSM1935145","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 103909","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935145/suppl/GSM1935145_20111122_20111122-9741-3_LGWU103909-1036918WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935145_20111122_20111122-9741-3_LGWU103909-1036918WU_04.RCC.gz"
"GSM1935146","LGWU107257-1036921WU","GSM1935146","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107257","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935146/suppl/GSM1935146_20111122_20111122-9741-3_LGWU107257-1036921WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935146_20111122_20111122-9741-3_LGWU107257-1036921WU_06.RCC.gz"
"GSM1935147","LGWU109038-1036916WU","GSM1935147","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109038","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935147/suppl/GSM1935147_20111122_20111122-9741-3_LGWU109038-1036916WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935147_20111122_20111122-9741-3_LGWU109038-1036916WU_02.RCC.gz"
"GSM1935148","LGWU109060-1036917WU","GSM1935148","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109060","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935148/suppl/GSM1935148_20111122_20111122-9741-3_LGWU109060-1036917WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935148_20111122_20111122-9741-3_LGWU109060-1036917WU_03.RCC.gz"
"GSM1935149","LGWU702403-1036927WU","GSM1935149","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702403","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935149/suppl/GSM1935149_20111122_20111122-9741-3_LGWU702403-1036927WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935149_20111122_20111122-9741-3_LGWU702403-1036927WU_12.RCC.gz"
"GSM1935150","LGWU102559-1036932WU","GSM1935150","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102559","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935150/suppl/GSM1935150_20111128_20111122-9741-4_LGWU102559-1036932WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935150_20111128_20111122-9741-4_LGWU102559-1036932WU_05.RCC.gz"
"GSM1935151","LGWU102567-1036930WU","GSM1935151","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102567","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935151/suppl/GSM1935151_20111128_20111122-9741-4_LGWU102567-1036930WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935151_20111128_20111122-9741-4_LGWU102567-1036930WU_03.RCC.gz"
"GSM1935152","LGWU102606-1036928WU","GSM1935152","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102606","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935152/suppl/GSM1935152_20111128_20111122-9741-4_LGWU102606-1036928WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935152_20111128_20111122-9741-4_LGWU102606-1036928WU_01.RCC.gz"
"GSM1935153","LGWU102695-1036933WU","GSM1935153","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102695","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935153/suppl/GSM1935153_20111128_20111122-9741-4_LGWU102695-1036933WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935153_20111128_20111122-9741-4_LGWU102695-1036933WU_06.RCC.gz"
"GSM1935154","LGWU102726-1036939WU","GSM1935154","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102726","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935154/suppl/GSM1935154_20111128_20111122-9741-4_LGWU102726-1036939WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935154_20111128_20111122-9741-4_LGWU102726-1036939WU_12.RCC.gz"
"GSM1935155","LGWU200974-1036931WU","GSM1935155","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200974","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935155/suppl/GSM1935155_20111128_20111122-9741-4_LGWU200974-1036931WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935155_20111128_20111122-9741-4_LGWU200974-1036931WU_04.RCC.gz"
"GSM1935156","LGWU702178-1036929WU","GSM1935156","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702178","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935156/suppl/GSM1935156_20111128_20111122-9741-4_LGWU702178-1036929WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935156_20111128_20111122-9741-4_LGWU702178-1036929WU_02.RCC.gz"
"GSM1935157","LGWU702210-1036936WU","GSM1935157","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702210","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935157/suppl/GSM1935157_20111128_20111122-9741-4_LGWU702210-1036936WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935157_20111128_20111122-9741-4_LGWU702210-1036936WU_09.RCC.gz"
"GSM1935158","LGWU702503-1036934WU","GSM1935158","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702503","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935158/suppl/GSM1935158_20111128_20111122-9741-4_LGWU702503-1036934WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935158_20111128_20111122-9741-4_LGWU702503-1036934WU_07.RCC.gz"
"GSM1935159","LGWU702512-1036935WU","GSM1935159","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702512","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935159/suppl/GSM1935159_20111128_20111122-9741-4_LGWU702512-1036935WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935159_20111128_20111122-9741-4_LGWU702512-1036935WU_08.RCC.gz"
"GSM1935160","LGWU702519-1036937WU","GSM1935160","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702519","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935160/suppl/GSM1935160_20111128_20111122-9741-4_LGWU702519-1036937WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935160_20111128_20111122-9741-4_LGWU702519-1036937WU_10.RCC.gz"
"GSM1935161","LGWU702532-1036938WU","GSM1935161","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702532","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935161/suppl/GSM1935161_20111128_20111122-9741-4_LGWU702532-1036938WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935161_20111128_20111122-9741-4_LGWU702532-1036938WU_11.RCC.gz"
"GSM1935162","LGWU102691-1036944WU","GSM1935162","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102691","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935162/suppl/GSM1935162_20111130_20111130-9741-1_LGWU102691-1036944WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935162_20111130_20111130-9741-1_LGWU102691-1036944WU_05.RCC.gz"
"GSM1935163","LGWU102713-1036945WU","GSM1935163","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102713","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935163/suppl/GSM1935163_20111130_20111130-9741-1_LGWU102713-1036945WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935163_20111130_20111130-9741-1_LGWU102713-1036945WU_06.RCC.gz"
"GSM1935164","LGWU107334-1036950WU","GSM1935164","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107334","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935164/suppl/GSM1935164_20111130_20111130-9741-1_LGWU107334-1036950WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935164_20111130_20111130-9741-1_LGWU107334-1036950WU_11.RCC.gz"
"GSM1935165","LGWU200752-1036942WU","GSM1935165","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200752","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935165/suppl/GSM1935165_20111130_20111130-9741-1_LGWU200752-1036942WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935165_20111130_20111130-9741-1_LGWU200752-1036942WU_03.RCC.gz"
"GSM1935166","LGWU200898-1036948WU","GSM1935166","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200898","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935166/suppl/GSM1935166_20111130_20111130-9741-1_LGWU200898-1036948WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935166_20111130_20111130-9741-1_LGWU200898-1036948WU_09.RCC.gz"
"GSM1935167","LGWU203509-1036941WU","GSM1935167","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203509","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935167/suppl/GSM1935167_20111130_20111130-9741-1_LGWU203509-1036941WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935167_20111130_20111130-9741-1_LGWU203509-1036941WU_02.RCC.gz"
"GSM1935168","LGWU702250-1036947WU","GSM1935168","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702250","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935168/suppl/GSM1935168_20111130_20111130-9741-1_LGWU702250-1036947WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935168_20111130_20111130-9741-1_LGWU702250-1036947WU_08.RCC.gz"
"GSM1935169","LGWU702553-1036940WU","GSM1935169","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702553","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935169/suppl/GSM1935169_20111130_20111130-9741-1_LGWU702553-1036940WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935169_20111130_20111130-9741-1_LGWU702553-1036940WU_01.RCC.gz"
"GSM1935170","LGWU702580-1036943WU","GSM1935170","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702580","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935170/suppl/GSM1935170_20111130_20111130-9741-1_LGWU702580-1036943WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935170_20111130_20111130-9741-1_LGWU702580-1036943WU_04.RCC.gz"
"GSM1935171","LGWU702609-1036946WU","GSM1935171","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702609","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935171/suppl/GSM1935171_20111130_20111130-9741-1_LGWU702609-1036946WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935171_20111130_20111130-9741-1_LGWU702609-1036946WU_07.RCC.gz"
"GSM1935172","LGWU702634-1036949WU","GSM1935172","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702634","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935172/suppl/GSM1935172_20111130_20111130-9741-1_LGWU702634-1036949WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935172_20111130_20111130-9741-1_LGWU702634-1036949WU_10.RCC.gz"
"GSM1935173","LGWU702654-1036951WU","GSM1935173","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702654","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935173/suppl/GSM1935173_20111130_20111130-9741-1_LGWU702654-1036951WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935173_20111130_20111130-9741-1_LGWU702654-1036951WU_12.RCC.gz"
"GSM1935174","LGWU107357-1036954WU","GSM1935174","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107357","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935174/suppl/GSM1935174_20111130_20111130-9741-2_LGWU107357-1036954WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935174_20111130_20111130-9741-2_LGWU107357-1036954WU_03.RCC.gz"
"GSM1935175","LGWU107399-1036963WU","GSM1935175","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107399","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935175/suppl/GSM1935175_20111130_20111130-9741-2_LGWU107399-1036963WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935175_20111130_20111130-9741-2_LGWU107399-1036963WU_12.RCC.gz"
"GSM1935176","LGWU108944-1036956WU","GSM1935176","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108944","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935176/suppl/GSM1935176_20111130_20111130-9741-2_LGWU108944-1036956WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935176_20111130_20111130-9741-2_LGWU108944-1036956WU_05.RCC.gz"
"GSM1935177","LGWU109058-1036953WU","GSM1935177","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109058","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935177/suppl/GSM1935177_20111130_20111130-9741-2_LGWU109058-1036953WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935177_20111130_20111130-9741-2_LGWU109058-1036953WU_02.RCC.gz"
"GSM1935178","LGWU109236-1036952WU","GSM1935178","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109236","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935178/suppl/GSM1935178_20111130_20111130-9741-2_LGWU109236-1036952WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935178_20111130_20111130-9741-2_LGWU109236-1036952WU_01.RCC.gz"
"GSM1935179","LGWU200935-1036955WU","GSM1935179","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200935","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935179/suppl/GSM1935179_20111130_20111130-9741-2_LGWU200935-1036955WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935179_20111130_20111130-9741-2_LGWU200935-1036955WU_04.RCC.gz"
"GSM1935180","LGWU702302-1036957WU","GSM1935180","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702302","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935180/suppl/GSM1935180_20111130_20111130-9741-2_LGWU702302-1036957WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935180_20111130_20111130-9741-2_LGWU702302-1036957WU_06.RCC.gz"
"GSM1935181","LGWU702308-1036958WU","GSM1935181","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702308","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935181/suppl/GSM1935181_20111130_20111130-9741-2_LGWU702308-1036958WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935181_20111130_20111130-9741-2_LGWU702308-1036958WU_07.RCC.gz"
"GSM1935182","LGWU702316-1036960WU","GSM1935182","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702316","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935182/suppl/GSM1935182_20111130_20111130-9741-2_LGWU702316-1036960WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935182_20111130_20111130-9741-2_LGWU702316-1036960WU_09.RCC.gz"
"GSM1935183","LGWU702730-1036959WU","GSM1935183","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702730","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935183/suppl/GSM1935183_20111130_20111130-9741-2_LGWU702730-1036959WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935183_20111130_20111130-9741-2_LGWU702730-1036959WU_08.RCC.gz"
"GSM1935184","LGWU703214-1036961WU","GSM1935184","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703214","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935184/suppl/GSM1935184_20111130_20111130-9741-2_LGWU703214-1036961WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935184_20111130_20111130-9741-2_LGWU703214-1036961WU_10.RCC.gz"
"GSM1935185","LGWU703227-1036962WU","GSM1935185","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703227","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935185/suppl/GSM1935185_20111130_20111130-9741-2_LGWU703227-1036962WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935185_20111130_20111130-9741-2_LGWU703227-1036962WU_11.RCC.gz"
"GSM1935186","LGWU103897-1036975WU","GSM1935186","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 103897","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935186/suppl/GSM1935186_20111201_20111201-9741-1_LGWU103897-1036975WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935186_20111201_20111201-9741-1_LGWU103897-1036975WU_12.RCC.gz"
"GSM1935187","LGWU109328-1036965WU","GSM1935187","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109328","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935187/suppl/GSM1935187_20111201_20111201-9741-1_LGWU109328-1036965WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935187_20111201_20111201-9741-1_LGWU109328-1036965WU_02.RCC.gz"
"GSM1935188","LGWU109398-1036967WU","GSM1935188","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109398","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935188/suppl/GSM1935188_20111201_20111201-9741-1_LGWU109398-1036967WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935188_20111201_20111201-9741-1_LGWU109398-1036967WU_04.RCC.gz"
"GSM1935189","LGWU109402-1036969WU","GSM1935189","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109402","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935189/suppl/GSM1935189_20111201_20111201-9741-1_LGWU109402-1036969WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935189_20111201_20111201-9741-1_LGWU109402-1036969WU_06.RCC.gz"
"GSM1935190","LGWU200746-1036972WU","GSM1935190","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200746","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935190/suppl/GSM1935190_20111201_20111201-9741-1_LGWU200746-1036972WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935190_20111201_20111201-9741-1_LGWU200746-1036972WU_09.RCC.gz"
"GSM1935191","LGWU203272-1036964WU","GSM1935191","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203272","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935191/suppl/GSM1935191_20111201_20111201-9741-1_LGWU203272-1036964WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935191_20111201_20111201-9741-1_LGWU203272-1036964WU_01.RCC.gz"
"GSM1935192","LGWU205002-1036974WU","GSM1935192","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 205002","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935192/suppl/GSM1935192_20111201_20111201-9741-1_LGWU205002-1036974WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935192_20111201_20111201-9741-1_LGWU205002-1036974WU_11.RCC.gz"
"GSM1935193","LGWU702360-1036973WU","GSM1935193","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702360","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935193/suppl/GSM1935193_20111201_20111201-9741-1_LGWU702360-1036973WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935193_20111201_20111201-9741-1_LGWU702360-1036973WU_10.RCC.gz"
"GSM1935194","LGWU702795-1036971WU","GSM1935194","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702795","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935194/suppl/GSM1935194_20111201_20111201-9741-1_LGWU702795-1036971WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935194_20111201_20111201-9741-1_LGWU702795-1036971WU_08.RCC.gz"
"GSM1935195","LGWU703302-1036966WU","GSM1935195","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703302","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935195/suppl/GSM1935195_20111201_20111201-9741-1_LGWU703302-1036966WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935195_20111201_20111201-9741-1_LGWU703302-1036966WU_03.RCC.gz"
"GSM1935196","LGWU703322-1036968WU","GSM1935196","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703322","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935196/suppl/GSM1935196_20111201_20111201-9741-1_LGWU703322-1036968WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935196_20111201_20111201-9741-1_LGWU703322-1036968WU_05.RCC.gz"
"GSM1935197","LGWU703325-1036970WU","GSM1935197","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703325","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935197/suppl/GSM1935197_20111201_20111201-9741-1_LGWU703325-1036970WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935197_20111201_20111201-9741-1_LGWU703325-1036970WU_07.RCC.gz"
"GSM1935198","LGWU101098-1036980WU","GSM1935198","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101098","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935198/suppl/GSM1935198_20111201_20111201-9741-2_LGWU101098-1036980WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935198_20111201_20111201-9741-2_LGWU101098-1036980WU_04.RCC.gz"
"GSM1935199","LGWU101105-1036978WU","GSM1935199","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101105","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935199/suppl/GSM1935199_20111201_20111201-9741-2_LGWU101105-1036978WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935199_20111201_20111201-9741-2_LGWU101105-1036978WU_02.RCC.gz"
"GSM1935200","LGWU103898-1036983WU","GSM1935200","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 103898","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935200/suppl/GSM1935200_20111201_20111201-9741-2_LGWU103898-1036983WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935200_20111201_20111201-9741-2_LGWU103898-1036983WU_06.RCC.gz"
"GSM1935201","LGWU202246-1036979WU","GSM1935201","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 202246","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935201/suppl/GSM1935201_20111201_20111201-9741-2_LGWU202246-1036979WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935201_20111201_20111201-9741-2_LGWU202246-1036979WU_03.RCC.gz"
"GSM1935202","LGWU702163-1036984WU","GSM1935202","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702163","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935202/suppl/GSM1935202_20111201_20111201-9741-2_LGWU702163-1036984WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935202_20111201_20111201-9741-2_LGWU702163-1036984WU_07.RCC.gz"
"GSM1935203","LGWU702253-1036986WU","GSM1935203","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702253","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935203/suppl/GSM1935203_20111201_20111201-9741-2_LGWU702253-1036986WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935203_20111201_20111201-9741-2_LGWU702253-1036986WU_09.RCC.gz"
"GSM1935204","LGWU702264-1036988WU","GSM1935204","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702264","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935204/suppl/GSM1935204_20111201_20111201-9741-2_LGWU702264-1036988WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935204_20111201_20111201-9741-2_LGWU702264-1036988WU_11.RCC.gz"
"GSM1935205","LGWU702460-1036985WU","GSM1935205","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702460","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935205/suppl/GSM1935205_20111201_20111201-9741-2_LGWU702460-1036985WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935205_20111201_20111201-9741-2_LGWU702460-1036985WU_08.RCC.gz"
"GSM1935206","LGWU703114-1036987WU","GSM1935206","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703114","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935206/suppl/GSM1935206_20111201_20111201-9741-2_LGWU703114-1036987WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935206_20111201_20111201-9741-2_LGWU703114-1036987WU_10.RCC.gz"
"GSM1935207","LGWU703147-1036989WU","GSM1935207","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703147","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935207/suppl/GSM1935207_20111201_20111201-9741-2_LGWU703147-1036989WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935207_20111201_20111201-9741-2_LGWU703147-1036989WU_12.RCC.gz"
"GSM1935208","LGWU703383-1036977WU","GSM1935208","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703383","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935208/suppl/GSM1935208_20111201_20111201-9741-2_LGWU703383-1036977WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935208_20111201_20111201-9741-2_LGWU703383-1036977WU_01.RCC.gz"
"GSM1935209","LGWU703422-1036981WU","GSM1935209","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703422","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935209/suppl/GSM1935209_20111201_20111201-9741-2_LGWU703422-1036981WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935209_20111201_20111201-9741-2_LGWU703422-1036981WU_05.RCC.gz"
"GSM1935210","LGWU102503-1037002WU","GSM1935210","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102503","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935210/suppl/GSM1935210_20111202_20111201-9741-3_LGWU102503-1037002WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935210_20111202_20111201-9741-3_LGWU102503-1037002WU_11.RCC.gz"
"GSM1935211","LGWU107251-1037003WU","GSM1935211","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107251","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935211/suppl/GSM1935211_20111202_20111201-9741-3_LGWU107251-1037003WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935211_20111202_20111201-9741-3_LGWU107251-1037003WU_12.RCC.gz"
"GSM1935212","LGWU109013-1036991WU","GSM1935212","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109013","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935212/suppl/GSM1935212_20111202_20111201-9741-3_LGWU109013-1036991WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935212_20111202_20111201-9741-3_LGWU109013-1036991WU_02.RCC.gz"
"GSM1935213","LGWU109183-1036990WU","GSM1935213","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109183","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935213/suppl/GSM1935213_20111202_20111201-9741-3_LGWU109183-1036990WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935213_20111202_20111201-9741-3_LGWU109183-1036990WU_01.RCC.gz"
"GSM1935214","LGWU702153-1037001WU","GSM1935214","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702153","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935214/suppl/GSM1935214_20111202_20111201-9741-3_LGWU702153-1037001WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935214_20111202_20111201-9741-3_LGWU702153-1037001WU_10.RCC.gz"
"GSM1935215","LGWU702319-1036992WU","GSM1935215","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702319","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935215/suppl/GSM1935215_20111202_20111201-9741-3_LGWU702319-1036992WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935215_20111202_20111201-9741-3_LGWU702319-1036992WU_03.RCC.gz"
"GSM1935216","LGWU702349-1036994WU","GSM1935216","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702349","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935216/suppl/GSM1935216_20111202_20111201-9741-3_LGWU702349-1036994WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935216_20111202_20111201-9741-3_LGWU702349-1036994WU_05.RCC.gz"
"GSM1935217","LGWU702372-1036999WU","GSM1935217","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702372","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935217/suppl/GSM1935217_20111202_20111201-9741-3_LGWU702372-1036999WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935217_20111202_20111201-9741-3_LGWU702372-1036999WU_09.RCC.gz"
"GSM1935218","LGWU702749-1036993WU","GSM1935218","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702749","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935218/suppl/GSM1935218_20111202_20111201-9741-3_LGWU702749-1036993WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935218_20111202_20111201-9741-3_LGWU702749-1036993WU_04.RCC.gz"
"GSM1935219","LGWU703317-1036995WU","GSM1935219","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703317","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935219/suppl/GSM1935219_20111202_20111201-9741-3_LGWU703317-1036995WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935219_20111202_20111201-9741-3_LGWU703317-1036995WU_06.RCC.gz"
"GSM1935220","LGWU703381-1036996WU","GSM1935220","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703381","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935220/suppl/GSM1935220_20111202_20111201-9741-3_LGWU703381-1036996WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935220_20111202_20111201-9741-3_LGWU703381-1036996WU_07.RCC.gz"
"GSM1935221","LGWU703388-1036997WU","GSM1935221","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703388","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935221/suppl/GSM1935221_20111202_20111201-9741-3_LGWU703388-1036997WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935221_20111202_20111201-9741-3_LGWU703388-1036997WU_08.RCC.gz"
"GSM1935222","LGWU102590-1037010WU","GSM1935222","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102590","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935222/suppl/GSM1935222_20111202_20111201-9741-4_LGWU102590-1037010WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935222_20111202_20111201-9741-4_LGWU102590-1037010WU_07.RCC.gz"
"GSM1935223","LGWU102673-1037013WU","GSM1935223","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102673","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935223/suppl/GSM1935223_20111202_20111201-9741-4_LGWU102673-1037013WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935223_20111202_20111201-9741-4_LGWU102673-1037013WU_10.RCC.gz"
"GSM1935224","LGWU102700-1037005WU","GSM1935224","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102700","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935224/suppl/GSM1935224_20111202_20111201-9741-4_LGWU102700-1037005WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935224_20111202_20111201-9741-4_LGWU102700-1037005WU_02.RCC.gz"
"GSM1935225","LGWU102744-1037015WU","GSM1935225","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102744","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935225/suppl/GSM1935225_20111202_20111201-9741-4_LGWU102744-1037015WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935225_20111202_20111201-9741-4_LGWU102744-1037015WU_12.RCC.gz"
"GSM1935226","LGWU200857-1037007WU","GSM1935226","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200857","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935226/suppl/GSM1935226_20111202_20111201-9741-4_LGWU200857-1037007WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935226_20111202_20111201-9741-4_LGWU200857-1037007WU_04.RCC.gz"
"GSM1935227","LGWU702157-1037004WU","GSM1935227","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702157","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935227/suppl/GSM1935227_20111202_20111201-9741-4_LGWU702157-1037004WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935227_20111202_20111201-9741-4_LGWU702157-1037004WU_01.RCC.gz"
"GSM1935228","LGWU702184-1037009WU","GSM1935228","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702184","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935228/suppl/GSM1935228_20111202_20111201-9741-4_LGWU702184-1037009WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935228_20111202_20111201-9741-4_LGWU702184-1037009WU_06.RCC.gz"
"GSM1935229","LGWU702217-1037012WU","GSM1935229","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702217","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935229/suppl/GSM1935229_20111202_20111201-9741-4_LGWU702217-1037012WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935229_20111202_20111201-9741-4_LGWU702217-1037012WU_09.RCC.gz"
"GSM1935230","LGWU702226-1037014WU","GSM1935230","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702226","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935230/suppl/GSM1935230_20111202_20111201-9741-4_LGWU702226-1037014WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935230_20111202_20111201-9741-4_LGWU702226-1037014WU_11.RCC.gz"
"GSM1935231","LGWU702394-1037006WU","GSM1935231","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702394","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935231/suppl/GSM1935231_20111202_20111201-9741-4_LGWU702394-1037006WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935231_20111202_20111201-9741-4_LGWU702394-1037006WU_03.RCC.gz"
"GSM1935232","LGWU702428-1037008WU","GSM1935232","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702428","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935232/suppl/GSM1935232_20111202_20111201-9741-4_LGWU702428-1037008WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935232_20111202_20111201-9741-4_LGWU702428-1037008WU_05.RCC.gz"
"GSM1935233","LGWU702468-1037011WU","GSM1935233","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702468","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935233/suppl/GSM1935233_20111202_20111201-9741-4_LGWU702468-1037011WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935233_20111202_20111201-9741-4_LGWU702468-1037011WU_08.RCC.gz"
"GSM1935234","LGWU102725-1037025WU","GSM1935234","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102725","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935234/suppl/GSM1935234_20111202_20111202-9741-1_LGWU102725-1037025WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935234_20111202_20111202-9741-1_LGWU102725-1037025WU_09.RCC.gz"
"GSM1935235","LGWU702233-1037016WU","GSM1935235","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702233","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935235/suppl/GSM1935235_20111202_20111202-9741-1_LGWU702233-1037016WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935235_20111202_20111202-9741-1_LGWU702233-1037016WU_01.RCC.gz"
"GSM1935236","LGWU702234-1037017WU","GSM1935236","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702234","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935236/suppl/GSM1935236_20111202_20111202-9741-1_LGWU702234-1037017WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935236_20111202_20111202-9741-1_LGWU702234-1037017WU_02.RCC.gz"
"GSM1935237","LGWU702235-1037018WU","GSM1935237","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702235","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935237/suppl/GSM1935237_20111202_20111202-9741-1_LGWU702235-1037018WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935237_20111202_20111202-9741-1_LGWU702235-1037018WU_03.RCC.gz"
"GSM1935238","LGWU702560-1037019WU","GSM1935238","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702560","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935238/suppl/GSM1935238_20111202_20111202-9741-1_LGWU702560-1037019WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935238_20111202_20111202-9741-1_LGWU702560-1037019WU_04.RCC.gz"
"GSM1935239","LGWU702592-1037021WU","GSM1935239","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702592","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935239/suppl/GSM1935239_20111202_20111202-9741-1_LGWU702592-1037021WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935239_20111202_20111202-9741-1_LGWU702592-1037021WU_05.RCC.gz"
"GSM1935240","LGWU702620-1037022WU","GSM1935240","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702620","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935240/suppl/GSM1935240_20111202_20111202-9741-1_LGWU702620-1037022WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935240_20111202_20111202-9741-1_LGWU702620-1037022WU_06.RCC.gz"
"GSM1935241","LGWU702622-1037023WU","GSM1935241","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702622","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935241/suppl/GSM1935241_20111202_20111202-9741-1_LGWU702622-1037023WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935241_20111202_20111202-9741-1_LGWU702622-1037023WU_07.RCC.gz"
"GSM1935242","LGWU702628-1037024WU","GSM1935242","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702628","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935242/suppl/GSM1935242_20111202_20111202-9741-1_LGWU702628-1037024WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935242_20111202_20111202-9741-1_LGWU702628-1037024WU_08.RCC.gz"
"GSM1935243","LGWU702661-1037026WU","GSM1935243","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702661","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935243/suppl/GSM1935243_20111202_20111202-9741-1_LGWU702661-1037026WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935243_20111202_20111202-9741-1_LGWU702661-1037026WU_10.RCC.gz"
"GSM1935244","LGWU703131-1037027WU","GSM1935244","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703131","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935244/suppl/GSM1935244_20111202_20111202-9741-1_LGWU703131-1037027WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935244_20111202_20111202-9741-1_LGWU703131-1037027WU_11.RCC.gz"
"GSM1935245","LGWU703140-1037029WU","GSM1935245","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703140","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935245/suppl/GSM1935245_20111202_20111202-9741-1_LGWU703140-1037029WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935245_20111202_20111202-9741-1_LGWU703140-1037029WU_12.RCC.gz"
"GSM1935246","LGWU107363-1037031WU","GSM1935246","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107363","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935246/suppl/GSM1935246_20111202_20111202-9741-2_LGWU107363-1037031WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935246_20111202_20111202-9741-2_LGWU107363-1037031WU_02.RCC.gz"
"GSM1935247","LGWU702299-1037033WU","GSM1935247","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702299","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935247/suppl/GSM1935247_20111202_20111202-9741-2_LGWU702299-1037033WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935247_20111202_20111202-9741-2_LGWU702299-1037033WU_04.RCC.gz"
"GSM1935248","LGWU702723-1037037WU","GSM1935248","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702723","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935248/suppl/GSM1935248_20111202_20111202-9741-2_LGWU702723-1037037WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935248_20111202_20111202-9741-2_LGWU702723-1037037WU_07.RCC.gz"
"GSM1935249","LGWU702740-1037040WU","GSM1935249","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702740","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935249/suppl/GSM1935249_20111202_20111202-9741-2_LGWU702740-1037040WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935249_20111202_20111202-9741-2_LGWU702740-1037040WU_09.RCC.gz"
"GSM1935250","LGWU702743-1037041WU","GSM1935250","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702743","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935250/suppl/GSM1935250_20111202_20111202-9741-2_LGWU702743-1037041WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935250_20111202_20111202-9741-2_LGWU702743-1037041WU_10.RCC.gz"
"GSM1935251","LGWU703151-1037030WU","GSM1935251","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703151","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935251/suppl/GSM1935251_20111202_20111202-9741-2_LGWU703151-1037030WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935251_20111202_20111202-9741-2_LGWU703151-1037030WU_01.RCC.gz"
"GSM1935252","LGWU703158-1037032WU","GSM1935252","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703158","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935252/suppl/GSM1935252_20111202_20111202-9741-2_LGWU703158-1037032WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935252_20111202_20111202-9741-2_LGWU703158-1037032WU_03.RCC.gz"
"GSM1935253","LGWU703170-1037034WU","GSM1935253","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703170","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935253/suppl/GSM1935253_20111202_20111202-9741-2_LGWU703170-1037034WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935253_20111202_20111202-9741-2_LGWU703170-1037034WU_05.RCC.gz"
"GSM1935254","LGWU703173-1037036WU","GSM1935254","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703173","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935254/suppl/GSM1935254_20111202_20111202-9741-2_LGWU703173-1037036WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935254_20111202_20111202-9741-2_LGWU703173-1037036WU_06.RCC.gz"
"GSM1935255","LGWU703201-1037039WU","GSM1935255","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703201","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935255/suppl/GSM1935255_20111202_20111202-9741-2_LGWU703201-1037039WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935255_20111202_20111202-9741-2_LGWU703201-1037039WU_08.RCC.gz"
"GSM1935256","LGWU703216-1037042WU","GSM1935256","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703216","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935256/suppl/GSM1935256_20111202_20111202-9741-2_LGWU703216-1037042WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935256_20111202_20111202-9741-2_LGWU703216-1037042WU_11.RCC.gz"
"GSM1935257","LGWU703219-1037043WU","GSM1935257","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703219","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935257/suppl/GSM1935257_20111202_20111202-9741-2_LGWU703219-1037043WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935257_20111202_20111202-9741-2_LGWU703219-1037043WU_12.RCC.gz"
"GSM1935258","LGWU101700-1037049WU","GSM1935258","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101700","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935258/suppl/GSM1935258_20111206_20111206-9741-1_LGWU101700-1037049WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935258_20111206_20111206-9741-1_LGWU101700-1037049WU_06.RCC.gz"
"GSM1935259","LGWU103906-1037045WU","GSM1935259","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 103906","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935259/suppl/GSM1935259_20111206_20111206-9741-1_LGWU103906-1037045WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935259_20111206_20111206-9741-1_LGWU103906-1037045WU_02.RCC.gz"
"GSM1935260","LGWU109090-1037047WU","GSM1935260","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109090","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935260/suppl/GSM1935260_20111206_20111206-9741-1_LGWU109090-1037047WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935260_20111206_20111206-9741-1_LGWU109090-1037047WU_04.RCC.gz"
"GSM1935261","LGWU109134-1037044WU","GSM1935261","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109134","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935261/suppl/GSM1935261_20111206_20111206-9741-1_LGWU109134-1037044WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935261_20111206_20111206-9741-1_LGWU109134-1037044WU_01.RCC.gz"
"GSM1935262","LGWU109186-1037053WU","GSM1935262","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109186","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935262/suppl/GSM1935262_20111206_20111206-9741-1_LGWU109186-1037053WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935262_20111206_20111206-9741-1_LGWU109186-1037053WU_10.RCC.gz"
"GSM1935263","LGWU200739-1037050WU","GSM1935263","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200739","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935263/suppl/GSM1935263_20111206_20111206-9741-1_LGWU200739-1037050WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935263_20111206_20111206-9741-1_LGWU200739-1037050WU_07.RCC.gz"
"GSM1935264","LGWU702347-1037051WU","GSM1935264","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702347","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935264/suppl/GSM1935264_20111206_20111206-9741-1_LGWU702347-1037051WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935264_20111206_20111206-9741-1_LGWU702347-1037051WU_08.RCC.gz"
"GSM1935265","LGWU702763-1037048WU","GSM1935265","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702763","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935265/suppl/GSM1935265_20111206_20111206-9741-1_LGWU702763-1037048WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935265_20111206_20111206-9741-1_LGWU702763-1037048WU_05.RCC.gz"
"GSM1935266","LGWU702803-1037055WU","GSM1935266","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702803","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935266/suppl/GSM1935266_20111206_20111206-9741-1_LGWU702803-1037055WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935266_20111206_20111206-9741-1_LGWU702803-1037055WU_12.RCC.gz"
"GSM1935267","LGWU703258-1037046WU","GSM1935267","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703258","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935267/suppl/GSM1935267_20111206_20111206-9741-1_LGWU703258-1037046WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935267_20111206_20111206-9741-1_LGWU703258-1037046WU_03.RCC.gz"
"GSM1935268","LGWU703323-1037052WU","GSM1935268","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703323","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935268/suppl/GSM1935268_20111206_20111206-9741-1_LGWU703323-1037052WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935268_20111206_20111206-9741-1_LGWU703323-1037052WU_09.RCC.gz"
"GSM1935269","LGWU703334-1037054WU","GSM1935269","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703334","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935269/suppl/GSM1935269_20111206_20111206-9741-1_LGWU703334-1037054WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935269_20111206_20111206-9741-1_LGWU703334-1037054WU_11.RCC.gz"
"GSM1935270","LGWU101097-1037063WU","GSM1935270","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101097","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935270/suppl/GSM1935270_20111206_20111206-9741-2_LGWU101097-1037063WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935270_20111206_20111206-9741-2_LGWU101097-1037063WU_07.RCC.gz"
"GSM1935271","LGWU101099-1037059WU","GSM1935271","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101099","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935271/suppl/GSM1935271_20111206_20111206-9741-2_LGWU101099-1037059WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935271_20111206_20111206-9741-2_LGWU101099-1037059WU_04.RCC.gz"
"GSM1935272","LGWU102573-1037068WU","GSM1935272","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102573","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935272/suppl/GSM1935272_20111206_20111206-9741-2_LGWU102573-1037068WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935272_20111206_20111206-9741-2_LGWU102573-1037068WU_12.RCC.gz"
"GSM1935273","LGWU107254-1037064WU","GSM1935273","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107254","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935273/suppl/GSM1935273_20111206_20111206-9741-2_LGWU107254-1037064WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935273_20111206_20111206-9741-2_LGWU107254-1037064WU_08.RCC.gz"
"GSM1935274","LGWU109387-1037057WU","GSM1935274","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109387","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935274/suppl/GSM1935274_20111206_20111206-9741-2_LGWU109387-1037057WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935274_20111206_20111206-9741-2_LGWU109387-1037057WU_02.RCC.gz"
"GSM1935275","LGWU702384-1037065WU","GSM1935275","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702384","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935275/suppl/GSM1935275_20111206_20111206-9741-2_LGWU702384-1037065WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935275_20111206_20111206-9741-2_LGWU702384-1037065WU_09.RCC.gz"
"GSM1935276","LGWU702438-1037066WU","GSM1935276","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702438","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935276/suppl/GSM1935276_20111206_20111206-9741-2_LGWU702438-1037066WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935276_20111206_20111206-9741-2_LGWU702438-1037066WU_10.RCC.gz"
"GSM1935277","LGWU702471-1037067WU","GSM1935277","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702471","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935277/suppl/GSM1935277_20111206_20111206-9741-2_LGWU702471-1037067WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935277_20111206_20111206-9741-2_LGWU702471-1037067WU_11.RCC.gz"
"GSM1935278","LGWU702841-1037061WU","GSM1935278","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702841","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935278/suppl/GSM1935278_20111206_20111206-9741-2_LGWU702841-1037061WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935278_20111206_20111206-9741-2_LGWU702841-1037061WU_06.RCC.gz"
"GSM1935279","LGWU703341-1037056WU","GSM1935279","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703341","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935279/suppl/GSM1935279_20111206_20111206-9741-2_LGWU703341-1037056WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935279_20111206_20111206-9741-2_LGWU703341-1037056WU_01.RCC.gz"
"GSM1935280","LGWU703390-1037058WU","GSM1935280","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703390","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935280/suppl/GSM1935280_20111206_20111206-9741-2_LGWU703390-1037058WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935280_20111206_20111206-9741-2_LGWU703390-1037058WU_03.RCC.gz"
"GSM1935281","LGWU703416-1037060WU","GSM1935281","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703416","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935281/suppl/GSM1935281_20111206_20111206-9741-2_LGWU703416-1037060WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935281_20111206_20111206-9741-2_LGWU703416-1037060WU_05.RCC.gz"
"GSM1935282","LGWU102704-1037070WU","GSM1935282","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102704","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935282/suppl/GSM1935282_20111206_20111206-9741-3_LGWU102704-1037070WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935282_20111206_20111206-9741-3_LGWU102704-1037070WU_02.RCC.gz"
"GSM1935283","LGWU112102-1037073WU","GSM1935283","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 112102","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935283/suppl/GSM1935283_20111206_20111206-9741-3_LGWU112102-1037073WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935283_20111206_20111206-9741-3_LGWU112102-1037073WU_04.RCC.gz"
"GSM1935284","LGWU201207-1037078WU","GSM1935284","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 201207","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935284/suppl/GSM1935284_20111206_20111206-9741-3_LGWU201207-1037078WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935284_20111206_20111206-9741-3_LGWU201207-1037078WU_09.RCC.gz"
"GSM1935285","LGWU203347-1037069WU","GSM1935285","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203347","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935285/suppl/GSM1935285_20111206_20111206-9741-3_LGWU203347-1037069WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935285_20111206_20111206-9741-3_LGWU203347-1037069WU_01.RCC.gz"
"GSM1935286","LGWU702339-1037075WU","GSM1935286","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702339","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935286/suppl/GSM1935286_20111206_20111206-9741-3_LGWU702339-1037075WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935286_20111206_20111206-9741-3_LGWU702339-1037075WU_06.RCC.gz"
"GSM1935287","LGWU702434-1037079WU","GSM1935287","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702434","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935287/suppl/GSM1935287_20111206_20111206-9741-3_LGWU702434-1037079WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935287_20111206_20111206-9741-3_LGWU702434-1037079WU_10.RCC.gz"
"GSM1935288","LGWU703135-1037072WU","GSM1935288","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703135","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935288/suppl/GSM1935288_20111206_20111206-9741-3_LGWU703135-1037072WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935288_20111206_20111206-9741-3_LGWU703135-1037072WU_03.RCC.gz"
"GSM1935289","LGWU703245-1037074WU","GSM1935289","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703245","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935289/suppl/GSM1935289_20111206_20111206-9741-3_LGWU703245-1037074WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935289_20111206_20111206-9741-3_LGWU703245-1037074WU_05.RCC.gz"
"GSM1935290","LGWU703247-1037081WU","GSM1935290","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703247","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935290/suppl/GSM1935290_20111206_20111206-9741-3_LGWU703247-1037081WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935290_20111206_20111206-9741-3_LGWU703247-1037081WU_12.RCC.gz"
"GSM1935291","LGWU703370-1037077WU","GSM1935291","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703370","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935291/suppl/GSM1935291_20111206_20111206-9741-3_LGWU703370-1037077WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935291_20111206_20111206-9741-3_LGWU703370-1037077WU_08.RCC.gz"
"GSM1935292","LGWU102482-1037094WU","GSM1935292","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102482","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935292/suppl/GSM1935292_20111206_20111206-9741-4_LGWU102482-1037094WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935292_20111206_20111206-9741-4_LGWU102482-1037094WU_08.RCC.gz"
"GSM1935293","LGWU102510-1037095WU","GSM1935293","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102510","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935293/suppl/GSM1935293_20111206_20111206-9741-4_LGWU102510-1037095WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935293_20111206_20111206-9741-4_LGWU102510-1037095WU_09.RCC.gz"
"GSM1935294","LGWU102549-1037083WU","GSM1935294","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102549","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935294/suppl/GSM1935294_20111206_20111206-9741-4_LGWU102549-1037083WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935294_20111206_20111206-9741-4_LGWU102549-1037083WU_02.RCC.gz"
"GSM1935295","LGWU102610-1037084WU","GSM1935295","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102610","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935295/suppl/GSM1935295_20111206_20111206-9741-4_LGWU102610-1037084WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935295_20111206_20111206-9741-4_LGWU102610-1037084WU_03.RCC.gz"
"GSM1935296","LGWU102618-1037086WU","GSM1935296","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102618","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935296/suppl/GSM1935296_20111206_20111206-9741-4_LGWU102618-1037086WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935296_20111206_20111206-9741-4_LGWU102618-1037086WU_05.RCC.gz"
"GSM1935297","LGWU102783-1037088WU","GSM1935297","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102783","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935297/suppl/GSM1935297_20111206_20111206-9741-4_LGWU102783-1037088WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935297_20111206_20111206-9741-4_LGWU102783-1037088WU_06.RCC.gz"
"GSM1935298","LGWU1053344-1037085WU","GSM1935298","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 105334","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935298/suppl/GSM1935298_20111206_20111206-9741-4_LGWU1053344-1037085WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935298_20111206_20111206-9741-4_LGWU1053344-1037085WU_04.RCC.gz"
"GSM1935299","LGWU107300-1037098WU","GSM1935299","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107300","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935299/suppl/GSM1935299_20111206_20111206-9741-4_LGWU107300-1037098WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935299_20111206_20111206-9741-4_LGWU107300-1037098WU_12.RCC.gz"
"GSM1935300","LGWU109083-1037097WU","GSM1935300","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109083","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935300/suppl/GSM1935300_20111206_20111206-9741-4_LGWU109083-1037097WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935300_20111206_20111206-9741-4_LGWU109083-1037097WU_11.RCC.gz"
"GSM1935301","LGWU109251-1037092WU","GSM1935301","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109251","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935301/suppl/GSM1935301_20111206_20111206-9741-4_LGWU109251-1037092WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935301_20111206_20111206-9741-4_LGWU109251-1037092WU_07.RCC.gz"
"GSM1935302","LGWU700463-1037096WU","GSM1935302","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 700463","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935302/suppl/GSM1935302_20111206_20111206-9741-4_LGWU700463-1037096WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935302_20111206_20111206-9741-4_LGWU700463-1037096WU_10.RCC.gz"
"GSM1935303","LGWU703374-1037082WU","GSM1935303","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703374","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935303/suppl/GSM1935303_20111206_20111206-9741-4_LGWU703374-1037082WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935303_20111206_20111206-9741-4_LGWU703374-1037082WU_01.RCC.gz"
"GSM1935304","LGWU101995-1037107WU","GSM1935304","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101995","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935304/suppl/GSM1935304_20111208_20111207-9741-1_LGWU101995-1037107WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935304_20111208_20111207-9741-1_LGWU101995-1037107WU_07.RCC.gz"
"GSM1935305","LGWU102014-1037111WU","GSM1935305","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102014","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935305/suppl/GSM1935305_20111208_20111207-9741-1_LGWU102014-1037111WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935305_20111208_20111207-9741-1_LGWU102014-1037111WU_11.RCC.gz"
"GSM1935306","LGWU107376-1037099WU","GSM1935306","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107376","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935306/suppl/GSM1935306_20111208_20111207-9741-1_LGWU107376-1037099WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935306_20111208_20111207-9741-1_LGWU107376-1037099WU_01.RCC.gz"
"GSM1935307","LGWU108993-1037112WU","GSM1935307","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108993","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935307/suppl/GSM1935307_20111208_20111207-9741-1_LGWU108993-1037112WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935307_20111208_20111207-9741-1_LGWU108993-1037112WU_12.RCC.gz"
"GSM1935308","LGWU109075-1037100WU","GSM1935308","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109075","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935308/suppl/GSM1935308_20111208_20111207-9741-1_LGWU109075-1037100WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935308_20111208_20111207-9741-1_LGWU109075-1037100WU_02.RCC.gz"
"GSM1935309","LGWU109234-1037109WU","GSM1935309","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109234","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935309/suppl/GSM1935309_20111208_20111207-9741-1_LGWU109234-1037109WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935309_20111208_20111207-9741-1_LGWU109234-1037109WU_09.RCC.gz"
"GSM1935310","LGWU109268-1037102WU","GSM1935310","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109268","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935310/suppl/GSM1935310_20111208_20111207-9741-1_LGWU109268-1037102WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935310_20111208_20111207-9741-1_LGWU109268-1037102WU_04.RCC.gz"
"GSM1935311","LGWU702356-1037110WU","GSM1935311","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702356","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935311/suppl/GSM1935311_20111208_20111207-9741-1_LGWU702356-1037110WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935311_20111208_20111207-9741-1_LGWU702356-1037110WU_10.RCC.gz"
"GSM1935312","LGWU702397-1037105WU","GSM1935312","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702397","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935312/suppl/GSM1935312_20111208_20111207-9741-1_LGWU702397-1037105WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935312_20111208_20111207-9741-1_LGWU702397-1037105WU_05.RCC.gz"
"GSM1935313","LGWU702619-1037106WU","GSM1935313","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702619","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935313/suppl/GSM1935313_20111208_20111207-9741-1_LGWU702619-1037106WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935313_20111208_20111207-9741-1_LGWU702619-1037106WU_06.RCC.gz"
"GSM1935314","LGWU703275-1037108WU","GSM1935314","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703275","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935314/suppl/GSM1935314_20111208_20111207-9741-1_LGWU703275-1037108WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935314_20111208_20111207-9741-1_LGWU703275-1037108WU_08.RCC.gz"
"GSM1935315","LGWU102557-1037124WU","GSM1935315","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102557","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935315/suppl/GSM1935315_20111208_20111207-9741-2_LGWU102557-1037124WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935315_20111208_20111207-9741-2_LGWU102557-1037124WU_10.RCC.gz"
"GSM1935316","LGWU109282-1037123WU","GSM1935316","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109282","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935316/suppl/GSM1935316_20111208_20111207-9741-2_LGWU109282-1037123WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935316_20111208_20111207-9741-2_LGWU109282-1037123WU_09.RCC.gz"
"GSM1935317","LGWU109357-1037125WU","GSM1935317","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109357","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935317/suppl/GSM1935317_20111208_20111207-9741-2_LGWU109357-1037125WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935317_20111208_20111207-9741-2_LGWU109357-1037125WU_11.RCC.gz"
"GSM1935318","LGWU200379-1037120WU","GSM1935318","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200379","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935318/suppl/GSM1935318_20111208_20111207-9741-2_LGWU200379-1037120WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935318_20111208_20111207-9741-2_LGWU200379-1037120WU_07.RCC.gz"
"GSM1935319","LGWU203492-1037113WU","GSM1935319","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203492","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935319/suppl/GSM1935319_20111208_20111207-9741-2_LGWU203492-1037113WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935319_20111208_20111207-9741-2_LGWU203492-1037113WU_01.RCC.gz"
"GSM1935320","LGWU203918-1037117WU","GSM1935320","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203918","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935320/suppl/GSM1935320_20111208_20111207-9741-2_LGWU203918-1037117WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935320_20111208_20111207-9741-2_LGWU203918-1037117WU_05.RCC.gz"
"GSM1935321","LGWU702295-1037115WU","GSM1935321","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702295","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935321/suppl/GSM1935321_20111208_20111207-9741-2_LGWU702295-1037115WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935321_20111208_20111207-9741-2_LGWU702295-1037115WU_03.RCC.gz"
"GSM1935322","LGWU702601-1037121WU","GSM1935322","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702601","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935322/suppl/GSM1935322_20111208_20111207-9741-2_LGWU702601-1037121WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935322_20111208_20111207-9741-2_LGWU702601-1037121WU_08.RCC.gz"
"GSM1935323","LGWU702632-1037118WU","GSM1935323","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702632","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935323/suppl/GSM1935323_20111208_20111207-9741-2_LGWU702632-1037118WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935323_20111208_20111207-9741-2_LGWU702632-1037118WU_06.RCC.gz"
"GSM1935324","LGWU702796-1037126WU","GSM1935324","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702796","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935324/suppl/GSM1935324_20111208_20111207-9741-2_LGWU702796-1037126WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935324_20111208_20111207-9741-2_LGWU702796-1037126WU_12.RCC.gz"
"GSM1935325","LGWU703130-1037116WU","GSM1935325","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703130","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935325/suppl/GSM1935325_20111208_20111207-9741-2_LGWU703130-1037116WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935325_20111208_20111207-9741-2_LGWU703130-1037116WU_04.RCC.gz"
"GSM1935326","LGWU102476-1037129WU","GSM1935326","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102476","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935326/suppl/GSM1935326_20111209_20111207-9741-3_LGWU102476-1037129WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935326_20111209_20111207-9741-3_LGWU102476-1037129WU_03.RCC.gz"
"GSM1935327","LGWU102620-1037137WU","GSM1935327","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102620","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935327/suppl/GSM1935327_20111209_20111207-9741-3_LGWU102620-1037137WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935327_20111209_20111207-9741-3_LGWU102620-1037137WU_11.RCC.gz"
"GSM1935328","LGWU107248-1037127WU","GSM1935328","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107248","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935328/suppl/GSM1935328_20111209_20111207-9741-3_LGWU107248-1037127WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935328_20111209_20111207-9741-3_LGWU107248-1037127WU_01.RCC.gz"
"GSM1935329","LGWU107268-1037133WU","GSM1935329","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107268","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935329/suppl/GSM1935329_20111209_20111207-9741-3_LGWU107268-1037133WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935329_20111209_20111207-9741-3_LGWU107268-1037133WU_07.RCC.gz"
"GSM1935330","LGWU107277-1037134WU","GSM1935330","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107277","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935330/suppl/GSM1935330_20111209_20111207-9741-3_LGWU107277-1037134WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935330_20111209_20111207-9741-3_LGWU107277-1037134WU_08.RCC.gz"
"GSM1935331","LGWU200910-1037128WU","GSM1935331","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200910","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935331/suppl/GSM1935331_20111209_20111207-9741-3_LGWU200910-1037128WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935331_20111209_20111207-9741-3_LGWU200910-1037128WU_02.RCC.gz"
"GSM1935332","LGWU209168-1037136WU","GSM1935332","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 209168","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935332/suppl/GSM1935332_20111209_20111207-9741-3_LGWU209168-1037136WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935332_20111209_20111207-9741-3_LGWU209168-1037136WU_10.RCC.gz"
"GSM1935333","LGWU702181-1037138WU","GSM1935333","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702181","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935333/suppl/GSM1935333_20111209_20111207-9741-3_LGWU702181-1037138WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935333_20111209_20111207-9741-3_LGWU702181-1037138WU_12.RCC.gz"
"GSM1935334","LGWU702374-1037130WU","GSM1935334","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702374","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935334/suppl/GSM1935334_20111209_20111207-9741-3_LGWU702374-1037130WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935334_20111209_20111207-9741-3_LGWU702374-1037130WU_04.RCC.gz"
"GSM1935335","LGWU702381-1037131WU","GSM1935335","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702381","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935335/suppl/GSM1935335_20111209_20111207-9741-3_LGWU702381-1037131WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935335_20111209_20111207-9741-3_LGWU702381-1037131WU_05.RCC.gz"
"GSM1935336","LGWU702416-1037135WU","GSM1935336","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702416","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935336/suppl/GSM1935336_20111209_20111207-9741-3_LGWU702416-1037135WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935336_20111209_20111207-9741-3_LGWU702416-1037135WU_09.RCC.gz"
"GSM1935337","LGWU102546-1037139WU","GSM1935337","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102546","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935337/suppl/GSM1935337_20111209_20111207-9741-4_LGWU102546-1037139WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935337_20111209_20111207-9741-4_LGWU102546-1037139WU_01.RCC.gz"
"GSM1935338","LGWU102580-1037141WU","GSM1935338","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102580","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935338/suppl/GSM1935338_20111209_20111207-9741-4_LGWU102580-1037141WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935338_20111209_20111207-9741-4_LGWU102580-1037141WU_03.RCC.gz"
"GSM1935339","LGWU102582-1037144WU","GSM1935339","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102582","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935339/suppl/GSM1935339_20111209_20111207-9741-4_LGWU102582-1037144WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935339_20111209_20111207-9741-4_LGWU102582-1037144WU_06.RCC.gz"
"GSM1935340","LGWU102602-1037145WU","GSM1935340","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102602","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935340/suppl/GSM1935340_20111209_20111207-9741-4_LGWU102602-1037145WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935340_20111209_20111207-9741-4_LGWU102602-1037145WU_07.RCC.gz"
"GSM1935341","LGWU102743-1037149WU","GSM1935341","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102743","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935341/suppl/GSM1935341_20111209_20111207-9741-4_LGWU102743-1037149WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935341_20111209_20111207-9741-4_LGWU102743-1037149WU_11.RCC.gz"
"GSM1935342","LGWU702436-1037140WU","GSM1935342","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702436","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935342/suppl/GSM1935342_20111209_20111207-9741-4_LGWU702436-1037140WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935342_20111209_20111207-9741-4_LGWU702436-1037140WU_02.RCC.gz"
"GSM1935343","LGWU702437-1037142WU","GSM1935343","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702437","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935343/suppl/GSM1935343_20111209_20111207-9741-4_LGWU702437-1037142WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935343_20111209_20111207-9741-4_LGWU702437-1037142WU_04.RCC.gz"
"GSM1935344","LGWU702472-1037143WU","GSM1935344","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702472","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935344/suppl/GSM1935344_20111209_20111207-9741-4_LGWU702472-1037143WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935344_20111209_20111207-9741-4_LGWU702472-1037143WU_05.RCC.gz"
"GSM1935345","LGWU702544-1037146WU","GSM1935345","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702544","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935345/suppl/GSM1935345_20111209_20111207-9741-4_LGWU702544-1037146WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935345_20111209_20111207-9741-4_LGWU702544-1037146WU_08.RCC.gz"
"GSM1935346","LGWU702547-1037147WU","GSM1935346","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702547","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935346/suppl/GSM1935346_20111209_20111207-9741-4_LGWU702547-1037147WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935346_20111209_20111207-9741-4_LGWU702547-1037147WU_09.RCC.gz"
"GSM1935347","LGWU702555-1037148WU","GSM1935347","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702555","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935347/suppl/GSM1935347_20111209_20111207-9741-4_LGWU702555-1037148WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935347_20111209_20111207-9741-4_LGWU702555-1037148WU_10.RCC.gz"
"GSM1935348","LGWU702564-1037150WU","GSM1935348","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702564","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935348/suppl/GSM1935348_20111209_20111207-9741-4_LGWU702564-1037150WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935348_20111209_20111207-9741-4_LGWU702564-1037150WU_12.RCC.gz"
"GSM1935349","LGWU101701-1037158WU","GSM1935349","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101701","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935349/suppl/GSM1935349_20111209_20111208-9741-1_LGWU101701-1037158WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935349_20111209_20111208-9741-1_LGWU101701-1037158WU_08.RCC.gz"
"GSM1935350","LGWU102683-1037151WU","GSM1935350","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102683","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935350/suppl/GSM1935350_20111209_20111208-9741-1_LGWU102683-1037151WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935350_20111209_20111208-9741-1_LGWU102683-1037151WU_01.RCC.gz"
"GSM1935351","LGWU102706-1037153WU","GSM1935351","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102706","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935351/suppl/GSM1935351_20111209_20111208-9741-1_LGWU102706-1037153WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935351_20111209_20111208-9741-1_LGWU102706-1037153WU_03.RCC.gz"
"GSM1935352","LGWU108955-1037162WU","GSM1935352","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108955","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935352/suppl/GSM1935352_20111209_20111208-9741-1_LGWU108955-1037162WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935352_20111209_20111208-9741-1_LGWU108955-1037162WU_12.RCC.gz"
"GSM1935353","LGWU109095-1037161WU","GSM1935353","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109095","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935353/suppl/GSM1935353_20111209_20111208-9741-1_LGWU109095-1037161WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935353_20111209_20111208-9741-1_LGWU109095-1037161WU_11.RCC.gz"
"GSM1935354","LGWU109266-1037154WU","GSM1935354","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109266","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935354/suppl/GSM1935354_20111209_20111208-9741-1_LGWU109266-1037154WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935354_20111209_20111208-9741-1_LGWU109266-1037154WU_04.RCC.gz"
"GSM1935355","LGWU702243-1037152WU","GSM1935355","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702243","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935355/suppl/GSM1935355_20111209_20111208-9741-1_LGWU702243-1037152WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935355_20111209_20111208-9741-1_LGWU702243-1037152WU_02.RCC.gz"
"GSM1935356","LGWU702273-1037156WU","GSM1935356","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702273","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935356/suppl/GSM1935356_20111209_20111208-9741-1_LGWU702273-1037156WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935356_20111209_20111208-9741-1_LGWU702273-1037156WU_06.RCC.gz"
"GSM1935357","LGWU702286-1037159WU","GSM1935357","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702286","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935357/suppl/GSM1935357_20111209_20111208-9741-1_LGWU702286-1037159WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935357_20111209_20111208-9741-1_LGWU702286-1037159WU_09.RCC.gz"
"GSM1935358","LGWU702288-1037160WU","GSM1935358","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702288","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935358/suppl/GSM1935358_20111209_20111208-9741-1_LGWU702288-1037160WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935358_20111209_20111208-9741-1_LGWU702288-1037160WU_10.RCC.gz"
"GSM1935359","LGWU702672-1037155WU","GSM1935359","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702672","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935359/suppl/GSM1935359_20111209_20111208-9741-1_LGWU702672-1037155WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935359_20111209_20111208-9741-1_LGWU702672-1037155WU_05.RCC.gz"
"GSM1935360","LGWU703133-1037157WU","GSM1935360","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703133","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935360/suppl/GSM1935360_20111209_20111208-9741-1_LGWU703133-1037157WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935360_20111209_20111208-9741-1_LGWU703133-1037157WU_07.RCC.gz"
"GSM1935361","LGWU102782-1037166WU","GSM1935361","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102782","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935361/suppl/GSM1935361_20111209_20111208-9741-2_LGWU102782-1037166WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935361_20111209_20111208-9741-2_LGWU102782-1037166WU_04.RCC.gz"
"GSM1935362","LGWU108988-1037171WU","GSM1935362","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108988","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935362/suppl/GSM1935362_20111209_20111208-9741-2_LGWU108988-1037171WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935362_20111209_20111208-9741-2_LGWU108988-1037171WU_09.RCC.gz"
"GSM1935363","LGWU109004-1037170WU","GSM1935363","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109004","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935363/suppl/GSM1935363_20111209_20111208-9741-2_LGWU109004-1037170WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935363_20111209_20111208-9741-2_LGWU109004-1037170WU_08.RCC.gz"
"GSM1935364","LGWU109039-1037174WU","GSM1935364","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109039","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935364/suppl/GSM1935364_20111209_20111208-9741-2_LGWU109039-1037174WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935364_20111209_20111208-9741-2_LGWU109039-1037174WU_12.RCC.gz"
"GSM1935365","LGWU200745-1037164WU","GSM1935365","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200745","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935365/suppl/GSM1935365_20111209_20111208-9741-2_LGWU200745-1037164WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935365_20111209_20111208-9741-2_LGWU200745-1037164WU_02.RCC.gz"
"GSM1935366","LGWU702306-1037167WU","GSM1935366","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702306","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935366/suppl/GSM1935366_20111209_20111208-9741-2_LGWU702306-1037167WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935366_20111209_20111208-9741-2_LGWU702306-1037167WU_05.RCC.gz"
"GSM1935367","LGWU702753-1037173WU","GSM1935367","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702753","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935367/suppl/GSM1935367_20111209_20111208-9741-2_LGWU702753-1037173WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935367_20111209_20111208-9741-2_LGWU702753-1037173WU_11.RCC.gz"
"GSM1935368","LGWU702929-1037165WU","GSM1935368","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702929","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935368/suppl/GSM1935368_20111209_20111208-9741-2_LGWU702929-1037165WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935368_20111209_20111208-9741-2_LGWU702929-1037165WU_03.RCC.gz"
"GSM1935369","LGWU703164-1037163WU","GSM1935369","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703164","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935369/suppl/GSM1935369_20111209_20111208-9741-2_LGWU703164-1037163WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935369_20111209_20111208-9741-2_LGWU703164-1037163WU_01.RCC.gz"
"GSM1935370","LGWU703178-1037168WU","GSM1935370","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703178","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935370/suppl/GSM1935370_20111209_20111208-9741-2_LGWU703178-1037168WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935370_20111209_20111208-9741-2_LGWU703178-1037168WU_06.RCC.gz"
"GSM1935371","LGWU703183-1037169WU","GSM1935371","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703183","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935371/suppl/GSM1935371_20111209_20111208-9741-2_LGWU703183-1037169WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935371_20111209_20111208-9741-2_LGWU703183-1037169WU_07.RCC.gz"
"GSM1935372","LGWU703206-1037172WU","GSM1935372","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703206","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935372/suppl/GSM1935372_20111209_20111208-9741-2_LGWU703206-1037172WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935372_20111209_20111208-9741-2_LGWU703206-1037172WU_10.RCC.gz"
"GSM1935373","LGWU102502-1037191WU","GSM1935373","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102502","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935373/suppl/GSM1935373_20111209_20111208-9741-4_LGWU102502-1037191WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935373_20111209_20111208-9741-4_LGWU102502-1037191WU_05.RCC.gz"
"GSM1935374","LGWU102537-1037192WU","GSM1935374","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102537","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935374/suppl/GSM1935374_20111209_20111208-9741-4_LGWU102537-1037192WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935374_20111209_20111208-9741-4_LGWU102537-1037192WU_06.RCC.gz"
"GSM1935375","LGWU109304-1037187WU","GSM1935375","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109304","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935375/suppl/GSM1935375_20111209_20111208-9741-4_LGWU109304-1037187WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935375_20111209_20111208-9741-4_LGWU109304-1037187WU_01.RCC.gz"
"GSM1935376","LGWU109395-1037188WU","GSM1935376","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109395","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935376/suppl/GSM1935376_20111209_20111208-9741-4_LGWU109395-1037188WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935376_20111209_20111208-9741-4_LGWU109395-1037188WU_02.RCC.gz"
"GSM1935377","LGWU209167-1037197WU","GSM1935377","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 209167","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935377/suppl/GSM1935377_20111209_20111208-9741-4_LGWU209167-1037197WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935377_20111209_20111208-9741-4_LGWU209167-1037197WU_11.RCC.gz"
"GSM1935378","LGWU702219-1037193WU","GSM1935378","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702219","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935378/suppl/GSM1935378_20111209_20111208-9741-4_LGWU702219-1037193WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935378_20111209_20111208-9741-4_LGWU702219-1037193WU_07.RCC.gz"
"GSM1935379","LGWU702244-1037194WU","GSM1935379","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702244","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935379/suppl/GSM1935379_20111209_20111208-9741-4_LGWU702244-1037194WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935379_20111209_20111208-9741-4_LGWU702244-1037194WU_08.RCC.gz"
"GSM1935380","LGWU702261-1037195WU","GSM1935380","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702261","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935380/suppl/GSM1935380_20111209_20111208-9741-4_LGWU702261-1037195WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935380_20111209_20111208-9741-4_LGWU702261-1037195WU_09.RCC.gz"
"GSM1935381","LGWU702280-1037196WU","GSM1935381","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702280","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935381/suppl/GSM1935381_20111209_20111208-9741-4_LGWU702280-1037196WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935381_20111209_20111208-9741-4_LGWU702280-1037196WU_10.RCC.gz"
"GSM1935382","LGWU702843-1037189WU","GSM1935382","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702843","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935382/suppl/GSM1935382_20111209_20111208-9741-4_LGWU702843-1037189WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935382_20111209_20111208-9741-4_LGWU702843-1037189WU_03.RCC.gz"
"GSM1935383","LGWU703309-1037198WU","GSM1935383","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703309","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935383/suppl/GSM1935383_20111209_20111208-9741-4_LGWU703309-1037198WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935383_20111209_20111208-9741-4_LGWU703309-1037198WU_12.RCC.gz"
"GSM1935384","LGWU703435-1037190WU","GSM1935384","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703435","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935384/suppl/GSM1935384_20111209_20111208-9741-4_LGWU703435-1037190WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935384_20111209_20111208-9741-4_LGWU703435-1037190WU_04.RCC.gz"
"GSM1935385","LGWU101096-1037177WU","GSM1935385","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101096","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935385/suppl/GSM1935385_20111212_20111208-9741-3_LGWU101096-1037177WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935385_20111212_20111208-9741-3_LGWU101096-1037177WU_03.RCC.gz"
"GSM1935386","LGWU109128-1037176WU","GSM1935386","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109128","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935386/suppl/GSM1935386_20111212_20111208-9741-3_LGWU109128-1037176WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935386_20111212_20111208-9741-3_LGWU109128-1037176WU_02.RCC.gz"
"GSM1935387","LGWU702328-1037175WU","GSM1935387","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702328","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935387/suppl/GSM1935387_20111212_20111208-9741-3_LGWU702328-1037175WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935387_20111212_20111208-9741-3_LGWU702328-1037175WU_01.RCC.gz"
"GSM1935388","LGWU702344-1037180WU","GSM1935388","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702344","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935388/suppl/GSM1935388_20111212_20111208-9741-3_LGWU702344-1037180WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935388_20111212_20111208-9741-3_LGWU702344-1037180WU_06.RCC.gz"
"GSM1935389","LGWU702352-1037184WU","GSM1935389","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702352","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935389/suppl/GSM1935389_20111212_20111208-9741-3_LGWU702352-1037184WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935389_20111212_20111208-9741-3_LGWU702352-1037184WU_10.RCC.gz"
"GSM1935390","LGWU702785-1037182WU","GSM1935390","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702785","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935390/suppl/GSM1935390_20111212_20111208-9741-3_LGWU702785-1037182WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935390_20111212_20111208-9741-3_LGWU702785-1037182WU_08.RCC.gz"
"GSM1935391","LGWU702792-1037185WU","GSM1935391","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702792","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935391/suppl/GSM1935391_20111212_20111208-9741-3_LGWU702792-1037185WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935391_20111212_20111208-9741-3_LGWU702792-1037185WU_11.RCC.gz"
"GSM1935392","LGWU702793-1037186WU","GSM1935392","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702793","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935392/suppl/GSM1935392_20111212_20111208-9741-3_LGWU702793-1037186WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935392_20111212_20111208-9741-3_LGWU702793-1037186WU_12.RCC.gz"
"GSM1935393","LGWU703272-1037178WU","GSM1935393","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703272","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935393/suppl/GSM1935393_20111212_20111208-9741-3_LGWU703272-1037178WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935393_20111212_20111208-9741-3_LGWU703272-1037178WU_04.RCC.gz"
"GSM1935394","LGWU703273-1037179WU","GSM1935394","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703273","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935394/suppl/GSM1935394_20111212_20111208-9741-3_LGWU703273-1037179WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935394_20111212_20111208-9741-3_LGWU703273-1037179WU_05.RCC.gz"
"GSM1935395","LGWU703290-1037181WU","GSM1935395","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703290","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935395/suppl/GSM1935395_20111212_20111208-9741-3_LGWU703290-1037181WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935395_20111212_20111208-9741-3_LGWU703290-1037181WU_07.RCC.gz"
"GSM1935396","LGWU703308-1037183WU","GSM1935396","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703308","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935396/suppl/GSM1935396_20111212_20111208-9741-3_LGWU703308-1037183WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935396_20111212_20111208-9741-3_LGWU703308-1037183WU_09.RCC.gz"
"GSM1935397","LGWU102479-1037204WU","GSM1935397","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102479","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935397/suppl/GSM1935397_20111213_20111213-9741-1_LGWU102479-1037204WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935397_20111213_20111213-9741-1_LGWU102479-1037204WU_06.RCC.gz"
"GSM1935398","LGWU102508-1037208WU","GSM1935398","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102508","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935398/suppl/GSM1935398_20111213_20111213-9741-1_LGWU102508-1037208WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935398_20111213_20111213-9741-1_LGWU102508-1037208WU_10.RCC.gz"
"GSM1935399","LGWU102519-1037210WU","GSM1935399","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102519","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935399/suppl/GSM1935399_20111213_20111213-9741-1_LGWU102519-1037210WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935399_20111213_20111213-9741-1_LGWU102519-1037210WU_12.RCC.gz"
"GSM1935400","LGWU102779-1037205WU","GSM1935400","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102779","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935400/suppl/GSM1935400_20111213_20111213-9741-1_LGWU102779-1037205WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935400_20111213_20111213-9741-1_LGWU102779-1037205WU_07.RCC.gz"
"GSM1935401","LGWU107276-1037209WU","GSM1935401","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107276","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935401/suppl/GSM1935401_20111213_20111213-9741-1_LGWU107276-1037209WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935401_20111213_20111213-9741-1_LGWU107276-1037209WU_11.RCC.gz"
"GSM1935402","LGWU107307-1037203WU","GSM1935402","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107307","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935402/suppl/GSM1935402_20111213_20111213-9741-1_LGWU107307-1037203WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935402_20111213_20111213-9741-1_LGWU107307-1037203WU_05.RCC.gz"
"GSM1935403","LGWU107308-1037200WU","GSM1935403","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107308","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935403/suppl/GSM1935403_20111213_20111213-9741-1_LGWU107308-1037200WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935403_20111213_20111213-9741-1_LGWU107308-1037200WU_02.RCC.gz"
"GSM1935404","LGWU702169-1037206WU","GSM1935404","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702169","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935404/suppl/GSM1935404_20111213_20111213-9741-1_LGWU702169-1037206WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935404_20111213_20111213-9741-1_LGWU702169-1037206WU_08.RCC.gz"
"GSM1935405","LGWU703190-1037201WU","GSM1935405","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703190","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935405/suppl/GSM1935405_20111213_20111213-9741-1_LGWU703190-1037201WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935405_20111213_20111213-9741-1_LGWU703190-1037201WU_03.RCC.gz"
"GSM1935406","LGWU703271-1037202WU","GSM1935406","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703271","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935406/suppl/GSM1935406_20111213_20111213-9741-1_LGWU703271-1037202WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935406_20111213_20111213-9741-1_LGWU703271-1037202WU_04.RCC.gz"
"GSM1935407","LGWU703347-1037199WU","GSM1935407","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703347","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935407/suppl/GSM1935407_20111213_20111213-9741-1_LGWU703347-1037199WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935407_20111213_20111213-9741-1_LGWU703347-1037199WU_01.RCC.gz"
"GSM1935408","LGWU102533-1037211WU","GSM1935408","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102533","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935408/suppl/GSM1935408_20111213_20111213-9741-2_LGWU102533-1037211WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935408_20111213_20111213-9741-2_LGWU102533-1037211WU_01.RCC.gz"
"GSM1935409","LGWU102601-1037219WU","GSM1935409","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102601","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935409/suppl/GSM1935409_20111213_20111213-9741-2_LGWU102601-1037219WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935409_20111213_20111213-9741-2_LGWU102601-1037219WU_08.RCC.gz"
"GSM1935410","LGWU107303-1037214WU","GSM1935410","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107303","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935410/suppl/GSM1935410_20111213_20111213-9741-2_LGWU107303-1037214WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935410_20111213_20111213-9741-2_LGWU107303-1037214WU_04.RCC.gz"
"GSM1935411","LGWU702204-1037218WU","GSM1935411","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702204","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935411/suppl/GSM1935411_20111213_20111213-9741-2_LGWU702204-1037218WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935411_20111213_20111213-9741-2_LGWU702204-1037218WU_07.RCC.gz"
"GSM1935412","LGWU702451-1037212WU","GSM1935412","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702451","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935412/suppl/GSM1935412_20111213_20111213-9741-2_LGWU702451-1037212WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935412_20111213_20111213-9741-2_LGWU702451-1037212WU_02.RCC.gz"
"GSM1935413","LGWU702455-1037213WU","GSM1935413","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702455","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935413/suppl/GSM1935413_20111213_20111213-9741-2_LGWU702455-1037213WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935413_20111213_20111213-9741-2_LGWU702455-1037213WU_03.RCC.gz"
"GSM1935414","LGWU702469-1037215WU","GSM1935414","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702469","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935414/suppl/GSM1935414_20111213_20111213-9741-2_LGWU702469-1037215WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935414_20111213_20111213-9741-2_LGWU702469-1037215WU_05.RCC.gz"
"GSM1935415","LGWU702484-1037216WU","GSM1935415","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702484","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935415/suppl/GSM1935415_20111213_20111213-9741-2_LGWU702484-1037216WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935415_20111213_20111213-9741-2_LGWU702484-1037216WU_06.RCC.gz"
"GSM1935416","LGWU702563-1037220WU","GSM1935416","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702563","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935416/suppl/GSM1935416_20111213_20111213-9741-2_LGWU702563-1037220WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935416_20111213_20111213-9741-2_LGWU702563-1037220WU_09.RCC.gz"
"GSM1935417","LGWU702570-1037221WU","GSM1935417","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702570","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935417/suppl/GSM1935417_20111213_20111213-9741-2_LGWU702570-1037221WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935417_20111213_20111213-9741-2_LGWU702570-1037221WU_10.RCC.gz"
"GSM1935418","LGWU702573-1037222WU","GSM1935418","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702573","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935418/suppl/GSM1935418_20111213_20111213-9741-2_LGWU702573-1037222WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935418_20111213_20111213-9741-2_LGWU702573-1037222WU_11.RCC.gz"
"GSM1935419","LGWU702590-1037223WU","GSM1935419","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702590","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935419/suppl/GSM1935419_20111213_20111213-9741-2_LGWU702590-1037223WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935419_20111213_20111213-9741-2_LGWU702590-1037223WU_12.RCC.gz"
"GSM1935420","LGWU102687-1037225WU","GSM1935420","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102687","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935420/suppl/GSM1935420_20111213_20111213-9741-3_LGWU102687-1037225WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935420_20111213_20111213-9741-3_LGWU102687-1037225WU_02.RCC.gz"
"GSM1935421","LGWU102718-1037227WU","GSM1935421","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102718","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935421/suppl/GSM1935421_20111213_20111213-9741-3_LGWU102718-1037227WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935421_20111213_20111213-9741-3_LGWU102718-1037227WU_04.RCC.gz"
"GSM1935422","LGWU103573-1037224WU","GSM1935422","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 103573","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935422/suppl/GSM1935422_20111213_20111213-9741-3_LGWU103573-1037224WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935422_20111213_20111213-9741-3_LGWU103573-1037224WU_01.RCC.gz"
"GSM1935423","LGWU107335-1037228WU","GSM1935423","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107335","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935423/suppl/GSM1935423_20111213_20111213-9741-3_LGWU107335-1037228WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935423_20111213_20111213-9741-3_LGWU107335-1037228WU_05.RCC.gz"
"GSM1935424","LGWU109062-1037230WU","GSM1935424","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109062","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935424/suppl/GSM1935424_20111213_20111213-9741-3_LGWU109062-1037230WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935424_20111213_20111213-9741-3_LGWU109062-1037230WU_07.RCC.gz"
"GSM1935425","LGWU109245-1037232WU","GSM1935425","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109245","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935425/suppl/GSM1935425_20111213_20111213-9741-3_LGWU109245-1037232WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935425_20111213_20111213-9741-3_LGWU109245-1037232WU_09.RCC.gz"
"GSM1935426","LGWU200741-1037233WU","GSM1935426","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200741","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935426/suppl/GSM1935426_20111213_20111213-9741-3_LGWU200741-1037233WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935426_20111213_20111213-9741-3_LGWU200741-1037233WU_10.RCC.gz"
"GSM1935427","LGWU702268-1037229WU","GSM1935427","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702268","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935427/suppl/GSM1935427_20111213_20111213-9741-3_LGWU702268-1037229WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935427_20111213_20111213-9741-3_LGWU702268-1037229WU_06.RCC.gz"
"GSM1935428","LGWU702275-1037231WU","GSM1935428","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702275","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935428/suppl/GSM1935428_20111213_20111213-9741-3_LGWU702275-1037231WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935428_20111213_20111213-9741-3_LGWU702275-1037231WU_08.RCC.gz"
"GSM1935429","LGWU702618-1037226WU","GSM1935429","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702618","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935429/suppl/GSM1935429_20111213_20111213-9741-3_LGWU702618-1037226WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935429_20111213_20111213-9741-3_LGWU702618-1037226WU_03.RCC.gz"
"GSM1935430","LGWU702715-1037235WU","GSM1935430","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702715","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935430/suppl/GSM1935430_20111213_20111213-9741-3_LGWU702715-1037235WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935430_20111213_20111213-9741-3_LGWU702715-1037235WU_12.RCC.gz"
"GSM1935431","LGWU703154-1037234WU","GSM1935431","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703154","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935431/suppl/GSM1935431_20111213_20111213-9741-3_LGWU703154-1037234WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935431_20111213_20111213-9741-3_LGWU703154-1037234WU_11.RCC.gz"
"GSM1935432","LGWU109019-1037244WU","GSM1935432","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109019","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935432/suppl/GSM1935432_20111213_20111213-9741-4_LGWU109019-1037244WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935432_20111213_20111213-9741-4_LGWU109019-1037244WU_09.RCC.gz"
"GSM1935433","LGWU109021-1037245WU","GSM1935433","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109021","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935433/suppl/GSM1935433_20111213_20111213-9741-4_LGWU109021-1037245WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935433_20111213_20111213-9741-4_LGWU109021-1037245WU_10.RCC.gz"
"GSM1935434","LGWU109366-1037246WU","GSM1935434","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109366","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935434/suppl/GSM1935434_20111213_20111213-9741-4_LGWU109366-1037246WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935434_20111213_20111213-9741-4_LGWU109366-1037246WU_11.RCC.gz"
"GSM1935435","LGWU200925-1037243WU","GSM1935435","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200925","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935435/suppl/GSM1935435_20111213_20111213-9741-4_LGWU200925-1037243WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935435_20111213_20111213-9741-4_LGWU200925-1037243WU_08.RCC.gz"
"GSM1935436","LGWU702719-1037237WU","GSM1935436","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702719","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935436/suppl/GSM1935436_20111213_20111213-9741-4_LGWU702719-1037237WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935436_20111213_20111213-9741-4_LGWU702719-1037237WU_02.RCC.gz"
"GSM1935437","LGWU702722-1037238WU","GSM1935437","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702722","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935437/suppl/GSM1935437_20111213_20111213-9741-4_LGWU702722-1037238WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935437_20111213_20111213-9741-4_LGWU702722-1037238WU_03.RCC.gz"
"GSM1935438","LGWU702732-1037241WU","GSM1935438","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702732","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935438/suppl/GSM1935438_20111213_20111213-9741-4_LGWU702732-1037241WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935438_20111213_20111213-9741-4_LGWU702732-1037241WU_06.RCC.gz"
"GSM1935439","LGWU703168-1037236WU","GSM1935439","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703168","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935439/suppl/GSM1935439_20111213_20111213-9741-4_LGWU703168-1037236WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935439_20111213_20111213-9741-4_LGWU703168-1037236WU_01.RCC.gz"
"GSM1935440","LGWU703177-1037239WU","GSM1935440","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703177","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935440/suppl/GSM1935440_20111213_20111213-9741-4_LGWU703177-1037239WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935440_20111213_20111213-9741-4_LGWU703177-1037239WU_04.RCC.gz"
"GSM1935441","LGWU703182-1037240WU","GSM1935441","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703182","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935441/suppl/GSM1935441_20111213_20111213-9741-4_LGWU703182-1037240WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935441_20111213_20111213-9741-4_LGWU703182-1037240WU_05.RCC.gz"
"GSM1935442","LGWU703192-1037242WU","GSM1935442","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703192","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935442/suppl/GSM1935442_20111213_20111213-9741-4_LGWU703192-1037242WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935442_20111213_20111213-9741-4_LGWU703192-1037242WU_07.RCC.gz"
"GSM1935443","LGWU703248-1037247WU","GSM1935443","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703248","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935443/suppl/GSM1935443_20111213_20111213-9741-4_LGWU703248-1037247WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935443_20111213_20111213-9741-4_LGWU703248-1037247WU_12.RCC.gz"
"GSM1935444","LGWU109082-1037248WU","GSM1935444","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109082","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935444/suppl/GSM1935444_20111215_20111214-9741-1_LGWU109082-1037248WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935444_20111215_20111214-9741-1_LGWU109082-1037248WU_01.RCC.gz"
"GSM1935445","LGWU109195-1037250WU","GSM1935445","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109195","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935445/suppl/GSM1935445_20111215_20111214-9741-1_LGWU109195-1037250WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935445_20111215_20111214-9741-1_LGWU109195-1037250WU_03.RCC.gz"
"GSM1935446","LGWU201327-1037253WU","GSM1935446","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 201327","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935446/suppl/GSM1935446_20111215_20111214-9741-1_LGWU201327-1037253WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935446_20111215_20111214-9741-1_LGWU201327-1037253WU_06.RCC.gz"
"GSM1935447","LGWU702342-1037249WU","GSM1935447","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702342","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935447/suppl/GSM1935447_20111215_20111214-9741-1_LGWU702342-1037249WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935447_20111215_20111214-9741-1_LGWU702342-1037249WU_02.RCC.gz"
"GSM1935448","LGWU702357-1037254WU","GSM1935448","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702357","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935448/suppl/GSM1935448_20111215_20111214-9741-1_LGWU702357-1037254WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935448_20111215_20111214-9741-1_LGWU702357-1037254WU_07.RCC.gz"
"GSM1935449","LGWU702799-1037255WU","GSM1935449","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702799","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935449/suppl/GSM1935449_20111215_20111214-9741-1_LGWU702799-1037255WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935449_20111215_20111214-9741-1_LGWU702799-1037255WU_08.RCC.gz"
"GSM1935450","LGWU702810-1037257WU","GSM1935450","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702810","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935450/suppl/GSM1935450_20111215_20111214-9741-1_LGWU702810-1037257WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935450_20111215_20111214-9741-1_LGWU702810-1037257WU_10.RCC.gz"
"GSM1935451","LGWU703298-1037251WU","GSM1935451","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703298","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935451/suppl/GSM1935451_20111215_20111214-9741-1_LGWU703298-1037251WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935451_20111215_20111214-9741-1_LGWU703298-1037251WU_04.RCC.gz"
"GSM1935452","LGWU703313-1037252WU","GSM1935452","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703313","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935452/suppl/GSM1935452_20111215_20111214-9741-1_LGWU703313-1037252WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935452_20111215_20111214-9741-1_LGWU703313-1037252WU_05.RCC.gz"
"GSM1935453","LGWU703346-1037256WU","GSM1935453","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703346","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935453/suppl/GSM1935453_20111215_20111214-9741-1_LGWU703346-1037256WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935453_20111215_20111214-9741-1_LGWU703346-1037256WU_09.RCC.gz"
"GSM1935454","LGWU703352-1037258WU","GSM1935454","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703352","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935454/suppl/GSM1935454_20111215_20111214-9741-1_LGWU703352-1037258WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935454_20111215_20111214-9741-1_LGWU703352-1037258WU_11.RCC.gz"
"GSM1935455","LGWU703360-1037259WU","GSM1935455","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703360","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935455/suppl/GSM1935455_20111215_20111214-9741-1_LGWU703360-1037259WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935455_20111215_20111214-9741-1_LGWU703360-1037259WU_12.RCC.gz"
"GSM1935456","LGWU101094-1037261WU","GSM1935456","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101094","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935456/suppl/GSM1935456_20111215_20111214-9741-2_LGWU101094-1037261WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935456_20111215_20111214-9741-2_LGWU101094-1037261WU_02.RCC.gz"
"GSM1935457","LGWU102564-1037262WU","GSM1935457","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102564","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935457/suppl/GSM1935457_20111215_20111214-9741-2_LGWU102564-1037262WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935457_20111215_20111214-9741-2_LGWU102564-1037262WU_03.RCC.gz"
"GSM1935458","LGWU107384-1037271WU","GSM1935458","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107384","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935458/suppl/GSM1935458_20111215_20111214-9741-2_LGWU107384-1037271WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935458_20111215_20111214-9741-2_LGWU107384-1037271WU_10.RCC.gz"
"GSM1935459","LGWU109287-1037265WU","GSM1935459","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109287","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935459/suppl/GSM1935459_20111215_20111214-9741-2_LGWU109287-1037265WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935459_20111215_20111214-9741-2_LGWU109287-1037265WU_06.RCC.gz"
"GSM1935460","LGWU209163-1037263WU","GSM1935460","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 209163","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935460/suppl/GSM1935460_20111215_20111214-9741-2_LGWU209163-1037263WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935460_20111215_20111214-9741-2_LGWU209163-1037263WU_04.RCC.gz"
"GSM1935461","LGWU702546-1037264WU","GSM1935461","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702546","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935461/suppl/GSM1935461_20111215_20111214-9741-2_LGWU702546-1037264WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935461_20111215_20111214-9741-2_LGWU702546-1037264WU_05.RCC.gz"
"GSM1935462","LGWU702673-1037268WU","GSM1935462","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702673","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935462/suppl/GSM1935462_20111215_20111214-9741-2_LGWU702673-1037268WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935462_20111215_20111214-9741-2_LGWU702673-1037268WU_08.RCC.gz"
"GSM1935463","LGWU702738-1037270WU","GSM1935463","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702738","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935463/suppl/GSM1935463_20111215_20111214-9741-2_LGWU702738-1037270WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935463_20111215_20111214-9741-2_LGWU702738-1037270WU_09.RCC.gz"
"GSM1935464","LGWU703116-1037266WU","GSM1935464","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703116","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935464/suppl/GSM1935464_20111215_20111214-9741-2_LGWU703116-1037266WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935464_20111215_20111214-9741-2_LGWU703116-1037266WU_07.RCC.gz"
"GSM1935465","LGWU703242-1037272WU","GSM1935465","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703242","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935465/suppl/GSM1935465_20111215_20111214-9741-2_LGWU703242-1037272WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935465_20111215_20111214-9741-2_LGWU703242-1037272WU_11.RCC.gz"
"GSM1935466","LGWU703264-1037273WU","GSM1935466","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703264","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935466/suppl/GSM1935466_20111215_20111214-9741-2_LGWU703264-1037273WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935466_20111215_20111214-9741-2_LGWU703264-1037273WU_12.RCC.gz"
"GSM1935467","LGWU703364-1037260WU","GSM1935467","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703364","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935467/suppl/GSM1935467_20111215_20111214-9741-2_LGWU703364-1037260WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935467_20111215_20111214-9741-2_LGWU703364-1037260WU_01.RCC.gz"
"GSM1935468","LGWU102003-1037278WU","GSM1935468","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102003","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935468/suppl/GSM1935468_20111216_20111214-9741-3_LGWU102003-1037278WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935468_20111216_20111214-9741-3_LGWU102003-1037278WU_05.RCC.gz"
"GSM1935469","LGWU102009-1037277WU","GSM1935469","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102009","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935469/suppl/GSM1935469_20111216_20111214-9741-3_LGWU102009-1037277WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935469_20111216_20111214-9741-3_LGWU102009-1037277WU_04.RCC.gz"
"GSM1935470","LGWU102542-1037281WU","GSM1935470","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102542","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935470/suppl/GSM1935470_20111216_20111214-9741-3_LGWU102542-1037281WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935470_20111216_20111214-9741-3_LGWU102542-1037281WU_08.RCC.gz"
"GSM1935471","LGWU102545-1037283WU","GSM1935471","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102545","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935471/suppl/GSM1935471_20111216_20111214-9741-3_LGWU102545-1037283WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935471_20111216_20111214-9741-3_LGWU102545-1037283WU_09.RCC.gz"
"GSM1935472","LGWU1054011-1037287WU","GSM1935472","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 105401","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935472/suppl/GSM1935472_20111216_20111214-9741-3_LGWU1054011-1037287WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935472_20111216_20111214-9741-3_LGWU1054011-1037287WU_10.RCC.gz"
"GSM1935473","LGWU1054012-1037288WU","GSM1935473","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 105401","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935473/suppl/GSM1935473_20111216_20111214-9741-3_LGWU1054012-1037288WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935473_20111216_20111214-9741-3_LGWU1054012-1037288WU_11.RCC.gz"
"GSM1935474","LGWU109056-1037280WU","GSM1935474","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109056","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935474/suppl/GSM1935474_20111216_20111214-9741-3_LGWU109056-1037280WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935474_20111216_20111214-9741-3_LGWU109056-1037280WU_07.RCC.gz"
"GSM1935475","LGWU109313-1037276WU","GSM1935475","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109313","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935475/suppl/GSM1935475_20111216_20111214-9741-3_LGWU109313-1037276WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935475_20111216_20111214-9741-3_LGWU109313-1037276WU_03.RCC.gz"
"GSM1935476","LGWU200378-1037279WU","GSM1935476","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200378","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935476/suppl/GSM1935476_20111216_20111214-9741-3_LGWU200378-1037279WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935476_20111216_20111214-9741-3_LGWU200378-1037279WU_06.RCC.gz"
"GSM1935477","LGWU703318-1037274WU","GSM1935477","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703318","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935477/suppl/GSM1935477_20111216_20111214-9741-3_LGWU703318-1037274WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935477_20111216_20111214-9741-3_LGWU703318-1037274WU_01.RCC.gz"
"GSM1935478","LGWU703373-1037275WU","GSM1935478","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703373","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935478/suppl/GSM1935478_20111216_20111214-9741-3_LGWU703373-1037275WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935478_20111216_20111214-9741-3_LGWU703373-1037275WU_02.RCC.gz"
"GSM1935479","LGWU102466-1037294WU","GSM1935479","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102466","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935479/suppl/GSM1935479_20111216_20111214-9741-4_LGWU102466-1037294WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935479_20111216_20111214-9741-4_LGWU102466-1037294WU_03.RCC.gz"
"GSM1935480","LGWU102469-1037293WU","GSM1935480","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102469","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935480/suppl/GSM1935480_20111216_20111214-9741-4_LGWU102469-1037293WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935480_20111216_20111214-9741-4_LGWU102469-1037293WU_02.RCC.gz"
"GSM1935481","LGWU102552-1037296WU","GSM1935481","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102552","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935481/suppl/GSM1935481_20111216_20111214-9741-4_LGWU102552-1037296WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935481_20111216_20111214-9741-4_LGWU102552-1037296WU_05.RCC.gz"
"GSM1935482","LGWU102617-1037295WU","GSM1935482","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102617","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935482/suppl/GSM1935482_20111216_20111214-9741-4_LGWU102617-1037295WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935482_20111216_20111214-9741-4_LGWU102617-1037295WU_04.RCC.gz"
"GSM1935483","LGWU1054018-1037298WU","GSM1935483","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 105401","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935483/suppl/GSM1935483_20111216_20111214-9741-4_LGWU1054018-1037298WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935483_20111216_20111214-9741-4_LGWU1054018-1037298WU_07.RCC.gz"
"GSM1935484","LGWU109097-1037300WU","GSM1935484","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109097","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935484/suppl/GSM1935484_20111216_20111214-9741-4_LGWU109097-1037300WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935484_20111216_20111214-9741-4_LGWU109097-1037300WU_09.RCC.gz"
"GSM1935485","LGWU109227-1037299WU","GSM1935485","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109227","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935485/suppl/GSM1935485_20111216_20111214-9741-4_LGWU109227-1037299WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935485_20111216_20111214-9741-4_LGWU109227-1037299WU_08.RCC.gz"
"GSM1935486","LGWU702156-1037303WU","GSM1935486","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702156","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935486/suppl/GSM1935486_20111216_20111214-9741-4_LGWU702156-1037303WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935486_20111216_20111214-9741-4_LGWU702156-1037303WU_11.RCC.gz"
"GSM1935487","LGWU702160-1037304WU","GSM1935487","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702160","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935487/suppl/GSM1935487_20111216_20111214-9741-4_LGWU702160-1037304WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935487_20111216_20111214-9741-4_LGWU702160-1037304WU_12.RCC.gz"
"GSM1935488","LGWU703541-1037291WU","GSM1935488","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703541","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935488/suppl/GSM1935488_20111216_20111214-9741-4_LGWU703541-1037291WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935488_20111216_20111214-9741-4_LGWU703541-1037291WU_01.RCC.gz"
"GSM1935489","LGWU101981-1037306WU","GSM1935489","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101981","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935489/suppl/GSM1935489_20111216_20111215-9741-1_LGWU101981-1037306WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935489_20111216_20111215-9741-1_LGWU101981-1037306WU_02.RCC.gz"
"GSM1935490","LGWU102781-1037307WU","GSM1935490","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102781","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935490/suppl/GSM1935490_20111216_20111215-9741-1_LGWU102781-1037307WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935490_20111216_20111215-9741-1_LGWU102781-1037307WU_03.RCC.gz"
"GSM1935491","LGWU702189-1037310WU","GSM1935491","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702189","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935491/suppl/GSM1935491_20111216_20111215-9741-1_LGWU702189-1037310WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935491_20111216_20111215-9741-1_LGWU702189-1037310WU_06.RCC.gz"
"GSM1935492","LGWU702192-1037311WU","GSM1935492","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702192","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935492/suppl/GSM1935492_20111216_20111215-9741-1_LGWU702192-1037311WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935492_20111216_20111215-9741-1_LGWU702192-1037311WU_07.RCC.gz"
"GSM1935493","LGWU702223-1037315WU","GSM1935493","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702223","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935493/suppl/GSM1935493_20111216_20111215-9741-1_LGWU702223-1037315WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935493_20111216_20111215-9741-1_LGWU702223-1037315WU_10.RCC.gz"
"GSM1935494","LGWU702389-1037305WU","GSM1935494","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702389","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935494/suppl/GSM1935494_20111216_20111215-9741-1_LGWU702389-1037305WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935494_20111216_20111215-9741-1_LGWU702389-1037305WU_01.RCC.gz"
"GSM1935495","LGWU702454-1037308WU","GSM1935495","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702454","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935495/suppl/GSM1935495_20111216_20111215-9741-1_LGWU702454-1037308WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935495_20111216_20111215-9741-1_LGWU702454-1037308WU_04.RCC.gz"
"GSM1935496","LGWU702456-1037309WU","GSM1935496","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702456","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935496/suppl/GSM1935496_20111216_20111215-9741-1_LGWU702456-1037309WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935496_20111216_20111215-9741-1_LGWU702456-1037309WU_05.RCC.gz"
"GSM1935497","LGWU702514-1037312WU","GSM1935497","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702514","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935497/suppl/GSM1935497_20111216_20111215-9741-1_LGWU702514-1037312WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935497_20111216_20111215-9741-1_LGWU702514-1037312WU_08.RCC.gz"
"GSM1935498","LGWU702523-1037313WU","GSM1935498","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702523","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935498/suppl/GSM1935498_20111216_20111215-9741-1_LGWU702523-1037313WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935498_20111216_20111215-9741-1_LGWU702523-1037313WU_09.RCC.gz"
"GSM1935499","LGWU702540-1037316WU","GSM1935499","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702540","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935499/suppl/GSM1935499_20111216_20111215-9741-1_LGWU702540-1037316WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935499_20111216_20111215-9741-1_LGWU702540-1037316WU_11.RCC.gz"
"GSM1935500","LGWU702545-1037317WU","GSM1935500","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702545","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935500/suppl/GSM1935500_20111216_20111215-9741-1_LGWU702545-1037317WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935500_20111216_20111215-9741-1_LGWU702545-1037317WU_12.RCC.gz"
"GSM1935501","LGWU102679-1037320WU","GSM1935501","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102679","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935501/suppl/GSM1935501_20111216_20111215-9741-2_LGWU102679-1037320WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935501_20111216_20111215-9741-2_LGWU102679-1037320WU_03.RCC.gz"
"GSM1935502","LGWU102686-1037323WU","GSM1935502","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102686","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935502/suppl/GSM1935502_20111216_20111215-9741-2_LGWU102686-1037323WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935502_20111216_20111215-9741-2_LGWU102686-1037323WU_06.RCC.gz"
"GSM1935503","LGWU103903-1037325WU","GSM1935503","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 103903","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935503/suppl/GSM1935503_20111216_20111215-9741-2_LGWU103903-1037325WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935503_20111216_20111215-9741-2_LGWU103903-1037325WU_08.RCC.gz"
"GSM1935504","LGWU103911-1037324WU","GSM1935504","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 103911","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935504/suppl/GSM1935504_20111216_20111215-9741-2_LGWU103911-1037324WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935504_20111216_20111215-9741-2_LGWU103911-1037324WU_07.RCC.gz"
"GSM1935505","LGWU202350-1037322WU","GSM1935505","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 202350","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935505/suppl/GSM1935505_20111216_20111215-9741-2_LGWU202350-1037322WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935505_20111216_20111215-9741-2_LGWU202350-1037322WU_05.RCC.gz"
"GSM1935506","LGWU702225-1037318WU","GSM1935506","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702225","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935506/suppl/GSM1935506_20111216_20111215-9741-2_LGWU702225-1037318WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935506_20111216_20111215-9741-2_LGWU702225-1037318WU_01.RCC.gz"
"GSM1935507","LGWU702239-1037319WU","GSM1935507","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702239","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935507/suppl/GSM1935507_20111216_20111215-9741-2_LGWU702239-1037319WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935507_20111216_20111215-9741-2_LGWU702239-1037319WU_02.RCC.gz"
"GSM1935508","LGWU702269-1037328WU","GSM1935508","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702269","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935508/suppl/GSM1935508_20111216_20111215-9741-2_LGWU702269-1037328WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935508_20111216_20111215-9741-2_LGWU702269-1037328WU_11.RCC.gz"
"GSM1935509","LGWU702594-1037321WU","GSM1935509","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702594","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935509/suppl/GSM1935509_20111216_20111215-9741-2_LGWU702594-1037321WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935509_20111216_20111215-9741-2_LGWU702594-1037321WU_04.RCC.gz"
"GSM1935510","LGWU702629-1037326WU","GSM1935510","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702629","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935510/suppl/GSM1935510_20111216_20111215-9741-2_LGWU702629-1037326WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935510_20111216_20111215-9741-2_LGWU702629-1037326WU_09.RCC.gz"
"GSM1935511","LGWU703127-1037327WU","GSM1935511","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703127","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935511/suppl/GSM1935511_20111216_20111215-9741-2_LGWU703127-1037327WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935511_20111216_20111215-9741-2_LGWU703127-1037327WU_10.RCC.gz"
"GSM1935512","LGWU703132-1037329WU","GSM1935512","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703132","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935512/suppl/GSM1935512_20111216_20111215-9741-2_LGWU703132-1037329WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935512_20111216_20111215-9741-2_LGWU703132-1037329WU_12.RCC.gz"
"GSM1935513","LGWU109022-1037344WU","GSM1935513","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109022","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935513/suppl/GSM1935513_20111216_20111215-9741-4_LGWU109022-1037344WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935513_20111216_20111215-9741-4_LGWU109022-1037344WU_03.RCC.gz"
"GSM1935514","LGWU109131-1037347WU","GSM1935514","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109131","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935514/suppl/GSM1935514_20111216_20111215-9741-4_LGWU109131-1037347WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935514_20111216_20111215-9741-4_LGWU109131-1037347WU_06.RCC.gz"
"GSM1935515","LGWU702323-1037345WU","GSM1935515","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702323","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935515/suppl/GSM1935515_20111216_20111215-9741-4_LGWU702323-1037345WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935515_20111216_20111215-9741-4_LGWU702323-1037345WU_04.RCC.gz"
"GSM1935516","LGWU702340-1037348WU","GSM1935516","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702340","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935516/suppl/GSM1935516_20111216_20111215-9741-4_LGWU702340-1037348WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935516_20111216_20111215-9741-4_LGWU702340-1037348WU_07.RCC.gz"
"GSM1935517","LGWU702345-1037349WU","GSM1935517","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702345","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935517/suppl/GSM1935517_20111216_20111215-9741-4_LGWU702345-1037349WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935517_20111216_20111215-9741-4_LGWU702345-1037349WU_08.RCC.gz"
"GSM1935518","LGWU702350-1037351WU","GSM1935518","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702350","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935518/suppl/GSM1935518_20111216_20111215-9741-4_LGWU702350-1037351WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935518_20111216_20111215-9741-4_LGWU702350-1037351WU_10.RCC.gz"
"GSM1935519","LGWU702354-1037352WU","GSM1935519","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702354","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935519/suppl/GSM1935519_20111216_20111215-9741-4_LGWU702354-1037352WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935519_20111216_20111215-9741-4_LGWU702354-1037352WU_11.RCC.gz"
"GSM1935520","LGWU703222-1037342WU","GSM1935520","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703222","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935520/suppl/GSM1935520_20111216_20111215-9741-4_LGWU703222-1037342WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935520_20111216_20111215-9741-4_LGWU703222-1037342WU_01.RCC.gz"
"GSM1935521","LGWU703232-1037343WU","GSM1935521","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703232","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935521/suppl/GSM1935521_20111216_20111215-9741-4_LGWU703232-1037343WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935521_20111216_20111215-9741-4_LGWU703232-1037343WU_02.RCC.gz"
"GSM1935522","LGWU703239-1037346WU","GSM1935522","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703239","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935522/suppl/GSM1935522_20111216_20111215-9741-4_LGWU703239-1037346WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935522_20111216_20111215-9741-4_LGWU703239-1037346WU_05.RCC.gz"
"GSM1935523","LGWU703310-1037350WU","GSM1935523","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703310","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935523/suppl/GSM1935523_20111216_20111215-9741-4_LGWU703310-1037350WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935523_20111216_20111215-9741-4_LGWU703310-1037350WU_09.RCC.gz"
"GSM1935524","LGWU703328-1037353WU","GSM1935524","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703328","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935524/suppl/GSM1935524_20111216_20111215-9741-4_LGWU703328-1037353WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935524_20111216_20111215-9741-4_LGWU703328-1037353WU_12.RCC.gz"
"GSM1935525","LGWU102738-1037335WU","GSM1935525","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102738","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935525/suppl/GSM1935525_20111219_20111215-9741-3_LGWU102738-1037335WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935525_20111219_20111215-9741-3_LGWU102738-1037335WU_06.RCC.gz"
"GSM1935526","LGWU108990-1037331WU","GSM1935526","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108990","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935526/suppl/GSM1935526_20111219_20111215-9741-3_LGWU108990-1037331WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935526_20111219_20111215-9741-3_LGWU108990-1037331WU_02.RCC.gz"
"GSM1935527","LGWU109015-1037336WU","GSM1935527","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109015","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935527/suppl/GSM1935527_20111219_20111215-9741-3_LGWU109015-1037336WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935527_20111219_20111215-9741-3_LGWU109015-1037336WU_07.RCC.gz"
"GSM1935528","LGWU109403-1037340WU","GSM1935528","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109403","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935528/suppl/GSM1935528_20111219_20111215-9741-3_LGWU109403-1037340WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935528_20111219_20111215-9741-3_LGWU109403-1037340WU_11.RCC.gz"
"GSM1935529","LGWU205729-1037332WU","GSM1935529","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 205729","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935529/suppl/GSM1935529_20111219_20111215-9741-3_LGWU205729-1037332WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935529_20111219_20111215-9741-3_LGWU205729-1037332WU_03.RCC.gz"
"GSM1935530","LGWU702281-1037334WU","GSM1935530","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702281","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935530/suppl/GSM1935530_20111219_20111215-9741-3_LGWU702281-1037334WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935530_20111219_20111215-9741-3_LGWU702281-1037334WU_05.RCC.gz"
"GSM1935531","LGWU702305-1037339WU","GSM1935531","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702305","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935531/suppl/GSM1935531_20111219_20111215-9741-3_LGWU702305-1037339WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935531_20111219_20111215-9741-3_LGWU702305-1037339WU_10.RCC.gz"
"GSM1935532","LGWU702317-1037341WU","GSM1935532","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702317","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935532/suppl/GSM1935532_20111219_20111215-9741-3_LGWU702317-1037341WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935532_20111219_20111215-9741-3_LGWU702317-1037341WU_12.RCC.gz"
"GSM1935533","LGWU702669-1037330WU","GSM1935533","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702669","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935533/suppl/GSM1935533_20111219_20111215-9741-3_LGWU702669-1037330WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935533_20111219_20111215-9741-3_LGWU702669-1037330WU_01.RCC.gz"
"GSM1935534","LGWU702689-1037333WU","GSM1935534","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702689","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935534/suppl/GSM1935534_20111219_20111215-9741-3_LGWU702689-1037333WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935534_20111219_20111215-9741-3_LGWU702689-1037333WU_04.RCC.gz"
"GSM1935535","LGWU702700-1037337WU","GSM1935535","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702700","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935535/suppl/GSM1935535_20111219_20111215-9741-3_LGWU702700-1037337WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935535_20111219_20111215-9741-3_LGWU702700-1037337WU_08.RCC.gz"
"GSM1935536","LGWU702706-1037338WU","GSM1935536","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702706","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935536/suppl/GSM1935536_20111219_20111215-9741-3_LGWU702706-1037338WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935536_20111219_20111215-9741-3_LGWU702706-1037338WU_09.RCC.gz"
"GSM1935537","LGWU101104-1037363WU","GSM1935537","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101104","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935537/suppl/GSM1935537_20111220_20111220-9741-1_LGWU101104-1037363WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935537_20111220_20111220-9741-1_LGWU101104-1037363WU_09.RCC.gz"
"GSM1935538","LGWU101699-1037354WU","GSM1935538","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101699","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935538/suppl/GSM1935538_20111220_20111220-9741-1_LGWU101699-1037354WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935538_20111220_20111220-9741-1_LGWU101699-1037354WU_01.RCC.gz"
"GSM1935539","LGWU109297-1037358WU","GSM1935539","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109297","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935539/suppl/GSM1935539_20111220_20111220-9741-1_LGWU109297-1037358WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935539_20111220_20111220-9741-1_LGWU109297-1037358WU_05.RCC.gz"
"GSM1935540","LGWU702359-1037355WU","GSM1935540","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702359","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935540/suppl/GSM1935540_20111220_20111220-9741-1_LGWU702359-1037355WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935540_20111220_20111220-9741-1_LGWU702359-1037355WU_02.RCC.gz"
"GSM1935541","LGWU702662-1037369WU","GSM1935541","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702662","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935541/suppl/GSM1935541_20111220_20111220-9741-1_LGWU702662-1037369WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935541_20111220_20111220-9741-1_LGWU702662-1037369WU_10.RCC.gz"
"GSM1935542","LGWU702811-1037357WU","GSM1935542","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702811","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935542/suppl/GSM1935542_20111220_20111220-9741-1_LGWU702811-1037357WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935542_20111220_20111220-9741-1_LGWU702811-1037357WU_04.RCC.gz"
"GSM1935543","LGWU703167-1037371WU","GSM1935543","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703167","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935543/suppl/GSM1935543_20111220_20111220-9741-1_LGWU703167-1037371WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935543_20111220_20111220-9741-1_LGWU703167-1037371WU_12.RCC.gz"
"GSM1935544","LGWU703340-1037356WU","GSM1935544","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703340","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935544/suppl/GSM1935544_20111220_20111220-9741-1_LGWU703340-1037356WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935544_20111220_20111220-9741-1_LGWU703340-1037356WU_03.RCC.gz"
"GSM1935545","LGWU703367-1037360WU","GSM1935545","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703367","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935545/suppl/GSM1935545_20111220_20111220-9741-1_LGWU703367-1037360WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935545_20111220_20111220-9741-1_LGWU703367-1037360WU_06.RCC.gz"
"GSM1935546","LGWU703377-1037361WU","GSM1935546","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703377","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935546/suppl/GSM1935546_20111220_20111220-9741-1_LGWU703377-1037361WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935546_20111220_20111220-9741-1_LGWU703377-1037361WU_07.RCC.gz"
"GSM1935547","LGWU703419-1037362WU","GSM1935547","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703419","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935547/suppl/GSM1935547_20111220_20111220-9741-1_LGWU703419-1037362WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935547_20111220_20111220-9741-1_LGWU703419-1037362WU_08.RCC.gz"
"GSM1935548","LGWU102012-1037379WU","GSM1935548","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102012","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935548/suppl/GSM1935548_20111220_20111220-9741-2_LGWU102012-1037379WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935548_20111220_20111220-9741-2_LGWU102012-1037379WU_07.RCC.gz"
"GSM1935549","LGWU102509-1037382WU","GSM1935549","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102509","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935549/suppl/GSM1935549_20111220_20111220-9741-2_LGWU102509-1037382WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935549_20111220_20111220-9741-2_LGWU102509-1037382WU_10.RCC.gz"
"GSM1935550","LGWU102697-1037383WU","GSM1935550","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102697","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935550/suppl/GSM1935550_20111220_20111220-9741-2_LGWU102697-1037383WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935550_20111220_20111220-9741-2_LGWU102697-1037383WU_11.RCC.gz"
"GSM1935551","LGWU107255-1037381WU","GSM1935551","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107255","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935551/suppl/GSM1935551_20111220_20111220-9741-2_LGWU107255-1037381WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935551_20111220_20111220-9741-2_LGWU107255-1037381WU_09.RCC.gz"
"GSM1935552","LGWU203299-1037376WU","GSM1935552","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203299","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935552/suppl/GSM1935552_20111220_20111220-9741-2_LGWU203299-1037376WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935552_20111220_20111220-9741-2_LGWU203299-1037376WU_04.RCC.gz"
"GSM1935553","LGWU702162-1037380WU","GSM1935553","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702162","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935553/suppl/GSM1935553_20111220_20111220-9741-2_LGWU702162-1037380WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935553_20111220_20111220-9741-2_LGWU702162-1037380WU_08.RCC.gz"
"GSM1935554","LGWU702433-1037384WU","GSM1935554","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702433","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935554/suppl/GSM1935554_20111220_20111220-9741-2_LGWU702433-1037384WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935554_20111220_20111220-9741-2_LGWU702433-1037384WU_12.RCC.gz"
"GSM1935555","LGWU702584-1037375WU","GSM1935555","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702584","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935555/suppl/GSM1935555_20111220_20111220-9741-2_LGWU702584-1037375WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935555_20111220_20111220-9741-2_LGWU702584-1037375WU_03.RCC.gz"
"GSM1935556","LGWU702781-1037378WU","GSM1935556","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702781","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935556/suppl/GSM1935556_20111220_20111220-9741-2_LGWU702781-1037378WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935556_20111220_20111220-9741-2_LGWU702781-1037378WU_06.RCC.gz"
"GSM1935557","LGWU703195-1037377WU","GSM1935557","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703195","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935557/suppl/GSM1935557_20111220_20111220-9741-2_LGWU703195-1037377WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935557_20111220_20111220-9741-2_LGWU703195-1037377WU_05.RCC.gz"
"GSM1935558","LGWU703197-1037372WU","GSM1935558","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703197","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935558/suppl/GSM1935558_20111220_20111220-9741-2_LGWU703197-1037372WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935558_20111220_20111220-9741-2_LGWU703197-1037372WU_01.RCC.gz"
"GSM1935559","LGWU102554-1037387WU","GSM1935559","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102554","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935559/suppl/GSM1935559_20111221_20111221-9741-1_LGWU102554-1037387WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935559_20111221_20111221-9741-1_LGWU102554-1037387WU_03.RCC.gz"
"GSM1935560","LGWU102613-1037385WU","GSM1935560","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102613","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935560/suppl/GSM1935560_20111221_20111221-9741-1_LGWU102613-1037385WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935560_20111221_20111221-9741-1_LGWU102613-1037385WU_01.RCC.gz"
"GSM1935561","LGWU102623-1037394WU","GSM1935561","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102623","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935561/suppl/GSM1935561_20111221_20111221-9741-1_LGWU102623-1037394WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935561_20111221_20111221-9741-1_LGWU102623-1037394WU_10.RCC.gz"
"GSM1935562","LGWU102698-1037392WU","GSM1935562","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102698","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935562/suppl/GSM1935562_20111221_20111221-9741-1_LGWU102698-1037392WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935562_20111221_20111221-9741-1_LGWU102698-1037392WU_08.RCC.gz"
"GSM1935563","LGWU207199-1037393WU","GSM1935563","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 207199","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935563/suppl/GSM1935563_20111221_20111221-9741-1_LGWU207199-1037393WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935563_20111221_20111221-9741-1_LGWU207199-1037393WU_09.RCC.gz"
"GSM1935564","LGWU702191-1037388WU","GSM1935564","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702191","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935564/suppl/GSM1935564_20111221_20111221-9741-1_LGWU702191-1037388WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935564_20111221_20111221-9741-1_LGWU702191-1037388WU_04.RCC.gz"
"GSM1935565","LGWU702195-1037390WU","GSM1935565","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702195","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935565/suppl/GSM1935565_20111221_20111221-9741-1_LGWU702195-1037390WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935565_20111221_20111221-9741-1_LGWU702195-1037390WU_06.RCC.gz"
"GSM1935566","LGWU702202-1037391WU","GSM1935566","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702202","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935566/suppl/GSM1935566_20111221_20111221-9741-1_LGWU702202-1037391WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935566_20111221_20111221-9741-1_LGWU702202-1037391WU_07.RCC.gz"
"GSM1935567","LGWU702213-1037395WU","GSM1935567","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702213","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935567/suppl/GSM1935567_20111221_20111221-9741-1_LGWU702213-1037395WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935567_20111221_20111221-9741-1_LGWU702213-1037395WU_11.RCC.gz"
"GSM1935568","LGWU702442-1037386WU","GSM1935568","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702442","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935568/suppl/GSM1935568_20111221_20111221-9741-1_LGWU702442-1037386WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935568_20111221_20111221-9741-1_LGWU702442-1037386WU_02.RCC.gz"
"GSM1935569","LGWU702473-1037389WU","GSM1935569","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702473","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935569/suppl/GSM1935569_20111221_20111221-9741-1_LGWU702473-1037389WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935569_20111221_20111221-9741-1_LGWU702473-1037389WU_05.RCC.gz"
"GSM1935570","LGWU702518-1037396WU","GSM1935570","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702518","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935570/suppl/GSM1935570_20111221_20111221-9741-1_LGWU702518-1037396WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935570_20111221_20111221-9741-1_LGWU702518-1037396WU_12.RCC.gz"
"GSM1935571","LGWU101993-1037403WU","GSM1935571","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101993","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935571/suppl/GSM1935571_20111221_20111221-9741-2_LGWU101993-1037403WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935571_20111221_20111221-9741-2_LGWU101993-1037403WU_07.RCC.gz"
"GSM1935572","LGWU102598-1037397WU","GSM1935572","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102598","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935572/suppl/GSM1935572_20111221_20111221-9741-2_LGWU102598-1037397WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935572_20111221_20111221-9741-2_LGWU102598-1037397WU_01.RCC.gz"
"GSM1935573","LGWU102615-1037402WU","GSM1935573","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102615","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935573/suppl/GSM1935573_20111221_20111221-9741-2_LGWU102615-1037402WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935573_20111221_20111221-9741-2_LGWU102615-1037402WU_06.RCC.gz"
"GSM1935574","LGWU102708-1037405WU","GSM1935574","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102708","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935574/suppl/GSM1935574_20111221_20111221-9741-2_LGWU102708-1037405WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935574_20111221_20111221-9741-2_LGWU102708-1037405WU_09.RCC.gz"
"GSM1935575","LGWU102742-1037401WU","GSM1935575","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102742","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935575/suppl/GSM1935575_20111221_20111221-9741-2_LGWU102742-1037401WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935575_20111221_20111221-9741-2_LGWU102742-1037401WU_05.RCC.gz"
"GSM1935576","LGWU109126-1037399WU","GSM1935576","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109126","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935576/suppl/GSM1935576_20111221_20111221-9741-2_LGWU109126-1037399WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935576_20111221_20111221-9741-2_LGWU109126-1037399WU_03.RCC.gz"
"GSM1935577","LGWU702262-1037407WU","GSM1935577","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702262","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935577/suppl/GSM1935577_20111221_20111221-9741-2_LGWU702262-1037407WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935577_20111221_20111221-9741-2_LGWU702262-1037407WU_11.RCC.gz"
"GSM1935578","LGWU702531-1037398WU","GSM1935578","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702531","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935578/suppl/GSM1935578_20111221_20111221-9741-2_LGWU702531-1037398WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935578_20111221_20111221-9741-2_LGWU702531-1037398WU_02.RCC.gz"
"GSM1935579","LGWU702552-1037400WU","GSM1935579","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702552","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935579/suppl/GSM1935579_20111221_20111221-9741-2_LGWU702552-1037400WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935579_20111221_20111221-9741-2_LGWU702552-1037400WU_04.RCC.gz"
"GSM1935580","LGWU702624-1037404WU","GSM1935580","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702624","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935580/suppl/GSM1935580_20111221_20111221-9741-2_LGWU702624-1037404WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935580_20111221_20111221-9741-2_LGWU702624-1037404WU_08.RCC.gz"
"GSM1935581","LGWU702645-1037406WU","GSM1935581","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702645","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935581/suppl/GSM1935581_20111221_20111221-9741-2_LGWU702645-1037406WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935581_20111221_20111221-9741-2_LGWU702645-1037406WU_10.RCC.gz"
"GSM1935582","LGWU702649-1037408WU","GSM1935582","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702649","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935582/suppl/GSM1935582_20111221_20111221-9741-2_LGWU702649-1037408WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935582_20111221_20111221-9741-2_LGWU702649-1037408WU_12.RCC.gz"
"GSM1935583","LGWU102769-1037409WU","GSM1935583","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102769","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935583/suppl/GSM1935583_20111222_20111221-9741-3_LGWU102769-1037409WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935583_20111222_20111221-9741-3_LGWU102769-1037409WU_01.RCC.gz"
"GSM1935584","LGWU107360-1037415WU","GSM1935584","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107360","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935584/suppl/GSM1935584_20111222_20111221-9741-3_LGWU107360-1037415WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935584_20111222_20111221-9741-3_LGWU107360-1037415WU_07.RCC.gz"
"GSM1935585","LGWU109081-1037418WU","GSM1935585","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109081","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935585/suppl/GSM1935585_20111222_20111221-9741-3_LGWU109081-1037418WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935585_20111222_20111221-9741-3_LGWU109081-1037418WU_10.RCC.gz"
"GSM1935586","LGWU200766-1037410WU","GSM1935586","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200766","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935586/suppl/GSM1935586_20111222_20111221-9741-3_LGWU200766-1037410WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935586_20111222_20111221-9741-3_LGWU200766-1037410WU_02.RCC.gz"
"GSM1935587","LGWU201673-1037413WU","GSM1935587","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 201673","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935587/suppl/GSM1935587_20111222_20111221-9741-3_LGWU201673-1037413WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935587_20111222_20111221-9741-3_LGWU201673-1037413WU_05.RCC.gz"
"GSM1935588","LGWU702291-1037414WU","GSM1935588","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702291","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935588/suppl/GSM1935588_20111222_20111221-9741-3_LGWU702291-1037414WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935588_20111222_20111221-9741-3_LGWU702291-1037414WU_06.RCC.gz"
"GSM1935589","LGWU702693-1037412WU","GSM1935589","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702693","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935589/suppl/GSM1935589_20111222_20111221-9741-3_LGWU702693-1037412WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935589_20111222_20111221-9741-3_LGWU702693-1037412WU_04.RCC.gz"
"GSM1935590","LGWU702720-1037416WU","GSM1935590","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702720","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935590/suppl/GSM1935590_20111222_20111221-9741-3_LGWU702720-1037416WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935590_20111222_20111221-9741-3_LGWU702720-1037416WU_08.RCC.gz"
"GSM1935591","LGWU702734-1037420WU","GSM1935591","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702734","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935591/suppl/GSM1935591_20111222_20111221-9741-3_LGWU702734-1037420WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935591_20111222_20111221-9741-3_LGWU702734-1037420WU_12.RCC.gz"
"GSM1935592","LGWU703172-1037417WU","GSM1935592","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703172","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935592/suppl/GSM1935592_20111222_20111221-9741-3_LGWU703172-1037417WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935592_20111222_20111221-9741-3_LGWU703172-1037417WU_09.RCC.gz"
"GSM1935593","LGWU703185-1037419WU","GSM1935593","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703185","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935593/suppl/GSM1935593_20111222_20111221-9741-3_LGWU703185-1037419WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935593_20111222_20111221-9741-3_LGWU703185-1037419WU_11.RCC.gz"
"GSM1935594","LGWU107396-1037431WU","GSM1935594","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107396","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935594/suppl/GSM1935594_20111222_20111221-9741-4_LGWU107396-1037431WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935594_20111222_20111221-9741-4_LGWU107396-1037431WU_10.RCC.gz"
"GSM1935595","LGWU109137-1037430WU","GSM1935595","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109137","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935595/suppl/GSM1935595_20111222_20111221-9741-4_LGWU109137-1037430WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935595_20111222_20111221-9741-4_LGWU109137-1037430WU_09.RCC.gz"
"GSM1935596","LGWU209840-1037428WU","GSM1935596","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 209840","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935596/suppl/GSM1935596_20111222_20111221-9741-4_LGWU209840-1037428WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935596_20111222_20111221-9741-4_LGWU209840-1037428WU_07.RCC.gz"
"GSM1935597","LGWU702337-1037427WU","GSM1935597","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702337","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935597/suppl/GSM1935597_20111222_20111221-9741-4_LGWU702337-1037427WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935597_20111222_20111221-9741-4_LGWU702337-1037427WU_06.RCC.gz"
"GSM1935598","LGWU702736-1037421WU","GSM1935598","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702736","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935598/suppl/GSM1935598_20111222_20111221-9741-4_LGWU702736-1037421WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935598_20111222_20111221-9741-4_LGWU702736-1037421WU_01.RCC.gz"
"GSM1935599","LGWU702748-1037423WU","GSM1935599","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702748","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935599/suppl/GSM1935599_20111222_20111221-9741-4_LGWU702748-1037423WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935599_20111222_20111221-9741-4_LGWU702748-1037423WU_02.RCC.gz"
"GSM1935600","LGWU702754-1037424WU","GSM1935600","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702754","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935600/suppl/GSM1935600_20111222_20111221-9741-4_LGWU702754-1037424WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935600_20111222_20111221-9741-4_LGWU702754-1037424WU_03.RCC.gz"
"GSM1935601","LGWU702760-1037426WU","GSM1935601","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702760","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935601/suppl/GSM1935601_20111222_20111221-9741-4_LGWU702760-1037426WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935601_20111222_20111221-9741-4_LGWU702760-1037426WU_05.RCC.gz"
"GSM1935602","LGWU702773-1037429WU","GSM1935602","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702773","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935602/suppl/GSM1935602_20111222_20111221-9741-4_LGWU702773-1037429WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935602_20111222_20111221-9741-4_LGWU702773-1037429WU_08.RCC.gz"
"GSM1935603","LGWU702807-1037433WU","GSM1935603","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702807","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935603/suppl/GSM1935603_20111222_20111221-9741-4_LGWU702807-1037433WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935603_20111222_20111221-9741-4_LGWU702807-1037433WU_12.RCC.gz"
"GSM1935604","LGWU703255-1037425WU","GSM1935604","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703255","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935604/suppl/GSM1935604_20111222_20111221-9741-4_LGWU703255-1037425WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935604_20111222_20111221-9741-4_LGWU703255-1037425WU_04.RCC.gz"
"GSM1935605","LGWU703337-1037432WU","GSM1935605","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703337","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935605/suppl/GSM1935605_20111222_20111221-9741-4_LGWU703337-1037432WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935605_20111222_20111221-9741-4_LGWU703337-1037432WU_11.RCC.gz"
"GSM1935606","LGWU101101-1036889WU","GSM1935606","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101101","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935606/suppl/GSM1935606_20111222_20111222-9741-1_LGWU101101-1036889WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935606_20111222_20111222-9741-1_LGWU101101-1036889WU_11.RCC.gz"
"GSM1935607","LGWU101989-1037436WU","GSM1935607","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101989","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935607/suppl/GSM1935607_20111222_20111222-9741-1_LGWU101989-1037436WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935607_20111222_20111222-9741-1_LGWU101989-1037436WU_03.RCC.gz"
"GSM1935608","LGWU102002-1037440WU","GSM1935608","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102002","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935608/suppl/GSM1935608_20111222_20111222-9741-1_LGWU102002-1037440WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935608_20111222_20111222-9741-1_LGWU102002-1037440WU_07.RCC.gz"
"GSM1935609","LGWU102536-1037442WU","GSM1935609","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102536","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935609/suppl/GSM1935609_20111222_20111222-9741-1_LGWU102536-1037442WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935609_20111222_20111222-9741-1_LGWU102536-1037442WU_09.RCC.gz"
"GSM1935610","LGWU202448-1037438WU","GSM1935610","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 202448","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935610/suppl/GSM1935610_20111222_20111222-9741-1_LGWU202448-1037438WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935610_20111222_20111222-9741-1_LGWU202448-1037438WU_05.RCC.gz"
"GSM1935611","LGWU702369-1037441WU","GSM1935611","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702369","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935611/suppl/GSM1935611_20111222_20111222-9741-1_LGWU702369-1037441WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935611_20111222_20111222-9741-1_LGWU702369-1037441WU_08.RCC.gz"
"GSM1935612","LGWU702444-1036890WU","GSM1935612","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702444","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935612/suppl/GSM1935612_20111222_20111222-9741-1_LGWU702444-1036890WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935612_20111222_20111222-9741-1_LGWU702444-1036890WU_12.RCC.gz"
"GSM1935613","LGWU702783-1036888WU","GSM1935613","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702783","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935613/suppl/GSM1935613_20111222_20111222-9741-1_LGWU702783-1036888WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935613_20111222_20111222-9741-1_LGWU702783-1036888WU_10.RCC.gz"
"GSM1935614","LGWU702809-1037434WU","GSM1935614","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702809","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935614/suppl/GSM1935614_20111222_20111222-9741-1_LGWU702809-1037434WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935614_20111222_20111222-9741-1_LGWU702809-1037434WU_01.RCC.gz"
"GSM1935615","LGWU703354-1037435WU","GSM1935615","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703354","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935615/suppl/GSM1935615_20111222_20111222-9741-1_LGWU703354-1037435WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935615_20111222_20111222-9741-1_LGWU703354-1037435WU_02.RCC.gz"
"GSM1935616","LGWU703375-1037437WU","GSM1935616","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703375","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935616/suppl/GSM1935616_20111222_20111222-9741-1_LGWU703375-1037437WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935616_20111222_20111222-9741-1_LGWU703375-1037437WU_04.RCC.gz"
"GSM1935617","LGWU703411-1037439WU","GSM1935617","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703411","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935617/suppl/GSM1935617_20111222_20111222-9741-1_LGWU703411-1037439WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935617_20111222_20111222-9741-1_LGWU703411-1037439WU_06.RCC.gz"
"GSM1935618","LGWU102010-1036894WU","GSM1935618","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102010","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935618/suppl/GSM1935618_20111222_20111222-9741-2_LGWU102010-1036894WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935618_20111222_20111222-9741-2_LGWU102010-1036894WU_04.RCC.gz"
"GSM1935619","LGWU102786-1037445WU","GSM1935619","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102786","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935619/suppl/GSM1935619_20111222_20111222-9741-2_LGWU102786-1037445WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935619_20111222_20111222-9741-2_LGWU102786-1037445WU_12.RCC.gz"
"GSM1935620","LGWU109104-1036902WU","GSM1935620","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109104","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935620/suppl/GSM1935620_20111222_20111222-9741-2_LGWU109104-1036902WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935620_20111222_20111222-9741-2_LGWU109104-1036902WU_08.RCC.gz"
"GSM1935621","LGWU203008-1036900WU","GSM1935621","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203008","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935621/suppl/GSM1935621_20111222_20111222-9741-2_LGWU203008-1036900WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935621_20111222_20111222-9741-2_LGWU203008-1036900WU_06.RCC.gz"
"GSM1935622","LGWU702227-1037122WU","GSM1935622","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702227","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935622/suppl/GSM1935622_20111222_20111222-9741-2_LGWU702227-1037122WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935622_20111222_20111222-9741-2_LGWU702227-1037122WU_09.RCC.gz"
"GSM1935623","LGWU702241-1036891WU","GSM1935623","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702241","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935623/suppl/GSM1935623_20111222_20111222-9741-2_LGWU702241-1036891WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935623_20111222_20111222-9741-2_LGWU702241-1036891WU_01.RCC.gz"
"GSM1935624","LGWU702258-1037444WU","GSM1935624","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702258","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935624/suppl/GSM1935624_20111222_20111222-9741-2_LGWU702258-1037444WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935624_20111222_20111222-9741-2_LGWU702258-1037444WU_11.RCC.gz"
"GSM1935625","LGWU702680-1036892WU","GSM1935625","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702680","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935625/suppl/GSM1935625_20111222_20111222-9741-2_LGWU702680-1036892WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935625_20111222_20111222-9741-2_LGWU702680-1036892WU_02.RCC.gz"
"GSM1935626","LGWU702685-1036893WU","GSM1935626","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702685","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935626/suppl/GSM1935626_20111222_20111222-9741-2_LGWU702685-1036893WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935626_20111222_20111222-9741-2_LGWU702685-1036893WU_03.RCC.gz"
"GSM1935627","LGWU102723-1037450WU","GSM1935627","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102723","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935627/suppl/GSM1935627_20111222_20111222-9741-3_LGWU102723-1037450WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935627_20111222_20111222-9741-3_LGWU102723-1037450WU_05.RCC.gz"
"GSM1935628","LGWU102739-1037458WU","GSM1935628","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102739","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935628/suppl/GSM1935628_20111222_20111222-9741-3_LGWU102739-1037458WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935628_20111222_20111222-9741-3_LGWU102739-1037458WU_11.RCC.gz"
"GSM1935629","LGWU1054022-1037453WU","GSM1935629","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 105402","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935629/suppl/GSM1935629_20111222_20111222-9741-3_LGWU1054022-1037453WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935629_20111222_20111222-9741-3_LGWU1054022-1037453WU_07.RCC.gz"
"GSM1935630","LGWU107283-1037448WU","GSM1935630","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107283","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935630/suppl/GSM1935630_20111222_20111222-9741-3_LGWU107283-1037448WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935630_20111222_20111222-9741-3_LGWU107283-1037448WU_03.RCC.gz"
"GSM1935631","LGWU107314-1037449WU","GSM1935631","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107314","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935631/suppl/GSM1935631_20111222_20111222-9741-3_LGWU107314-1037449WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935631_20111222_20111222-9741-3_LGWU107314-1037449WU_04.RCC.gz"
"GSM1935632","LGWU109036-1037454WU","GSM1935632","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109036","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935632/suppl/GSM1935632_20111222_20111222-9741-3_LGWU109036-1037454WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935632_20111222_20111222-9741-3_LGWU109036-1037454WU_08.RCC.gz"
"GSM1935633","LGWU109118-1037452WU","GSM1935633","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109118","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935633/suppl/GSM1935633_20111222_20111222-9741-3_LGWU109118-1037452WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935633_20111222_20111222-9741-3_LGWU109118-1037452WU_06.RCC.gz"
"GSM1935634","LGWU109210-1037456WU","GSM1935634","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109210","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935634/suppl/GSM1935634_20111222_20111222-9741-3_LGWU109210-1037456WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935634_20111222_20111222-9741-3_LGWU109210-1037456WU_09.RCC.gz"
"GSM1935635","LGWU703218-1037446WU","GSM1935635","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703218","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935635/suppl/GSM1935635_20111222_20111222-9741-3_LGWU703218-1037446WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935635_20111222_20111222-9741-3_LGWU703218-1037446WU_01.RCC.gz"
"GSM1935636","LGWU102465-1037469WU","GSM1935636","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102465","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935636/suppl/GSM1935636_20111228_20111227-9741-1-0023_LGWU102465-1037469WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935636_20111228_20111227-9741-1-0023_LGWU102465-1037469WU_06.RCC.gz"
"GSM1935637","LGWU102477-1037470WU","GSM1935637","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102477","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935637/suppl/GSM1935637_20111228_20111227-9741-1-0023_LGWU102477-1037470WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935637_20111228_20111227-9741-1-0023_LGWU102477-1037470WU_07.RCC.gz"
"GSM1935638","LGWU102543-1037473WU","GSM1935638","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102543","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935638/suppl/GSM1935638_20111228_20111227-9741-1-0023_LGWU102543-1037473WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935638_20111228_20111227-9741-1-0023_LGWU102543-1037473WU_10.RCC.gz"
"GSM1935639","LGWU1054028-1037465WU","GSM1935639","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 105402","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935639/suppl/GSM1935639_20111228_20111227-9741-1-0023_LGWU1054028-1037465WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935639_20111228_20111227-9741-1-0023_LGWU1054028-1037465WU_03.RCC.gz"
"GSM1935640","LGWU109037-1037463WU","GSM1935640","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109037","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935640/suppl/GSM1935640_20111228_20111227-9741-1-0023_LGWU109037-1037463WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935640_20111228_20111227-9741-1-0023_LGWU109037-1037463WU_02.RCC.gz"
"GSM1935641","LGWU203011-1037467WU","GSM1935641","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203011","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935641/suppl/GSM1935641_20111228_20111227-9741-1-0023_LGWU203011-1037467WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935641_20111228_20111227-9741-1-0023_LGWU203011-1037467WU_05.RCC.gz"
"GSM1935642","LGWU206187-1037466WU","GSM1935642","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 206187","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935642/suppl/GSM1935642_20111228_20111227-9741-1-0023_LGWU206187-1037466WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935642_20111228_20111227-9741-1-0023_LGWU206187-1037466WU_04.RCC.gz"
"GSM1935643","LGWU702154-1037471WU","GSM1935643","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702154","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935643/suppl/GSM1935643_20111228_20111227-9741-1-0023_LGWU702154-1037471WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935643_20111228_20111227-9741-1-0023_LGWU702154-1037471WU_08.RCC.gz"
"GSM1935644","LGWU702161-1037472WU","GSM1935644","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702161","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935644/suppl/GSM1935644_20111228_20111227-9741-1-0023_LGWU702161-1037472WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935644_20111228_20111227-9741-1-0023_LGWU702161-1037472WU_09.RCC.gz"
"GSM1935645","LGWU702171-1037474WU","GSM1935645","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702171","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935645/suppl/GSM1935645_20111228_20111227-9741-1-0023_LGWU702171-1037474WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935645_20111228_20111227-9741-1-0023_LGWU702171-1037474WU_11.RCC.gz"
"GSM1935646","LGWU702179-1037475WU","GSM1935646","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702179","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935646/suppl/GSM1935646_20111228_20111227-9741-1-0023_LGWU702179-1037475WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935646_20111228_20111227-9741-1-0023_LGWU702179-1037475WU_12.RCC.gz"
"GSM1935647","LGWU102561-1037478WU","GSM1935647","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102561","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935647/suppl/GSM1935647_20111228_20111227-9741-2-0044_LGWU102561-1037478WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935647_20111228_20111227-9741-2-0044_LGWU102561-1037478WU_03.RCC.gz"
"GSM1935648","LGWU102593-1037483WU","GSM1935648","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102593","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935648/suppl/GSM1935648_20111228_20111227-9741-2-0044_LGWU102593-1037483WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935648_20111228_20111227-9741-2-0044_LGWU102593-1037483WU_08.RCC.gz"
"GSM1935649","LGWU102619-1037484WU","GSM1935649","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102619","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935649/suppl/GSM1935649_20111228_20111227-9741-2-0044_LGWU102619-1037484WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935649_20111228_20111227-9741-2-0044_LGWU102619-1037484WU_09.RCC.gz"
"GSM1935650","LGWU107282-1037479WU","GSM1935650","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107282","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935650/suppl/GSM1935650_20111228_20111227-9741-2-0044_LGWU107282-1037479WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935650_20111228_20111227-9741-2-0044_LGWU107282-1037479WU_04.RCC.gz"
"GSM1935651","LGWU200939-1037487WU","GSM1935651","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200939","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935651/suppl/GSM1935651_20111228_20111227-9741-2-0044_LGWU200939-1037487WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935651_20111228_20111227-9741-2-0044_LGWU200939-1037487WU_12.RCC.gz"
"GSM1935652","LGWU702188-1037480WU","GSM1935652","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702188","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935652/suppl/GSM1935652_20111228_20111227-9741-2-0044_LGWU702188-1037480WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935652_20111228_20111227-9741-2-0044_LGWU702188-1037480WU_05.RCC.gz"
"GSM1935653","LGWU702194-1037481WU","GSM1935653","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702194","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935653/suppl/GSM1935653_20111228_20111227-9741-2-0044_LGWU702194-1037481WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935653_20111228_20111227-9741-2-0044_LGWU702194-1037481WU_06.RCC.gz"
"GSM1935654","LGWU702208-1037482WU","GSM1935654","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702208","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935654/suppl/GSM1935654_20111228_20111227-9741-2-0044_LGWU702208-1037482WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935654_20111228_20111227-9741-2-0044_LGWU702208-1037482WU_07.RCC.gz"
"GSM1935655","LGWU702425-1037476WU","GSM1935655","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702425","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935655/suppl/GSM1935655_20111228_20111227-9741-2-0044_LGWU702425-1037476WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935655_20111228_20111227-9741-2-0044_LGWU702425-1037476WU_01.RCC.gz"
"GSM1935656","LGWU702431-1037477WU","GSM1935656","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702431","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935656/suppl/GSM1935656_20111228_20111227-9741-2-0044_LGWU702431-1037477WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935656_20111228_20111227-9741-2-0044_LGWU702431-1037477WU_02.RCC.gz"
"GSM1935657","LGWU702538-1037485WU","GSM1935657","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702538","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935657/suppl/GSM1935657_20111228_20111227-9741-2-0044_LGWU702538-1037485WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935657_20111228_20111227-9741-2-0044_LGWU702538-1037485WU_10.RCC.gz"
"GSM1935658","LGWU702550-1037486WU","GSM1935658","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702550","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935658/suppl/GSM1935658_20111228_20111227-9741-2-0044_LGWU702550-1037486WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935658_20111228_20111227-9741-2-0044_LGWU702550-1037486WU_11.RCC.gz"
"GSM1935659","LGWU102707-1037490WU","GSM1935659","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102707","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935659/suppl/GSM1935659_20111228_20111227-9741-3-0023_LGWU102707-1037490WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935659_20111228_20111227-9741-3-0023_LGWU102707-1037490WU_03.RCC.gz"
"GSM1935660","LGWU102719-1037491WU","GSM1935660","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102719","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935660/suppl/GSM1935660_20111228_20111227-9741-3-0023_LGWU102719-1037491WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935660_20111228_20111227-9741-3-0023_LGWU102719-1037491WU_04.RCC.gz"
"GSM1935661","LGWU102755-1037488WU","GSM1935661","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102755","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935661/suppl/GSM1935661_20111228_20111227-9741-3-0023_LGWU102755-1037488WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935661_20111228_20111227-9741-3-0023_LGWU102755-1037488WU_01.RCC.gz"
"GSM1935662","LGWU102772-1037496WU","GSM1935662","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102772","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935662/suppl/GSM1935662_20111228_20111227-9741-3-0023_LGWU102772-1037496WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935662_20111228_20111227-9741-3-0023_LGWU102772-1037496WU_09.RCC.gz"
"GSM1935663","LGWU108941-1037498WU","GSM1935663","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108941","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935663/suppl/GSM1935663_20111228_20111227-9741-3-0023_LGWU108941-1037498WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935663_20111228_20111227-9741-3-0023_LGWU108941-1037498WU_11.RCC.gz"
"GSM1935664","LGWU201454-1037492WU","GSM1935664","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 201454","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935664/suppl/GSM1935664_20111228_20111227-9741-3-0023_LGWU201454-1037492WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935664_20111228_20111227-9741-3-0023_LGWU201454-1037492WU_05.RCC.gz"
"GSM1935665","LGWU702290-1037497WU","GSM1935665","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702290","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935665/suppl/GSM1935665_20111228_20111227-9741-3-0023_LGWU702290-1037497WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935665_20111228_20111227-9741-3-0023_LGWU702290-1037497WU_10.RCC.gz"
"GSM1935666","LGWU702598-1037489WU","GSM1935666","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702598","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935666/suppl/GSM1935666_20111228_20111227-9741-3-0023_LGWU702598-1037489WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935666_20111228_20111227-9741-3-0023_LGWU702598-1037489WU_02.RCC.gz"
"GSM1935667","LGWU702674-1037493WU","GSM1935667","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702674","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935667/suppl/GSM1935667_20111228_20111227-9741-3-0023_LGWU702674-1037493WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935667_20111228_20111227-9741-3-0023_LGWU702674-1037493WU_06.RCC.gz"
"GSM1935668","LGWU702681-1037494WU","GSM1935668","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702681","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935668/suppl/GSM1935668_20111228_20111227-9741-3-0023_LGWU702681-1037494WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935668_20111228_20111227-9741-3-0023_LGWU702681-1037494WU_07.RCC.gz"
"GSM1935669","LGWU702716-1037499WU","GSM1935669","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702716","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935669/suppl/GSM1935669_20111228_20111227-9741-3-0023_LGWU702716-1037499WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935669_20111228_20111227-9741-3-0023_LGWU702716-1037499WU_12.RCC.gz"
"GSM1935670","LGWU703141-1037495WU","GSM1935670","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703141","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935670/suppl/GSM1935670_20111228_20111227-9741-3-0023_LGWU703141-1037495WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935670_20111228_20111227-9741-3-0023_LGWU703141-1037495WU_08.RCC.gz"
"GSM1935671","LGWU101987-1037509WU","GSM1935671","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101987","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935671/suppl/GSM1935671_20111229_20111227-9741-4-0044_LGWU101987-1037509WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935671_20111229_20111227-9741-4-0044_LGWU101987-1037509WU_10.RCC.gz"
"GSM1935672","LGWU103910-1037510WU","GSM1935672","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 103910","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935672/suppl/GSM1935672_20111229_20111227-9741-4-0044_LGWU103910-1037510WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935672_20111229_20111227-9741-4-0044_LGWU103910-1037510WU_11.RCC.gz"
"GSM1935673","LGWU108952-1037503WU","GSM1935673","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108952","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935673/suppl/GSM1935673_20111229_20111227-9741-4-0044_LGWU108952-1037503WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935673_20111229_20111227-9741-4-0044_LGWU108952-1037503WU_04.RCC.gz"
"GSM1935674","LGWU109018-1037506WU","GSM1935674","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109018","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935674/suppl/GSM1935674_20111229_20111227-9741-4-0044_LGWU109018-1037506WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935674_20111229_20111227-9741-4-0044_LGWU109018-1037506WU_07.RCC.gz"
"GSM1935675","LGWU702310-1037501WU","GSM1935675","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702310","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935675/suppl/GSM1935675_20111229_20111227-9741-4-0044_LGWU702310-1037501WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935675_20111229_20111227-9741-4-0044_LGWU702310-1037501WU_02.RCC.gz"
"GSM1935676","LGWU702334-1037511WU","GSM1935676","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702334","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935676/suppl/GSM1935676_20111229_20111227-9741-4-0044_LGWU702334-1037511WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935676_20111229_20111227-9741-4-0044_LGWU702334-1037511WU_12.RCC.gz"
"GSM1935677","LGWU702742-1037505WU","GSM1935677","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702742","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935677/suppl/GSM1935677_20111229_20111227-9741-4-0044_LGWU702742-1037505WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935677_20111229_20111227-9741-4-0044_LGWU702742-1037505WU_06.RCC.gz"
"GSM1935678","LGWU702751-1037507WU","GSM1935678","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702751","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935678/suppl/GSM1935678_20111229_20111227-9741-4-0044_LGWU702751-1037507WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935678_20111229_20111227-9741-4-0044_LGWU702751-1037507WU_08.RCC.gz"
"GSM1935679","LGWU703169-1037500WU","GSM1935679","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703169","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935679/suppl/GSM1935679_20111229_20111227-9741-4-0044_LGWU703169-1037500WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935679_20111229_20111227-9741-4-0044_LGWU703169-1037500WU_01.RCC.gz"
"GSM1935680","LGWU703184-1037502WU","GSM1935680","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703184","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935680/suppl/GSM1935680_20111229_20111227-9741-4-0044_LGWU703184-1037502WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935680_20111229_20111227-9741-4-0044_LGWU703184-1037502WU_03.RCC.gz"
"GSM1935681","LGWU703207-1037504WU","GSM1935681","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703207","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935681/suppl/GSM1935681_20111229_20111227-9741-4-0044_LGWU703207-1037504WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935681_20111229_20111227-9741-4-0044_LGWU703207-1037504WU_05.RCC.gz"
"GSM1935682","LGWU703234-1037508WU","GSM1935682","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703234","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935682/suppl/GSM1935682_20111229_20111227-9741-4-0044_LGWU703234-1037508WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935682_20111229_20111227-9741-4-0044_LGWU703234-1037508WU_09.RCC.gz"
"GSM1935683","LGWU109149-1037516WU","GSM1935683","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109149","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935683/suppl/GSM1935683_20111230_20111228-9741-1-0023_LGWU109149-1037516WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935683_20111230_20111228-9741-1-0023_LGWU109149-1037516WU_05.RCC.gz"
"GSM1935684","LGWU109190-1037514WU","GSM1935684","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109190","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935684/suppl/GSM1935684_20111230_20111228-9741-1-0023_LGWU109190-1037514WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935684_20111230_20111228-9741-1-0023_LGWU109190-1037514WU_03.RCC.gz"
"GSM1935685","LGWU109326-1037520WU","GSM1935685","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109326","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935685/suppl/GSM1935685_20111230_20111228-9741-1-0023_LGWU109326-1037520WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935685_20111230_20111228-9741-1-0023_LGWU109326-1037520WU_09.RCC.gz"
"GSM1935686","LGWU207960-1037515WU","GSM1935686","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 207960","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935686/suppl/GSM1935686_20111230_20111228-9741-1-0023_LGWU207960-1037515WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935686_20111230_20111228-9741-1-0023_LGWU207960-1037515WU_04.RCC.gz"
"GSM1935687","LGWU702358-1037517WU","GSM1935687","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702358","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935687/suppl/GSM1935687_20111230_20111228-9741-1-0023_LGWU702358-1037517WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935687_20111230_20111228-9741-1-0023_LGWU702358-1037517WU_06.RCC.gz"
"GSM1935688","LGWU702367-1037522WU","GSM1935688","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702367","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935688/suppl/GSM1935688_20111230_20111228-9741-1-0023_LGWU702367-1037522WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935688_20111230_20111228-9741-1-0023_LGWU702367-1037522WU_11.RCC.gz"
"GSM1935689","LGWU702829-1037521WU","GSM1935689","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702829","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935689/suppl/GSM1935689_20111230_20111228-9741-1-0023_LGWU702829-1037521WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935689_20111230_20111228-9741-1-0023_LGWU702829-1037521WU_10.RCC.gz"
"GSM1935690","LGWU703278-1037512WU","GSM1935690","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703278","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935690/suppl/GSM1935690_20111230_20111228-9741-1-0023_LGWU703278-1037512WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935690_20111230_20111228-9741-1-0023_LGWU703278-1037512WU_01.RCC.gz"
"GSM1935691","LGWU703303-1037513WU","GSM1935691","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703303","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935691/suppl/GSM1935691_20111230_20111228-9741-1-0023_LGWU703303-1037513WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935691_20111230_20111228-9741-1-0023_LGWU703303-1037513WU_02.RCC.gz"
"GSM1935692","LGWU703339-1037518WU","GSM1935692","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703339","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935692/suppl/GSM1935692_20111230_20111228-9741-1-0023_LGWU703339-1037518WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935692_20111230_20111228-9741-1-0023_LGWU703339-1037518WU_07.RCC.gz"
"GSM1935693","LGWU703353-1037519WU","GSM1935693","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703353","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935693/suppl/GSM1935693_20111230_20111228-9741-1-0023_LGWU703353-1037519WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935693_20111230_20111228-9741-1-0023_LGWU703353-1037519WU_08.RCC.gz"
"GSM1935694","LGWU703420-1037523WU","GSM1935694","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703420","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935694/suppl/GSM1935694_20111230_20111228-9741-1-0023_LGWU703420-1037523WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935694_20111230_20111228-9741-1-0023_LGWU703420-1037523WU_12.RCC.gz"
"GSM1935695","LGWU102471-1037527WU","GSM1935695","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102471","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935695/suppl/GSM1935695_20111230_20111228-9741-2-0044_LGWU102471-1037527WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935695_20111230_20111228-9741-2-0044_LGWU102471-1037527WU_04.RCC.gz"
"GSM1935696","LGWU200389-1037525WU","GSM1935696","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200389","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935696/suppl/GSM1935696_20111230_20111228-9741-2-0044_LGWU200389-1037525WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935696_20111230_20111228-9741-2-0044_LGWU200389-1037525WU_02.RCC.gz"
"GSM1935697","LGWU201668-1037526WU","GSM1935697","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 201668","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935697/suppl/GSM1935697_20111230_20111228-9741-2-0044_LGWU201668-1037526WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935697_20111230_20111228-9741-2-0044_LGWU201668-1037526WU_03.RCC.gz"
"GSM1935698","LGWU203345-1037530WU","GSM1935698","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203345","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935698/suppl/GSM1935698_20111230_20111228-9741-2-0044_LGWU203345-1037530WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935698_20111230_20111228-9741-2-0044_LGWU203345-1037530WU_07.RCC.gz"
"GSM1935699","LGWU205703-1037528WU","GSM1935699","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 205703","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935699/suppl/GSM1935699_20111230_20111228-9741-2-0044_LGWU205703-1037528WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935699_20111230_20111228-9741-2-0044_LGWU205703-1037528WU_05.RCC.gz"
"GSM1935700","LGWU220412-1037524WU","GSM1935700","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 220412","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935700/suppl/GSM1935700_20111230_20111228-9741-2-0044_LGWU220412-1037524WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935700_20111230_20111228-9741-2-0044_LGWU220412-1037524WU_01.RCC.gz"
"GSM1935701","LGWU702289-1037533WU","GSM1935701","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702289","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935701/suppl/GSM1935701_20111230_20111228-9741-2-0044_LGWU702289-1037533WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935701_20111230_20111228-9741-2-0044_LGWU702289-1037533WU_10.RCC.gz"
"GSM1935702","LGWU702398-1037529WU","GSM1935702","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702398","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935702/suppl/GSM1935702_20111230_20111228-9741-2-0044_LGWU702398-1037529WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935702_20111230_20111228-9741-2-0044_LGWU702398-1037529WU_06.RCC.gz"
"GSM1935703","LGWU703117-1037531WU","GSM1935703","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703117","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935703/suppl/GSM1935703_20111230_20111228-9741-2-0044_LGWU703117-1037531WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935703_20111230_20111228-9741-2-0044_LGWU703117-1037531WU_08.RCC.gz"
"GSM1935704","LGWU703148-1037532WU","GSM1935704","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703148","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935704/suppl/GSM1935704_20111230_20111228-9741-2-0044_LGWU703148-1037532WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935704_20111230_20111228-9741-2-0044_LGWU703148-1037532WU_09.RCC.gz"
"GSM1935705","LGWU703212-1037534WU","GSM1935705","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703212","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935705/suppl/GSM1935705_20111230_20111228-9741-2-0044_LGWU703212-1037534WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935705_20111230_20111228-9741-2-0044_LGWU703212-1037534WU_11.RCC.gz"
"GSM1935706","LGWU703244-1037535WU","GSM1935706","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703244","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935706/suppl/GSM1935706_20111230_20111228-9741-2-0044_LGWU703244-1037535WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935706_20111230_20111228-9741-2-0044_LGWU703244-1037535WU_12.RCC.gz"
"GSM1935707","LGWU102488-1037541WU","GSM1935707","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102488","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935707/suppl/GSM1935707_20111230_20111228-9741-3-0023_LGWU102488-1037541WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935707_20111230_20111228-9741-3-0023_LGWU102488-1037541WU_06.RCC.gz"
"GSM1935708","LGWU109335-1037540WU","GSM1935708","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109335","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935708/suppl/GSM1935708_20111230_20111228-9741-3-0023_LGWU109335-1037540WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935708_20111230_20111228-9741-3-0023_LGWU109335-1037540WU_05.RCC.gz"
"GSM1935709","LGWU702170-1037542WU","GSM1935709","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702170","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935709/suppl/GSM1935709_20111230_20111228-9741-3-0023_LGWU702170-1037542WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935709_20111230_20111228-9741-3-0023_LGWU702170-1037542WU_07.RCC.gz"
"GSM1935710","LGWU702200-1037547WU","GSM1935710","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702200","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935710/suppl/GSM1935710_20111230_20111228-9741-3-0023_LGWU702200-1037547WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935710_20111230_20111228-9741-3-0023_LGWU702200-1037547WU_12.RCC.gz"
"GSM1935711","LGWU702376-1037539WU","GSM1935711","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702376","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935711/suppl/GSM1935711_20111230_20111228-9741-3-0023_LGWU702376-1037539WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935711_20111230_20111228-9741-3-0023_LGWU702376-1037539WU_04.RCC.gz"
"GSM1935712","LGWU702390-1037543WU","GSM1935712","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702390","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935712/suppl/GSM1935712_20111230_20111228-9741-3-0023_LGWU702390-1037543WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935712_20111230_20111228-9741-3-0023_LGWU702390-1037543WU_08.RCC.gz"
"GSM1935713","LGWU702395-1037544WU","GSM1935713","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702395","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935713/suppl/GSM1935713_20111230_20111228-9741-3-0023_LGWU702395-1037544WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935713_20111230_20111228-9741-3-0023_LGWU702395-1037544WU_09.RCC.gz"
"GSM1935714","LGWU702427-1037545WU","GSM1935714","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702427","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935714/suppl/GSM1935714_20111230_20111228-9741-3-0023_LGWU702427-1037545WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935714_20111230_20111228-9741-3-0023_LGWU702427-1037545WU_10.RCC.gz"
"GSM1935715","LGWU702485-1037546WU","GSM1935715","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702485","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935715/suppl/GSM1935715_20111230_20111228-9741-3-0023_LGWU702485-1037546WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935715_20111230_20111228-9741-3-0023_LGWU702485-1037546WU_11.RCC.gz"
"GSM1935716","LGWU702764-1037536WU","GSM1935716","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702764","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935716/suppl/GSM1935716_20111230_20111228-9741-3-0023_LGWU702764-1037536WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935716_20111230_20111228-9741-3-0023_LGWU702764-1037536WU_01.RCC.gz"
"GSM1935717","LGWU703413-1037537WU","GSM1935717","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703413","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935717/suppl/GSM1935717_20111230_20111228-9741-3-0023_LGWU703413-1037537WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935717_20111230_20111228-9741-3-0023_LGWU703413-1037537WU_02.RCC.gz"
"GSM1935718","LGWU102603-1037556WU","GSM1935718","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102603","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935718/suppl/GSM1935718_20111230_20111228-9741-4-0044_LGWU102603-1037556WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935718_20111230_20111228-9741-4-0044_LGWU102603-1037556WU_09.RCC.gz"
"GSM1935719","LGWU102672-1037558WU","GSM1935719","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102672","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935719/suppl/GSM1935719_20111230_20111228-9741-4-0044_LGWU102672-1037558WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935719_20111230_20111228-9741-4-0044_LGWU102672-1037558WU_11.RCC.gz"
"GSM1935720","LGWU102709-1037559WU","GSM1935720","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102709","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935720/suppl/GSM1935720_20111230_20111228-9741-4-0044_LGWU102709-1037559WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935720_20111230_20111228-9741-4-0044_LGWU102709-1037559WU_12.RCC.gz"
"GSM1935721","LGWU107327-1037555WU","GSM1935721","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107327","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935721/suppl/GSM1935721_20111230_20111228-9741-4-0044_LGWU107327-1037555WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935721_20111230_20111228-9741-4-0044_LGWU107327-1037555WU_08.RCC.gz"
"GSM1935722","LGWU109085-1037557WU","GSM1935722","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109085","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935722/suppl/GSM1935722_20111230_20111228-9741-4-0044_LGWU109085-1037557WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935722_20111230_20111228-9741-4-0044_LGWU109085-1037557WU_10.RCC.gz"
"GSM1935723","LGWU702205-1037549WU","GSM1935723","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702205","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935723/suppl/GSM1935723_20111230_20111228-9741-4-0044_LGWU702205-1037549WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935723_20111230_20111228-9741-4-0044_LGWU702205-1037549WU_02.RCC.gz"
"GSM1935724","LGWU702206-1037550WU","GSM1935724","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702206","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935724/suppl/GSM1935724_20111230_20111228-9741-4-0044_LGWU702206-1037550WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935724_20111230_20111228-9741-4-0044_LGWU702206-1037550WU_03.RCC.gz"
"GSM1935725","LGWU702209-1037552WU","GSM1935725","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702209","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935725/suppl/GSM1935725_20111230_20111228-9741-4-0044_LGWU702209-1037552WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935725_20111230_20111228-9741-4-0044_LGWU702209-1037552WU_05.RCC.gz"
"GSM1935726","LGWU702211-1037553WU","GSM1935726","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702211","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935726/suppl/GSM1935726_20111230_20111228-9741-4-0044_LGWU702211-1037553WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935726_20111230_20111228-9741-4-0044_LGWU702211-1037553WU_06.RCC.gz"
"GSM1935727","LGWU702494-1037548WU","GSM1935727","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702494","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935727/suppl/GSM1935727_20111230_20111228-9741-4-0044_LGWU702494-1037548WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935727_20111230_20111228-9741-4-0044_LGWU702494-1037548WU_01.RCC.gz"
"GSM1935728","LGWU702510-1037551WU","GSM1935728","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702510","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935728/suppl/GSM1935728_20111230_20111228-9741-4-0044_LGWU702510-1037551WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935728_20111230_20111228-9741-4-0044_LGWU702510-1037551WU_04.RCC.gz"
"GSM1935729","LGWU702533-1037554WU","GSM1935729","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702533","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935729/suppl/GSM1935729_20111230_20111228-9741-4-0044_LGWU702533-1037554WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935729_20111230_20111228-9741-4-0044_LGWU702533-1037554WU_07.RCC.gz"
"GSM1935730","LGWU102740-1037565WU","GSM1935730","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102740","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935730/suppl/GSM1935730_20111230_20111229-9741-1-0023_LGWU102740-1037565WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935730_20111230_20111229-9741-1-0023_LGWU102740-1037565WU_06.RCC.gz"
"GSM1935731","LGWU200931-1037562WU","GSM1935731","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200931","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935731/suppl/GSM1935731_20111230_20111229-9741-1-0023_LGWU200931-1037562WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935731_20111230_20111229-9741-1-0023_LGWU200931-1037562WU_03.RCC.gz"
"GSM1935732","LGWU702256-1037563WU","GSM1935732","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702256","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935732/suppl/GSM1935732_20111230_20111229-9741-1-0023_LGWU702256-1037563WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935732_20111230_20111229-9741-1-0023_LGWU702256-1037563WU_04.RCC.gz"
"GSM1935733","LGWU702267-1037564WU","GSM1935733","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702267","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935733/suppl/GSM1935733_20111230_20111229-9741-1-0023_LGWU702267-1037564WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935733_20111230_20111229-9741-1-0023_LGWU702267-1037564WU_05.RCC.gz"
"GSM1935734","LGWU702603-1037560WU","GSM1935734","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702603","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935734/suppl/GSM1935734_20111230_20111229-9741-1-0023_LGWU702603-1037560WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935734_20111230_20111229-9741-1-0023_LGWU702603-1037560WU_01.RCC.gz"
"GSM1935735","LGWU702691-1037568WU","GSM1935735","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702691","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935735/suppl/GSM1935735_20111230_20111229-9741-1-0023_LGWU702691-1037568WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935735_20111230_20111229-9741-1-0023_LGWU702691-1037568WU_09.RCC.gz"
"GSM1935736","LGWU702696-1037570WU","GSM1935736","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702696","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935736/suppl/GSM1935736_20111230_20111229-9741-1-0023_LGWU702696-1037570WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935736_20111230_20111229-9741-1-0023_LGWU702696-1037570WU_11.RCC.gz"
"GSM1935737","LGWU702705-1037571WU","GSM1935737","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702705","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935737/suppl/GSM1935737_20111230_20111229-9741-1-0023_LGWU702705-1037571WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935737_20111230_20111229-9741-1-0023_LGWU702705-1037571WU_12.RCC.gz"
"GSM1935738","LGWU703110-1037561WU","GSM1935738","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703110","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935738/suppl/GSM1935738_20111230_20111229-9741-1-0023_LGWU703110-1037561WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935738_20111230_20111229-9741-1-0023_LGWU703110-1037561WU_02.RCC.gz"
"GSM1935739","LGWU703136-1037566WU","GSM1935739","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703136","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935739/suppl/GSM1935739_20111230_20111229-9741-1-0023_LGWU703136-1037566WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935739_20111230_20111229-9741-1-0023_LGWU703136-1037566WU_07.RCC.gz"
"GSM1935740","LGWU703139-1037567WU","GSM1935740","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703139","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935740/suppl/GSM1935740_20111230_20111229-9741-1-0023_LGWU703139-1037567WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935740_20111230_20111229-9741-1-0023_LGWU703139-1037567WU_08.RCC.gz"
"GSM1935741","LGWU703146-1037569WU","GSM1935741","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703146","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935741/suppl/GSM1935741_20111230_20111229-9741-1-0023_LGWU703146-1037569WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935741_20111230_20111229-9741-1-0023_LGWU703146-1037569WU_10.RCC.gz"
"GSM1935742","LGWU101088-1037572WU","GSM1935742","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101088","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935742/suppl/GSM1935742_20120104_20120103-9741-1-0023_LGWU101088-1037572WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935742_20120104_20120103-9741-1-0023_LGWU101088-1037572WU_01.RCC.gz"
"GSM1935743","LGWU109006-1037573WU","GSM1935743","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109006","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935743/suppl/GSM1935743_20120104_20120103-9741-1-0023_LGWU109006-1037573WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935743_20120104_20120103-9741-1-0023_LGWU109006-1037573WU_02.RCC.gz"
"GSM1935744","LGWU202880-1037583WU","GSM1935744","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 202880","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935744/suppl/GSM1935744_20120104_20120103-9741-1-0023_LGWU202880-1037583WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935744_20120104_20120103-9741-1-0023_LGWU202880-1037583WU_12.RCC.gz"
"GSM1935745","LGWU203917-1037576WU","GSM1935745","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203917","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935745/suppl/GSM1935745_20120104_20120103-9741-1-0023_LGWU203917-1037576WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935745_20120104_20120103-9741-1-0023_LGWU203917-1037576WU_05.RCC.gz"
"GSM1935746","LGWU702329-1037580WU","GSM1935746","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702329","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935746/suppl/GSM1935746_20120104_20120103-9741-1-0023_LGWU702329-1037580WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935746_20120104_20120103-9741-1-0023_LGWU702329-1037580WU_09.RCC.gz"
"GSM1935747","LGWU702733-1037575WU","GSM1935747","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702733","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935747/suppl/GSM1935747_20120104_20120103-9741-1-0023_LGWU702733-1037575WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935747_20120104_20120103-9741-1-0023_LGWU702733-1037575WU_04.RCC.gz"
"GSM1935748","LGWU702747-1037577WU","GSM1935748","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702747","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935748/suppl/GSM1935748_20120104_20120103-9741-1-0023_LGWU702747-1037577WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935748_20120104_20120103-9741-1-0023_LGWU702747-1037577WU_06.RCC.gz"
"GSM1935749","LGWU702758-1037581WU","GSM1935749","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702758","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935749/suppl/GSM1935749_20120104_20120103-9741-1-0023_LGWU702758-1037581WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935749_20120104_20120103-9741-1-0023_LGWU702758-1037581WU_10.RCC.gz"
"GSM1935750","LGWU703191-1037574WU","GSM1935750","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703191","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935750/suppl/GSM1935750_20120104_20120103-9741-1-0023_LGWU703191-1037574WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935750_20120104_20120103-9741-1-0023_LGWU703191-1037574WU_03.RCC.gz"
"GSM1935751","LGWU703226-1037578WU","GSM1935751","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703226","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935751/suppl/GSM1935751_20120104_20120103-9741-1-0023_LGWU703226-1037578WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935751_20120104_20120103-9741-1-0023_LGWU703226-1037578WU_07.RCC.gz"
"GSM1935752","LGWU703231-1037579WU","GSM1935752","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703231","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935752/suppl/GSM1935752_20120104_20120103-9741-1-0023_LGWU703231-1037579WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935752_20120104_20120103-9741-1-0023_LGWU703231-1037579WU_08.RCC.gz"
"GSM1935753","LGWU703280-1037582WU","GSM1935753","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703280","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935753/suppl/GSM1935753_20120104_20120103-9741-1-0023_LGWU703280-1037582WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935753_20120104_20120103-9741-1-0023_LGWU703280-1037582WU_11.RCC.gz"
"GSM1935754","LGWU107400-1037588WU","GSM1935754","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107400","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935754/suppl/GSM1935754_20120104_20120103-9741-2-0044_LGWU107400-1037588WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935754_20120104_20120103-9741-2-0044_LGWU107400-1037588WU_05.RCC.gz"
"GSM1935755","LGWU109172-1037585WU","GSM1935755","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109172","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935755/suppl/GSM1935755_20120104_20120103-9741-2-0044_LGWU109172-1037585WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935755_20120104_20120103-9741-2-0044_LGWU109172-1037585WU_02.RCC.gz"
"GSM1935756","LGWU209113-1037595WU","GSM1935756","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 209113","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935756/suppl/GSM1935756_20120104_20120103-9741-2-0044_LGWU209113-1037595WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935756_20120104_20120103-9741-2-0044_LGWU209113-1037595WU_12.RCC.gz"
"GSM1935757","LGWU702388-1037594WU","GSM1935757","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702388","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935757/suppl/GSM1935757_20120104_20120103-9741-2-0044_LGWU702388-1037594WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935757_20120104_20120103-9741-2-0044_LGWU702388-1037594WU_11.RCC.gz"
"GSM1935758","LGWU702822-1037589WU","GSM1935758","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702822","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935758/suppl/GSM1935758_20120104_20120103-9741-2-0044_LGWU702822-1037589WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935758_20120104_20120103-9741-2-0044_LGWU702822-1037589WU_06.RCC.gz"
"GSM1935759","LGWU702840-1037592WU","GSM1935759","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702840","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935759/suppl/GSM1935759_20120104_20120103-9741-2-0044_LGWU702840-1037592WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935759_20120104_20120103-9741-2-0044_LGWU702840-1037592WU_09.RCC.gz"
"GSM1935760","LGWU702844-1037593WU","GSM1935760","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702844","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935760/suppl/GSM1935760_20120104_20120103-9741-2-0044_LGWU702844-1037593WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935760_20120104_20120103-9741-2-0044_LGWU702844-1037593WU_10.RCC.gz"
"GSM1935761","LGWU703292-1037584WU","GSM1935761","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703292","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935761/suppl/GSM1935761_20120104_20120103-9741-2-0044_LGWU703292-1037584WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935761_20120104_20120103-9741-2-0044_LGWU703292-1037584WU_01.RCC.gz"
"GSM1935762","LGWU703345-1037586WU","GSM1935762","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703345","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935762/suppl/GSM1935762_20120104_20120103-9741-2-0044_LGWU703345-1037586WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935762_20120104_20120103-9741-2-0044_LGWU703345-1037586WU_03.RCC.gz"
"GSM1935763","LGWU703348-1037587WU","GSM1935763","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703348","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935763/suppl/GSM1935763_20120104_20120103-9741-2-0044_LGWU703348-1037587WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935763_20120104_20120103-9741-2-0044_LGWU703348-1037587WU_04.RCC.gz"
"GSM1935764","LGWU703409-1037590WU","GSM1935764","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703409","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935764/suppl/GSM1935764_20120104_20120103-9741-2-0044_LGWU703409-1037590WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935764_20120104_20120103-9741-2-0044_LGWU703409-1037590WU_07.RCC.gz"
"GSM1935765","LGWU703424-1037591WU","GSM1935765","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703424","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935765/suppl/GSM1935765_20120104_20120103-9741-2-0044_LGWU703424-1037591WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935765_20120104_20120103-9741-2-0044_LGWU703424-1037591WU_08.RCC.gz"
"GSM1935766","LGWU102464-1037606WU","GSM1935766","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102464","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935766/suppl/GSM1935766_20120104_20120103-9741-3-0023_LGWU102464-1037606WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935766_20120104_20120103-9741-3-0023_LGWU102464-1037606WU_11.RCC.gz"
"GSM1935767","LGWU107315-1037597WU","GSM1935767","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107315","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935767/suppl/GSM1935767_20120104_20120103-9741-3-0023_LGWU107315-1037597WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935767_20120104_20120103-9741-3-0023_LGWU107315-1037597WU_02.RCC.gz"
"GSM1935768","LGWU216390-1037605WU","GSM1935768","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 216390","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935768/suppl/GSM1935768_20120104_20120103-9741-3-0023_LGWU216390-1037605WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935768_20120104_20120103-9741-3-0023_LGWU216390-1037605WU_10.RCC.gz"
"GSM1935769","LGWU702282-1037600WU","GSM1935769","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702282","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935769/suppl/GSM1935769_20120104_20120103-9741-3-0023_LGWU702282-1037600WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935769_20120104_20120103-9741-3-0023_LGWU702282-1037600WU_05.RCC.gz"
"GSM1935770","LGWU702292-1037607WU","GSM1935770","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702292","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935770/suppl/GSM1935770_20120104_20120103-9741-3-0023_LGWU702292-1037607WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935770_20120104_20120103-9741-3-0023_LGWU702292-1037607WU_12.RCC.gz"
"GSM1935771","LGWU702325-1037603WU","GSM1935771","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702325","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935771/suppl/GSM1935771_20120104_20120103-9741-3-0023_LGWU702325-1037603WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935771_20120104_20120103-9741-3-0023_LGWU702325-1037603WU_08.RCC.gz"
"GSM1935772","LGWU702486-1037596WU","GSM1935772","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702486","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935772/suppl/GSM1935772_20120104_20120103-9741-3-0023_LGWU702486-1037596WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935772_20120104_20120103-9741-3-0023_LGWU702486-1037596WU_01.RCC.gz"
"GSM1935773","LGWU702597-1037598WU","GSM1935773","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702597","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935773/suppl/GSM1935773_20120104_20120103-9741-3-0023_LGWU702597-1037598WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935773_20120104_20120103-9741-3-0023_LGWU702597-1037598WU_03.RCC.gz"
"GSM1935774","LGWU702928-1037599WU","GSM1935774","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702928","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935774/suppl/GSM1935774_20120104_20120103-9741-3-0023_LGWU702928-1037599WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935774_20120104_20120103-9741-3-0023_LGWU702928-1037599WU_04.RCC.gz"
"GSM1935775","LGWU703160-1037601WU","GSM1935775","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703160","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935775/suppl/GSM1935775_20120104_20120103-9741-3-0023_LGWU703160-1037601WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935775_20120104_20120103-9741-3-0023_LGWU703160-1037601WU_06.RCC.gz"
"GSM1935776","LGWU703175-1037602WU","GSM1935776","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703175","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935776/suppl/GSM1935776_20120104_20120103-9741-3-0023_LGWU703175-1037602WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935776_20120104_20120103-9741-3-0023_LGWU703175-1037602WU_07.RCC.gz"
"GSM1935777","LGWU703279-1037604WU","GSM1935777","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703279","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935777/suppl/GSM1935777_20120104_20120103-9741-3-0023_LGWU703279-1037604WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935777_20120104_20120103-9741-3-0023_LGWU703279-1037604WU_09.RCC.gz"
"GSM1935778","LGWU102498-1037611WU","GSM1935778","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102498","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935778/suppl/GSM1935778_20120104_20120103-9741-4-0044_LGWU102498-1037611WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935778_20120104_20120103-9741-4-0044_LGWU102498-1037611WU_04.RCC.gz"
"GSM1935779","LGWU102563-1037613WU","GSM1935779","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102563","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935779/suppl/GSM1935779_20120104_20120103-9741-4-0044_LGWU102563-1037613WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935779_20120104_20120103-9741-4-0044_LGWU102563-1037613WU_06.RCC.gz"
"GSM1935780","LGWU102609-1037614WU","GSM1935780","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102609","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935780/suppl/GSM1935780_20120104_20120103-9741-4-0044_LGWU102609-1037614WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935780_20120104_20120103-9741-4-0044_LGWU102609-1037614WU_07.RCC.gz"
"GSM1935781","LGWU102737-1037617WU","GSM1935781","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102737","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935781/suppl/GSM1935781_20120104_20120103-9741-4-0044_LGWU102737-1037617WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935781_20120104_20120103-9741-4-0044_LGWU102737-1037617WU_10.RCC.gz"
"GSM1935782","LGWU102784-1037616WU","GSM1935782","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102784","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935782/suppl/GSM1935782_20120104_20120103-9741-4-0044_LGWU102784-1037616WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935782_20120104_20120103-9741-4-0044_LGWU102784-1037616WU_09.RCC.gz"
"GSM1935783","LGWU107280-1037612WU","GSM1935783","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107280","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935783/suppl/GSM1935783_20120104_20120103-9741-4-0044_LGWU107280-1037612WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935783_20120104_20120103-9741-4-0044_LGWU107280-1037612WU_05.RCC.gz"
"GSM1935784","LGWU107310-1037615WU","GSM1935784","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107310","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935784/suppl/GSM1935784_20120104_20120103-9741-4-0044_LGWU107310-1037615WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935784_20120104_20120103-9741-4-0044_LGWU107310-1037615WU_08.RCC.gz"
"GSM1935785","LGWU108964-1037619WU","GSM1935785","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108964","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935785/suppl/GSM1935785_20120104_20120103-9741-4-0044_LGWU108964-1037619WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935785_20120104_20120103-9741-4-0044_LGWU108964-1037619WU_12.RCC.gz"
"GSM1935786","LGWU108970-1037618WU","GSM1935786","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108970","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935786/suppl/GSM1935786_20120104_20120103-9741-4-0044_LGWU108970-1037618WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935786_20120104_20120103-9741-4-0044_LGWU108970-1037618WU_11.RCC.gz"
"GSM1935787","LGWU207172-1037610WU","GSM1935787","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 207172","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935787/suppl/GSM1935787_20120104_20120103-9741-4-0044_LGWU207172-1037610WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935787_20120104_20120103-9741-4-0044_LGWU207172-1037610WU_03.RCC.gz"
"GSM1935788","LGWU702756-1037609WU","GSM1935788","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702756","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935788/suppl/GSM1935788_20120104_20120103-9741-4-0044_LGWU702756-1037609WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935788_20120104_20120103-9741-4-0044_LGWU702756-1037609WU_02.RCC.gz"
"GSM1935789","LGWU703162-1037608WU","GSM1935789","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703162","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935789/suppl/GSM1935789_20120104_20120103-9741-4-0044_LGWU703162-1037608WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935789_20120104_20120103-9741-4-0044_LGWU703162-1037608WU_01.RCC.gz"
"GSM1935790","LGWU102585-1037628WU","GSM1935790","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102585","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935790/suppl/GSM1935790_20120105_20120104-9741-1-0023_LGWU102585-1037628WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935790_20120105_20120104-9741-1-0023_LGWU102585-1037628WU_09.RCC.gz"
"GSM1935791","LGWU102611-1037627WU","GSM1935791","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102611","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935791/suppl/GSM1935791_20120105_20120104-9741-1-0023_LGWU102611-1037627WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935791_20120105_20120104-9741-1-0023_LGWU102611-1037627WU_08.RCC.gz"
"GSM1935792","LGWU102721-1037626WU","GSM1935792","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102721","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935792/suppl/GSM1935792_20120105_20120104-9741-1-0023_LGWU102721-1037626WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935792_20120105_20120104-9741-1-0023_LGWU102721-1037626WU_07.RCC.gz"
"GSM1935793","LGWU102724-1037629WU","GSM1935793","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102724","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935793/suppl/GSM1935793_20120105_20120104-9741-1-0023_LGWU102724-1037629WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935793_20120105_20120104-9741-1-0023_LGWU102724-1037629WU_10.RCC.gz"
"GSM1935794","LGWU1054031-1037620WU","GSM1935794","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 105403","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935794/suppl/GSM1935794_20120105_20120104-9741-1-0023_LGWU1054031-1037620WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935794_20120105_20120104-9741-1-0023_LGWU1054031-1037620WU_01.RCC.gz"
"GSM1935795","LGWU1054033-1037625WU","GSM1935795","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 105403","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935795/suppl/GSM1935795_20120105_20120104-9741-1-0023_LGWU1054033-1037625WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935795_20120105_20120104-9741-1-0023_LGWU1054033-1037625WU_06.RCC.gz"
"GSM1935796","LGWU108924-1037631WU","GSM1935796","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108924","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935796/suppl/GSM1935796_20120105_20120104-9741-1-0023_LGWU108924-1037631WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935796_20120105_20120104-9741-1-0023_LGWU108924-1037631WU_12.RCC.gz"
"GSM1935797","LGWU109110-1037621WU","GSM1935797","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109110","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935797/suppl/GSM1935797_20120105_20120104-9741-1-0023_LGWU109110-1037621WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935797_20120105_20120104-9741-1-0023_LGWU109110-1037621WU_02.RCC.gz"
"GSM1935798","LGWU109176-1037630WU","GSM1935798","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109176","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935798/suppl/GSM1935798_20120105_20120104-9741-1-0023_LGWU109176-1037630WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935798_20120105_20120104-9741-1-0023_LGWU109176-1037630WU_11.RCC.gz"
"GSM1935799","LGWU109393-1037624WU","GSM1935799","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109393","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935799/suppl/GSM1935799_20120105_20120104-9741-1-0023_LGWU109393-1037624WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935799_20120105_20120104-9741-1-0023_LGWU109393-1037624WU_05.RCC.gz"
"GSM1935800","LGWU102006-1037636WU","GSM1935800","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102006","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935800/suppl/GSM1935800_20120106_20120104-9741-2-0044_LGWU102006-1037636WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935800_20120106_20120104-9741-2-0044_LGWU102006-1037636WU_04.RCC.gz"
"GSM1935801","LGWU102496-1037642WU","GSM1935801","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102496","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935801/suppl/GSM1935801_20120106_20120104-9741-2-0044_LGWU102496-1037642WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935801_20120106_20120104-9741-2-0044_LGWU102496-1037642WU_09.RCC.gz"
"GSM1935802","LGWU102560-1037644WU","GSM1935802","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102560","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935802/suppl/GSM1935802_20120106_20120104-9741-2-0044_LGWU102560-1037644WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935802_20120106_20120104-9741-2-0044_LGWU102560-1037644WU_11.RCC.gz"
"GSM1935803","LGWU103904-1037633WU","GSM1935803","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 103904","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935803/suppl/GSM1935803_20120106_20120104-9741-2-0044_LGWU103904-1037633WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935803_20120106_20120104-9741-2-0044_LGWU103904-1037633WU_02.RCC.gz"
"GSM1935804","LGWU107296-1037643WU","GSM1935804","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107296","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935804/suppl/GSM1935804_20120106_20120104-9741-2-0044_LGWU107296-1037643WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935804_20120106_20120104-9741-2-0044_LGWU107296-1037643WU_10.RCC.gz"
"GSM1935805","LGWU108947-1037632WU","GSM1935805","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108947","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935805/suppl/GSM1935805_20120106_20120104-9741-2-0044_LGWU108947-1037632WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935805_20120106_20120104-9741-2-0044_LGWU108947-1037632WU_01.RCC.gz"
"GSM1935806","LGWU200916-1037641WU","GSM1935806","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200916","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935806/suppl/GSM1935806_20120106_20120104-9741-2-0044_LGWU200916-1037641WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935806_20120106_20120104-9741-2-0044_LGWU200916-1037641WU_08.RCC.gz"
"GSM1935807","LGWU702221-1037638WU","GSM1935807","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702221","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935807/suppl/GSM1935807_20120106_20120104-9741-2-0044_LGWU702221-1037638WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935807_20120106_20120104-9741-2-0044_LGWU702221-1037638WU_06.RCC.gz"
"GSM1935808","LGWU702375-1037640WU","GSM1935808","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702375","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935808/suppl/GSM1935808_20120106_20120104-9741-2-0044_LGWU702375-1037640WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935808_20120106_20120104-9741-2-0044_LGWU702375-1037640WU_07.RCC.gz"
"GSM1935809","LGWU702404-1037645WU","GSM1935809","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702404","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935809/suppl/GSM1935809_20120106_20120104-9741-2-0044_LGWU702404-1037645WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935809_20120106_20120104-9741-2-0044_LGWU702404-1037645WU_12.RCC.gz"
"GSM1935810","LGWU102530-1037647WU","GSM1935810","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102530","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935810/suppl/GSM1935810_20120106_20120104-9741-3-0023_LGWU102530-1037647WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935810_20120106_20120104-9741-3-0023_LGWU102530-1037647WU_02.RCC.gz"
"GSM1935811","LGWU102594-1037654WU","GSM1935811","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102594","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935811/suppl/GSM1935811_20120106_20120104-9741-3-0023_LGWU102594-1037654WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935811_20120106_20120104-9741-3-0023_LGWU102594-1037654WU_09.RCC.gz"
"GSM1935812","LGWU107297-1037656WU","GSM1935812","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107297","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935812/suppl/GSM1935812_20120106_20120104-9741-3-0023_LGWU107297-1037656WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935812_20120106_20120104-9741-3-0023_LGWU107297-1037656WU_11.RCC.gz"
"GSM1935813","LGWU107374-1037650WU","GSM1935813","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107374","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935813/suppl/GSM1935813_20120106_20120104-9741-3-0023_LGWU107374-1037650WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935813_20120106_20120104-9741-3-0023_LGWU107374-1037650WU_05.RCC.gz"
"GSM1935814","LGWU200883-1037657WU","GSM1935814","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200883","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935814/suppl/GSM1935814_20120106_20120104-9741-3-0023_LGWU200883-1037657WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935814_20120106_20120104-9741-3-0023_LGWU200883-1037657WU_12.RCC.gz"
"GSM1935815","LGWU209110-1037655WU","GSM1935815","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 209110","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935815/suppl/GSM1935815_20120106_20120104-9741-3-0023_LGWU209110-1037655WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935815_20120106_20120104-9741-3-0023_LGWU209110-1037655WU_10.RCC.gz"
"GSM1935816","LGWU702180-1037649WU","GSM1935816","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702180","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935816/suppl/GSM1935816_20120106_20120104-9741-3-0023_LGWU702180-1037649WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935816_20120106_20120104-9741-3-0023_LGWU702180-1037649WU_04.RCC.gz"
"GSM1935817","LGWU702409-1037646WU","GSM1935817","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702409","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935817/suppl/GSM1935817_20120106_20120104-9741-3-0023_LGWU702409-1037646WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935817_20120106_20120104-9741-3-0023_LGWU702409-1037646WU_01.RCC.gz"
"GSM1935818","LGWU702422-1037648WU","GSM1935818","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702422","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935818/suppl/GSM1935818_20120106_20120104-9741-3-0023_LGWU702422-1037648WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935818_20120106_20120104-9741-3-0023_LGWU702422-1037648WU_03.RCC.gz"
"GSM1935819","LGWU702439-1037651WU","GSM1935819","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702439","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935819/suppl/GSM1935819_20120106_20120104-9741-3-0023_LGWU702439-1037651WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935819_20120106_20120104-9741-3-0023_LGWU702439-1037651WU_06.RCC.gz"
"GSM1935820","LGWU702462-1037652WU","GSM1935820","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702462","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935820/suppl/GSM1935820_20120106_20120104-9741-3-0023_LGWU702462-1037652WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935820_20120106_20120104-9741-3-0023_LGWU702462-1037652WU_07.RCC.gz"
"GSM1935821","LGWU702466-1037653WU","GSM1935821","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702466","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935821/suppl/GSM1935821_20120106_20120104-9741-3-0023_LGWU702466-1037653WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935821_20120106_20120104-9741-3-0023_LGWU702466-1037653WU_08.RCC.gz"
"GSM1935822","LGWU102745-1037666WU","GSM1935822","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102745","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935822/suppl/GSM1935822_20120106_20120104-9741-4-0044_LGWU102745-1037666WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935822_20120106_20120104-9741-4-0044_LGWU102745-1037666WU_09.RCC.gz"
"GSM1935823","LGWU200930-1037659WU","GSM1935823","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200930","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935823/suppl/GSM1935823_20120106_20120104-9741-4-0044_LGWU200930-1037659WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935823_20120106_20120104-9741-4-0044_LGWU200930-1037659WU_02.RCC.gz"
"GSM1935824","LGWU702236-1037660WU","GSM1935824","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702236","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935824/suppl/GSM1935824_20120106_20120104-9741-4-0044_LGWU702236-1037660WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935824_20120106_20120104-9741-4-0044_LGWU702236-1037660WU_03.RCC.gz"
"GSM1935825","LGWU702246-1037665WU","GSM1935825","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702246","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935825/suppl/GSM1935825_20120106_20120104-9741-4-0044_LGWU702246-1037665WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935825_20120106_20120104-9741-4-0044_LGWU702246-1037665WU_08.RCC.gz"
"GSM1935826","LGWU702534-1037658WU","GSM1935826","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702534","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935826/suppl/GSM1935826_20120106_20120104-9741-4-0044_LGWU702534-1037658WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935826_20120106_20120104-9741-4-0044_LGWU702534-1037658WU_01.RCC.gz"
"GSM1935827","LGWU702578-1037661WU","GSM1935827","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702578","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935827/suppl/GSM1935827_20120106_20120104-9741-4-0044_LGWU702578-1037661WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935827_20120106_20120104-9741-4-0044_LGWU702578-1037661WU_04.RCC.gz"
"GSM1935828","LGWU702591-1037662WU","GSM1935828","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702591","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935828/suppl/GSM1935828_20120106_20120104-9741-4-0044_LGWU702591-1037662WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935828_20120106_20120104-9741-4-0044_LGWU702591-1037662WU_05.RCC.gz"
"GSM1935829","LGWU702602-1037663WU","GSM1935829","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702602","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935829/suppl/GSM1935829_20120106_20120104-9741-4-0044_LGWU702602-1037663WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935829_20120106_20120104-9741-4-0044_LGWU702602-1037663WU_06.RCC.gz"
"GSM1935830","LGWU702607-1037664WU","GSM1935830","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702607","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935830/suppl/GSM1935830_20120106_20120104-9741-4-0044_LGWU702607-1037664WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935830_20120106_20120104-9741-4-0044_LGWU702607-1037664WU_07.RCC.gz"
"GSM1935831","LGWU702638-1037667WU","GSM1935831","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702638","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935831/suppl/GSM1935831_20120106_20120104-9741-4-0044_LGWU702638-1037667WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935831_20120106_20120104-9741-4-0044_LGWU702638-1037667WU_10.RCC.gz"
"GSM1935832","LGWU702648-1037668WU","GSM1935832","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702648","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935832/suppl/GSM1935832_20120106_20120104-9741-4-0044_LGWU702648-1037668WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935832_20120106_20120104-9741-4-0044_LGWU702648-1037668WU_11.RCC.gz"
"GSM1935833","LGWU702665-1037669WU","GSM1935833","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702665","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935833/suppl/GSM1935833_20120106_20120104-9741-4-0044_LGWU702665-1037669WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935833_20120106_20120104-9741-4-0044_LGWU702665-1037669WU_12.RCC.gz"
"GSM1935834","LGWU102595-1037671WU","GSM1935834","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102595","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935834/suppl/GSM1935834_20120106_20120105-9741-1-0023_LGWU102595-1037671WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935834_20120106_20120105-9741-1-0023_LGWU102595-1037671WU_02.RCC.gz"
"GSM1935835","LGWU102785-1037674WU","GSM1935835","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102785","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935835/suppl/GSM1935835_20120106_20120105-9741-1-0023_LGWU102785-1037674WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935835_20120106_20120105-9741-1-0023_LGWU102785-1037674WU_05.RCC.gz"
"GSM1935836","LGWU109094-1037677WU","GSM1935836","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109094","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935836/suppl/GSM1935836_20120106_20120105-9741-1-0023_LGWU109094-1037677WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935836_20120106_20120105-9741-1-0023_LGWU109094-1037677WU_08.RCC.gz"
"GSM1935837","LGWU202239-1037675WU","GSM1935837","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 202239","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935837/suppl/GSM1935837_20120106_20120105-9741-1-0023_LGWU202239-1037675WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935837_20120106_20120105-9741-1-0023_LGWU202239-1037675WU_06.RCC.gz"
"GSM1935838","LGWU702294-1037673WU","GSM1935838","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702294","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935838/suppl/GSM1935838_20120106_20120105-9741-1-0023_LGWU702294-1037673WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935838_20120106_20120105-9741-1-0023_LGWU702294-1037673WU_04.RCC.gz"
"GSM1935839","LGWU702322-1037676WU","GSM1935839","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702322","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935839/suppl/GSM1935839_20120106_20120105-9741-1-0023_LGWU702322-1037676WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935839_20120106_20120105-9741-1-0023_LGWU702322-1037676WU_07.RCC.gz"
"GSM1935840","LGWU702332-1037678WU","GSM1935840","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702332","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935840/suppl/GSM1935840_20120106_20120105-9741-1-0023_LGWU702332-1037678WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935840_20120106_20120105-9741-1-0023_LGWU702332-1037678WU_09.RCC.gz"
"GSM1935841","LGWU702668-1037670WU","GSM1935841","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702668","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935841/suppl/GSM1935841_20120106_20120105-9741-1-0023_LGWU702668-1037670WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935841_20120106_20120105-9741-1-0023_LGWU702668-1037670WU_01.RCC.gz"
"GSM1935842","LGWU702694-1037672WU","GSM1935842","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702694","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935842/suppl/GSM1935842_20120106_20120105-9741-1-0023_LGWU702694-1037672WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935842_20120106_20120105-9741-1-0023_LGWU702694-1037672WU_03.RCC.gz"
"GSM1935843","LGWU702768-1037679WU","GSM1935843","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702768","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935843/suppl/GSM1935843_20120106_20120105-9741-1-0023_LGWU702768-1037679WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935843_20120106_20120105-9741-1-0023_LGWU702768-1037679WU_10.RCC.gz"
"GSM1935844","LGWU702779-1037680WU","GSM1935844","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702779","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935844/suppl/GSM1935844_20120106_20120105-9741-1-0023_LGWU702779-1037680WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935844_20120106_20120105-9741-1-0023_LGWU702779-1037680WU_11.RCC.gz"
"GSM1935845","LGWU703304-1037681WU","GSM1935845","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703304","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935845/suppl/GSM1935845_20120106_20120105-9741-1-0023_LGWU703304-1037681WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935845_20120106_20120105-9741-1-0023_LGWU703304-1037681WU_12.RCC.gz"
"GSM1935846","LGWU109189-1037683WU","GSM1935846","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109189","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935846/suppl/GSM1935846_20120106_20120105-9741-2-0044_LGWU109189-1037683WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935846_20120106_20120105-9741-2-0044_LGWU109189-1037683WU_02.RCC.gz"
"GSM1935847","LGWU109330-1037689WU","GSM1935847","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109330","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935847/suppl/GSM1935847_20120106_20120105-9741-2-0044_LGWU109330-1037689WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935847_20120106_20120105-9741-2-0044_LGWU109330-1037689WU_08.RCC.gz"
"GSM1935848","LGWU207150-1037688WU","GSM1935848","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 207150","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935848/suppl/GSM1935848_20120106_20120105-9741-2-0044_LGWU207150-1037688WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935848_20120106_20120105-9741-2-0044_LGWU207150-1037688WU_07.RCC.gz"
"GSM1935849","LGWU703312-1037682WU","GSM1935849","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703312","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935849/suppl/GSM1935849_20120106_20120105-9741-2-0044_LGWU703312-1037682WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935849_20120106_20120105-9741-2-0044_LGWU703312-1037682WU_01.RCC.gz"
"GSM1935850","LGWU703324-1037684WU","GSM1935850","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703324","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935850/suppl/GSM1935850_20120106_20120105-9741-2-0044_LGWU703324-1037684WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935850_20120106_20120105-9741-2-0044_LGWU703324-1037684WU_03.RCC.gz"
"GSM1935851","LGWU703349-1037685WU","GSM1935851","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703349","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935851/suppl/GSM1935851_20120106_20120105-9741-2-0044_LGWU703349-1037685WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935851_20120106_20120105-9741-2-0044_LGWU703349-1037685WU_04.RCC.gz"
"GSM1935852","LGWU703356-1037686WU","GSM1935852","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703356","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935852/suppl/GSM1935852_20120106_20120105-9741-2-0044_LGWU703356-1037686WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935852_20120106_20120105-9741-2-0044_LGWU703356-1037686WU_05.RCC.gz"
"GSM1935853","LGWU703362-1037687WU","GSM1935853","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703362","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935853/suppl/GSM1935853_20120106_20120105-9741-2-0044_LGWU703362-1037687WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935853_20120106_20120105-9741-2-0044_LGWU703362-1037687WU_06.RCC.gz"
"GSM1935854","LGWU703393-1037690WU","GSM1935854","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703393","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935854/suppl/GSM1935854_20120106_20120105-9741-2-0044_LGWU703393-1037690WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935854_20120106_20120105-9741-2-0044_LGWU703393-1037690WU_09.RCC.gz"
"GSM1935855","LGWU703427-1037692WU","GSM1935855","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703427","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935855/suppl/GSM1935855_20120106_20120105-9741-2-0044_LGWU703427-1037692WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935855_20120106_20120105-9741-2-0044_LGWU703427-1037692WU_11.RCC.gz"
"GSM1935856","LGWU703430-1037693WU","GSM1935856","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703430","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935856/suppl/GSM1935856_20120106_20120105-9741-2-0044_LGWU703430-1037693WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935856_20120106_20120105-9741-2-0044_LGWU703430-1037693WU_12.RCC.gz"
"GSM1935857","LGWU101990-1037696WU","GSM1935857","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101990","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935857/suppl/GSM1935857_20120110_20120109-9741-1-0023_LGWU101990-1037696WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935857_20120110_20120109-9741-1-0023_LGWU101990-1037696WU_03.RCC.gz"
"GSM1935858","LGWU101996-1037694WU","GSM1935858","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101996","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935858/suppl/GSM1935858_20120110_20120109-9741-1-0023_LGWU101996-1037694WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935858_20120110_20120109-9741-1-0023_LGWU101996-1037694WU_01.RCC.gz"
"GSM1935859","LGWU102628-1037698WU","GSM1935859","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102628","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935859/suppl/GSM1935859_20120110_20120109-9741-1-0023_LGWU102628-1037698WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935859_20120110_20120109-9741-1-0023_LGWU102628-1037698WU_05.RCC.gz"
"GSM1935860","LGWU102722-1037699WU","GSM1935860","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102722","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935860/suppl/GSM1935860_20120110_20120109-9741-1-0023_LGWU102722-1037699WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935860_20120110_20120109-9741-1-0023_LGWU102722-1037699WU_06.RCC.gz"
"GSM1935861","LGWU200390-1037705WU","GSM1935861","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200390","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935861/suppl/GSM1935861_20120110_20120109-9741-1-0023_LGWU200390-1037705WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935861_20120110_20120109-9741-1-0023_LGWU200390-1037705WU_12.RCC.gz"
"GSM1935862","LGWU702287-1037700WU","GSM1935862","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702287","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935862/suppl/GSM1935862_20120110_20120109-9741-1-0023_LGWU702287-1037700WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935862_20120110_20120109-9741-1-0023_LGWU702287-1037700WU_07.RCC.gz"
"GSM1935863","LGWU702303-1037701WU","GSM1935863","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702303","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935863/suppl/GSM1935863_20120110_20120109-9741-1-0023_LGWU702303-1037701WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935863_20120110_20120109-9741-1-0023_LGWU702303-1037701WU_08.RCC.gz"
"GSM1935864","LGWU702304-1037702WU","GSM1935864","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702304","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935864/suppl/GSM1935864_20120110_20120109-9741-1-0023_LGWU702304-1037702WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935864_20120110_20120109-9741-1-0023_LGWU702304-1037702WU_09.RCC.gz"
"GSM1935865","LGWU702511-1037697WU","GSM1935865","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702511","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935865/suppl/GSM1935865_20120110_20120109-9741-1-0023_LGWU702511-1037697WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935865_20120110_20120109-9741-1-0023_LGWU702511-1037697WU_04.RCC.gz"
"GSM1935866","LGWU702842-1037695WU","GSM1935866","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702842","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935866/suppl/GSM1935866_20120110_20120109-9741-1-0023_LGWU702842-1037695WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935866_20120110_20120109-9741-1-0023_LGWU702842-1037695WU_02.RCC.gz"
"GSM1935867","LGWU703209-1037703WU","GSM1935867","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703209","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935867/suppl/GSM1935867_20120110_20120109-9741-1-0023_LGWU703209-1037703WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935867_20120110_20120109-9741-1-0023_LGWU703209-1037703WU_10.RCC.gz"
"GSM1935868","LGWU703284-1037704WU","GSM1935868","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703284","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935868/suppl/GSM1935868_20120110_20120109-9741-1-0023_LGWU703284-1037704WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935868_20120110_20120109-9741-1-0023_LGWU703284-1037704WU_11.RCC.gz"
"GSM1935869","LGWU102016-1037708WU","GSM1935869","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102016","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935869/suppl/GSM1935869_20120110_20120109-9741-2-0044_LGWU102016-1037708WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935869_20120110_20120109-9741-2-0044_LGWU102016-1037708WU_02.RCC.gz"
"GSM1935870","LGWU102487-1037710WU","GSM1935870","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102487","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935870/suppl/GSM1935870_20120110_20120109-9741-2-0044_LGWU102487-1037710WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935870_20120110_20120109-9741-2-0044_LGWU102487-1037710WU_04.RCC.gz"
"GSM1935871","LGWU102518-1037715WU","GSM1935871","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102518","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935871/suppl/GSM1935871_20120110_20120109-9741-2-0044_LGWU102518-1037715WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935871_20120110_20120109-9741-2-0044_LGWU102518-1037715WU_09.RCC.gz"
"GSM1935872","LGWU102528-1037713WU","GSM1935872","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102528","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935872/suppl/GSM1935872_20120110_20120109-9741-2-0044_LGWU102528-1037713WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935872_20120110_20120109-9741-2-0044_LGWU102528-1037713WU_07.RCC.gz"
"GSM1935873","LGWU102579-1037716WU","GSM1935873","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102579","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935873/suppl/GSM1935873_20120110_20120109-9741-2-0044_LGWU102579-1037716WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935873_20120110_20120109-9741-2-0044_LGWU102579-1037716WU_10.RCC.gz"
"GSM1935874","LGWU107253-1037712WU","GSM1935874","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107253","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935874/suppl/GSM1935874_20120110_20120109-9741-2-0044_LGWU107253-1037712WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935874_20120110_20120109-9741-2-0044_LGWU107253-1037712WU_06.RCC.gz"
"GSM1935875","LGWU205214-1037706WU","GSM1935875","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 205214","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935875/suppl/GSM1935875_20120110_20120109-9741-2-0044_LGWU205214-1037706WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935875_20120110_20120109-9741-2-0044_LGWU205214-1037706WU_01.RCC.gz"
"GSM1935876","LGWU206253-1037718WU","GSM1935876","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 206253","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935876/suppl/GSM1935876_20120110_20120109-9741-2-0044_LGWU206253-1037718WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935876_20120110_20120109-9741-2-0044_LGWU206253-1037718WU_12.RCC.gz"
"GSM1935877","LGWU702158-1037711WU","GSM1935877","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702158","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935877/suppl/GSM1935877_20120110_20120109-9741-2-0044_LGWU702158-1037711WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935877_20120110_20120109-9741-2-0044_LGWU702158-1037711WU_05.RCC.gz"
"GSM1935878","LGWU702396-1037714WU","GSM1935878","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702396","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935878/suppl/GSM1935878_20120110_20120109-9741-2-0044_LGWU702396-1037714WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935878_20120110_20120109-9741-2-0044_LGWU702396-1037714WU_08.RCC.gz"
"GSM1935879","LGWU702429-1037717WU","GSM1935879","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702429","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935879/suppl/GSM1935879_20120110_20120109-9741-2-0044_LGWU702429-1037717WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935879_20120110_20120109-9741-2-0044_LGWU702429-1037717WU_11.RCC.gz"
"GSM1935880","LGWU702767-1037709WU","GSM1935880","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702767","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935880/suppl/GSM1935880_20120110_20120109-9741-2-0044_LGWU702767-1037709WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935880_20120110_20120109-9741-2-0044_LGWU702767-1037709WU_03.RCC.gz"
"GSM1935881","LGWU102622-1037728WU","GSM1935881","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102622","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935881/suppl/GSM1935881_20120110_20120109-9741-3-0023_LGWU102622-1037728WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935881_20120110_20120109-9741-3-0023_LGWU102622-1037728WU_10.RCC.gz"
"GSM1935882","LGWU102636-1037725WU","GSM1935882","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102636","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935882/suppl/GSM1935882_20120110_20120109-9741-3-0023_LGWU102636-1037725WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935882_20120110_20120109-9741-3-0023_LGWU102636-1037725WU_07.RCC.gz"
"GSM1935883","LGWU702228-1037729WU","GSM1935883","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702228","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935883/suppl/GSM1935883_20120110_20120109-9741-3-0023_LGWU702228-1037729WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935883_20120110_20120109-9741-3-0023_LGWU702228-1037729WU_11.RCC.gz"
"GSM1935884","LGWU702488-1037722WU","GSM1935884","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702488","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935884/suppl/GSM1935884_20120110_20120109-9741-3-0023_LGWU702488-1037722WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935884_20120110_20120109-9741-3-0023_LGWU702488-1037722WU_04.RCC.gz"
"GSM1935885","LGWU702539-1037727WU","GSM1935885","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702539","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935885/suppl/GSM1935885_20120110_20120109-9741-3-0023_LGWU702539-1037727WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935885_20120110_20120109-9741-3-0023_LGWU702539-1037727WU_09.RCC.gz"
"GSM1935886","LGWU702582-1037730WU","GSM1935886","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702582","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935886/suppl/GSM1935886_20120110_20120109-9741-3-0023_LGWU702582-1037730WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935886_20120110_20120109-9741-3-0023_LGWU702582-1037730WU_12.RCC.gz"
"GSM1935887","LGWU102717-1037734WU","GSM1935887","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102717","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935887/suppl/GSM1935887_20120110_20120109-9741-4-0044_LGWU102717-1037734WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935887_20120110_20120109-9741-4-0044_LGWU102717-1037734WU_03.RCC.gz"
"GSM1935888","LGWU200913-1037740WU","GSM1935888","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200913","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935888/suppl/GSM1935888_20120110_20120109-9741-4-0044_LGWU200913-1037740WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935888_20120110_20120109-9741-4-0044_LGWU200913-1037740WU_09.RCC.gz"
"GSM1935889","LGWU702270-1037737WU","GSM1935889","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702270","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935889/suppl/GSM1935889_20120110_20120109-9741-4-0044_LGWU702270-1037737WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935889_20120110_20120109-9741-4-0044_LGWU702270-1037737WU_06.RCC.gz"
"GSM1935890","LGWU702636-1037733WU","GSM1935890","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702636","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935890/suppl/GSM1935890_20120110_20120109-9741-4-0044_LGWU702636-1037733WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935890_20120110_20120109-9741-4-0044_LGWU702636-1037733WU_02.RCC.gz"
"GSM1935891","LGWU702664-1037736WU","GSM1935891","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702664","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935891/suppl/GSM1935891_20120110_20120109-9741-4-0044_LGWU702664-1037736WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935891_20120110_20120109-9741-4-0044_LGWU702664-1037736WU_05.RCC.gz"
"GSM1935892","LGWU702737-1037743WU","GSM1935892","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702737","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935892/suppl/GSM1935892_20120110_20120109-9741-4-0044_LGWU702737-1037743WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935892_20120110_20120109-9741-4-0044_LGWU702737-1037743WU_12.RCC.gz"
"GSM1935893","LGWU703119-1037735WU","GSM1935893","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703119","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935893/suppl/GSM1935893_20120110_20120109-9741-4-0044_LGWU703119-1037735WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935893_20120110_20120109-9741-4-0044_LGWU703119-1037735WU_04.RCC.gz"
"GSM1935894","LGWU703161-1037738WU","GSM1935894","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703161","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935894/suppl/GSM1935894_20120110_20120109-9741-4-0044_LGWU703161-1037738WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935894_20120110_20120109-9741-4-0044_LGWU703161-1037738WU_07.RCC.gz"
"GSM1935895","LGWU703186-1037741WU","GSM1935895","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703186","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935895/suppl/GSM1935895_20120110_20120109-9741-4-0044_LGWU703186-1037741WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935895_20120110_20120109-9741-4-0044_LGWU703186-1037741WU_10.RCC.gz"
"GSM1935896","LGWU703200-1037742WU","GSM1935896","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703200","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935896/suppl/GSM1935896_20120110_20120109-9741-4-0044_LGWU703200-1037742WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935896_20120110_20120109-9741-4-0044_LGWU703200-1037742WU_11.RCC.gz"
"GSM1935897","LGWU101698-1037750WU","GSM1935897","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101698","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935897/suppl/GSM1935897_20120111_20120110-9741-1-0023_LGWU101698-1037750WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935897_20120111_20120110-9741-1-0023_LGWU101698-1037750WU_06.RCC.gz"
"GSM1935898","LGWU109129-1037749WU","GSM1935898","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109129","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935898/suppl/GSM1935898_20120111_20120110-9741-1-0023_LGWU109129-1037749WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935898_20120111_20120110-9741-1-0023_LGWU109129-1037749WU_05.RCC.gz"
"GSM1935899","LGWU112082-1037747WU","GSM1935899","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 112082","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935899/suppl/GSM1935899_20120111_20120110-9741-1-0023_LGWU112082-1037747WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935899_20120111_20120110-9741-1-0023_LGWU112082-1037747WU_03.RCC.gz"
"GSM1935900","LGWU200391-1037751WU","GSM1935900","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200391","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935900/suppl/GSM1935900_20120111_20120110-9741-1-0023_LGWU200391-1037751WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935900_20120111_20120110-9741-1-0023_LGWU200391-1037751WU_07.RCC.gz"
"GSM1935901","LGWU702364-1037754WU","GSM1935901","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702364","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935901/suppl/GSM1935901_20120111_20120110-9741-1-0023_LGWU702364-1037754WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935901_20120111_20120110-9741-1-0023_LGWU702364-1037754WU_10.RCC.gz"
"GSM1935902","LGWU702365-1037756WU","GSM1935902","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702365","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935902/suppl/GSM1935902_20120111_20120110-9741-1-0023_LGWU702365-1037756WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935902_20120111_20120110-9741-1-0023_LGWU702365-1037756WU_12.RCC.gz"
"GSM1935903","LGWU702770-1037746WU","GSM1935903","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702770","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935903/suppl/GSM1935903_20120111_20120110-9741-1-0023_LGWU702770-1037746WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935903_20120111_20120110-9741-1-0023_LGWU702770-1037746WU_02.RCC.gz"
"GSM1935904","LGWU702774-1037748WU","GSM1935904","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702774","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935904/suppl/GSM1935904_20120111_20120110-9741-1-0023_LGWU702774-1037748WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935904_20120111_20120110-9741-1-0023_LGWU702774-1037748WU_04.RCC.gz"
"GSM1935905","LGWU702818-1037753WU","GSM1935905","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702818","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935905/suppl/GSM1935905_20120111_20120110-9741-1-0023_LGWU702818-1037753WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935905_20120111_20120110-9741-1-0023_LGWU702818-1037753WU_09.RCC.gz"
"GSM1935906","LGWU702826-1037755WU","GSM1935906","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702826","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935906/suppl/GSM1935906_20120111_20120110-9741-1-0023_LGWU702826-1037755WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935906_20120111_20120110-9741-1-0023_LGWU702826-1037755WU_11.RCC.gz"
"GSM1935907","LGWU703223-1037744WU","GSM1935907","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703223","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935907/suppl/GSM1935907_20120111_20120110-9741-1-0023_LGWU703223-1037744WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935907_20120111_20120110-9741-1-0023_LGWU703223-1037744WU_01.RCC.gz"
"GSM1935908","LGWU703358-1037752WU","GSM1935908","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703358","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935908/suppl/GSM1935908_20120111_20120110-9741-1-0023_LGWU703358-1037752WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935908_20120111_20120110-9741-1-0023_LGWU703358-1037752WU_08.RCC.gz"
"GSM1935909","LGWU101089-1037758WU","GSM1935909","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101089","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935909/suppl/GSM1935909_20120119_20120110-9741-2-0044-rescan_LGWU101089-1037758WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935909_20120119_20120110-9741-2-0044-rescan_LGWU101089-1037758WU_02.RCC.gz"
"GSM1935910","LGWU102761-1037764WU","GSM1935910","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102761","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935910/suppl/GSM1935910_20120119_20120110-9741-2-0044-rescan_LGWU102761-1037764WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935910_20120119_20120110-9741-2-0044-rescan_LGWU102761-1037764WU_08.RCC.gz"
"GSM1935911","LGWU107273-1037759WU","GSM1935911","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107273","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935911/suppl/GSM1935911_20120119_20120110-9741-2-0044-rescan_LGWU107273-1037759WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935911_20120119_20120110-9741-2-0044-rescan_LGWU107273-1037759WU_03.RCC.gz"
"GSM1935912","LGWU200731-1037763WU","GSM1935912","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200731","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935912/suppl/GSM1935912_20120119_20120110-9741-2-0044-rescan_LGWU200731-1037763WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935912_20120119_20120110-9741-2-0044-rescan_LGWU200731-1037763WU_07.RCC.gz"
"GSM1935913","LGWU200855-1037768WU","GSM1935913","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200855","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935913/suppl/GSM1935913_20120119_20120110-9741-2-0044-rescan_LGWU200855-1037768WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935913_20120119_20120110-9741-2-0044-rescan_LGWU200855-1037768WU_11.RCC.gz"
"GSM1935914","LGWU205500-1037762WU","GSM1935914","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 205500","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935914/suppl/GSM1935914_20120119_20120110-9741-2-0044-rescan_LGWU205500-1037762WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935914_20120119_20120110-9741-2-0044-rescan_LGWU205500-1037762WU_06.RCC.gz"
"GSM1935915","LGWU209112-1037761WU","GSM1935915","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 209112","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935915/suppl/GSM1935915_20120119_20120110-9741-2-0044-rescan_LGWU209112-1037761WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935915_20120119_20120110-9741-2-0044-rescan_LGWU209112-1037761WU_05.RCC.gz"
"GSM1935916","LGWU702186-1037760WU","GSM1935916","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702186","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935916/suppl/GSM1935916_20120119_20120110-9741-2-0044-rescan_LGWU702186-1037760WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935916_20120119_20120110-9741-2-0044-rescan_LGWU702186-1037760WU_04.RCC.gz"
"GSM1935917","LGWU702610-1037766WU","GSM1935917","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702610","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935917/suppl/GSM1935917_20120119_20120110-9741-2-0044-rescan_LGWU702610-1037766WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935917_20120119_20120110-9741-2-0044-rescan_LGWU702610-1037766WU_09.RCC.gz"
"GSM1935918","LGWU702651-1037767WU","GSM1935918","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702651","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935918/suppl/GSM1935918_20120119_20120110-9741-2-0044-rescan_LGWU702651-1037767WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935918_20120119_20120110-9741-2-0044-rescan_LGWU702651-1037767WU_10.RCC.gz"
"GSM1935919","LGWU702659-1037769WU","GSM1935919","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702659","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935919/suppl/GSM1935919_20120119_20120110-9741-2-0044-rescan_LGWU702659-1037769WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935919_20120119_20120110-9741-2-0044-rescan_LGWU702659-1037769WU_12.RCC.gz"
"GSM1935920","LGWU702836-1037757WU","GSM1935920","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702836","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935920/suppl/GSM1935920_20120119_20120110-9741-2-0044-rescan_LGWU702836-1037757WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935920_20120119_20120110-9741-2-0044-rescan_LGWU702836-1037757WU_01.RCC.gz"
"GSM1935921","LGWU101994-1037779WU","GSM1935921","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101994","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935921/suppl/GSM1935921_20120119_20120110-9741-3-0023_LGWU101994-1037779WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935921_20120119_20120110-9741-3-0023_LGWU101994-1037779WU_10.RCC.gz"
"GSM1935922","LGWU102017-1037773WU","GSM1935922","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102017","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935922/suppl/GSM1935922_20120119_20120110-9741-3-0023_LGWU102017-1037773WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935922_20120119_20120110-9741-3-0023_LGWU102017-1037773WU_04.RCC.gz"
"GSM1935923","LGWU102584-1037781WU","GSM1935923","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102584","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935923/suppl/GSM1935923_20120119_20120110-9741-3-0023_LGWU102584-1037781WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935923_20120119_20120110-9741-3-0023_LGWU102584-1037781WU_12.RCC.gz"
"GSM1935924","LGWU203489-1037775WU","GSM1935924","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203489","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935924/suppl/GSM1935924_20120119_20120110-9741-3-0023_LGWU203489-1037775WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935924_20120119_20120110-9741-3-0023_LGWU203489-1037775WU_06.RCC.gz"
"GSM1935925","LGWU221535-1037772WU","GSM1935925","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 221535","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935925/suppl/GSM1935925_20120119_20120110-9741-3-0023_LGWU221535-1037772WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935925_20120119_20120110-9741-3-0023_LGWU221535-1037772WU_03.RCC.gz"
"GSM1935926","LGWU702168-1037780WU","GSM1935926","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702168","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935926/suppl/GSM1935926_20120119_20120110-9741-3-0023_LGWU702168-1037780WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935926_20120119_20120110-9741-3-0023_LGWU702168-1037780WU_11.RCC.gz"
"GSM1935927","LGWU702274-1037770WU","GSM1935927","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702274","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935927/suppl/GSM1935927_20120119_20120110-9741-3-0023_LGWU702274-1037770WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935927_20120119_20120110-9741-3-0023_LGWU702274-1037770WU_01.RCC.gz"
"GSM1935928","LGWU702279-1037771WU","GSM1935928","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702279","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935928/suppl/GSM1935928_20120119_20120110-9741-3-0023_LGWU702279-1037771WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935928_20120119_20120110-9741-3-0023_LGWU702279-1037771WU_02.RCC.gz"
"GSM1935929","LGWU702336-1037776WU","GSM1935929","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702336","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935929/suppl/GSM1935929_20120119_20120110-9741-3-0023_LGWU702336-1037776WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935929_20120119_20120110-9741-3-0023_LGWU702336-1037776WU_07.RCC.gz"
"GSM1935930","LGWU702368-1037778WU","GSM1935930","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702368","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935930/suppl/GSM1935930_20120119_20120110-9741-3-0023_LGWU702368-1037778WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935930_20120119_20120110-9741-3-0023_LGWU702368-1037778WU_09.RCC.gz"
"GSM1935931","LGWU702713-1037774WU","GSM1935931","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702713","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935931/suppl/GSM1935931_20120119_20120110-9741-3-0023_LGWU702713-1037774WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935931_20120119_20120110-9741-3-0023_LGWU702713-1037774WU_05.RCC.gz"
"GSM1935932","LGWU703306-1037777WU","GSM1935932","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703306","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935932/suppl/GSM1935932_20120119_20120110-9741-3-0023_LGWU703306-1037777WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935932_20120119_20120110-9741-3-0023_LGWU703306-1037777WU_08.RCC.gz"
"GSM1935933","LGWU102681-1037792WU","GSM1935933","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102681","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935933/suppl/GSM1935933_20120119_20120110-9741-4-0044_LGWU102681-1037792WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935933_20120119_20120110-9741-4-0044_LGWU102681-1037792WU_11.RCC.gz"
"GSM1935934","LGWU203300-1037791WU","GSM1935934","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 203300","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935934/suppl/GSM1935934_20120119_20120110-9741-4-0044_LGWU203300-1037791WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935934_20120119_20120110-9741-4-0044_LGWU203300-1037791WU_10.RCC.gz"
"GSM1935935","LGWU702174-1037782WU","GSM1935935","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702174","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935935/suppl/GSM1935935_20120119_20120110-9741-4-0044_LGWU702174-1037782WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935935_20120119_20120110-9741-4-0044_LGWU702174-1037782WU_01.RCC.gz"
"GSM1935936","LGWU702240-1037788WU","GSM1935936","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702240","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935936/suppl/GSM1935936_20120119_20120110-9741-4-0044_LGWU702240-1037788WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935936_20120119_20120110-9741-4-0044_LGWU702240-1037788WU_07.RCC.gz"
"GSM1935937","LGWU702242-1037789WU","GSM1935937","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702242","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935937/suppl/GSM1935937_20120119_20120110-9741-4-0044_LGWU702242-1037789WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935937_20120119_20120110-9741-4-0044_LGWU702242-1037789WU_08.RCC.gz"
"GSM1935938","LGWU702247-1037793WU","GSM1935938","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702247","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935938/suppl/GSM1935938_20120119_20120110-9741-4-0044_LGWU702247-1037793WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935938_20120119_20120110-9741-4-0044_LGWU702247-1037793WU_12.RCC.gz"
"GSM1935939","LGWU702447-1037784WU","GSM1935939","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702447","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935939/suppl/GSM1935939_20120119_20120110-9741-4-0044_LGWU702447-1037784WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935939_20120119_20120110-9741-4-0044_LGWU702447-1037784WU_03.RCC.gz"
"GSM1935940","LGWU702506-1037785WU","GSM1935940","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702506","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935940/suppl/GSM1935940_20120119_20120110-9741-4-0044_LGWU702506-1037785WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935940_20120119_20120110-9741-4-0044_LGWU702506-1037785WU_04.RCC.gz"
"GSM1935941","LGWU702521-1037786WU","GSM1935941","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702521","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935941/suppl/GSM1935941_20120119_20120110-9741-4-0044_LGWU702521-1037786WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935941_20120119_20120110-9741-4-0044_LGWU702521-1037786WU_05.RCC.gz"
"GSM1935942","LGWU702536-1037787WU","GSM1935942","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702536","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935942/suppl/GSM1935942_20120119_20120110-9741-4-0044_LGWU702536-1037787WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935942_20120119_20120110-9741-4-0044_LGWU702536-1037787WU_06.RCC.gz"
"GSM1935943","LGWU702595-1037790WU","GSM1935943","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702595","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935943/suppl/GSM1935943_20120119_20120110-9741-4-0044_LGWU702595-1037790WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935943_20120119_20120110-9741-4-0044_LGWU702595-1037790WU_09.RCC.gz"
"GSM1935944","LGWU102732-1037795WU","GSM1935944","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102732","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935944/suppl/GSM1935944_20120120_20120112-9741-1-0023_LGWU102732-1037795WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935944_20120120_20120112-9741-1-0023_LGWU102732-1037795WU_02.RCC.gz"
"GSM1935945","LGWU102770-1037798WU","GSM1935945","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102770","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935945/suppl/GSM1935945_20120120_20120112-9741-1-0023_LGWU102770-1037798WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935945_20120120_20120112-9741-1-0023_LGWU102770-1037798WU_05.RCC.gz"
"GSM1935946","LGWU103899-1037801WU","GSM1935946","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 103899","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935946/suppl/GSM1935946_20120120_20120112-9741-1-0023_LGWU103899-1037801WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935946_20120120_20120112-9741-1-0023_LGWU103899-1037801WU_08.RCC.gz"
"GSM1935947","LGWU107387-1037802WU","GSM1935947","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107387","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935947/suppl/GSM1935947_20120120_20120112-9741-1-0023_LGWU107387-1037802WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935947_20120120_20120112-9741-1-0023_LGWU107387-1037802WU_09.RCC.gz"
"GSM1935948","LGWU202066-1037800WU","GSM1935948","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 202066","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935948/suppl/GSM1935948_20120120_20120112-9741-1-0023_LGWU202066-1037800WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935948_20120120_20120112-9741-1-0023_LGWU202066-1037800WU_07.RCC.gz"
"GSM1935949","LGWU702318-1037805WU","GSM1935949","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702318","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935949/suppl/GSM1935949_20120120_20120112-9741-1-0023_LGWU702318-1037805WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935949_20120120_20120112-9741-1-0023_LGWU702318-1037805WU_12.RCC.gz"
"GSM1935950","LGWU702745-1037804WU","GSM1935950","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702745","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935950/suppl/GSM1935950_20120120_20120112-9741-1-0023_LGWU702745-1037804WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935950_20120120_20120112-9741-1-0023_LGWU702745-1037804WU_11.RCC.gz"
"GSM1935951","LGWU703129-1037796WU","GSM1935951","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703129","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935951/suppl/GSM1935951_20120120_20120112-9741-1-0023_LGWU703129-1037796WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935951_20120120_20120112-9741-1-0023_LGWU703129-1037796WU_03.RCC.gz"
"GSM1935952","LGWU703134-1037797WU","GSM1935952","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703134","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935952/suppl/GSM1935952_20120120_20120112-9741-1-0023_LGWU703134-1037797WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935952_20120120_20120112-9741-1-0023_LGWU703134-1037797WU_04.RCC.gz"
"GSM1935953","LGWU703155-1037799WU","GSM1935953","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703155","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935953/suppl/GSM1935953_20120120_20120112-9741-1-0023_LGWU703155-1037799WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935953_20120120_20120112-9741-1-0023_LGWU703155-1037799WU_06.RCC.gz"
"GSM1935954","LGWU703205-1037803WU","GSM1935954","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703205","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935954/suppl/GSM1935954_20120120_20120112-9741-1-0023_LGWU703205-1037803WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935954_20120120_20120112-9741-1-0023_LGWU703205-1037803WU_10.RCC.gz"
"GSM1935955","LGWU101102-1037810WU","GSM1935955","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 101102","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935955/suppl/GSM1935955_20120120_20120112-9741-2-0044_LGWU101102-1037810WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935955_20120120_20120112-9741-2-0044_LGWU101102-1037810WU_05.RCC.gz"
"GSM1935956","LGWU102495-1037817WU","GSM1935956","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102495","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935956/suppl/GSM1935956_20120120_20120112-9741-2-0044_LGWU102495-1037817WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935956_20120120_20120112-9741-2-0044_LGWU102495-1037817WU_11.RCC.gz"
"GSM1935957","LGWU102532-1037816WU","GSM1935957","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102532","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935957/suppl/GSM1935957_20120120_20120112-9741-2-0044_LGWU102532-1037816WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935957_20120120_20120112-9741-2-0044_LGWU102532-1037816WU_10.RCC.gz"
"GSM1935958","LGWU102544-1037818WU","GSM1935958","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102544","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935958/suppl/GSM1935958_20120120_20120112-9741-2-0044_LGWU102544-1037818WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935958_20120120_20120112-9741-2-0044_LGWU102544-1037818WU_12.RCC.gz"
"GSM1935959","LGWU102587-1037815WU","GSM1935959","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102587","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935959/suppl/GSM1935959_20120120_20120112-9741-2-0044_LGWU102587-1037815WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935959_20120120_20120112-9741-2-0044_LGWU102587-1037815WU_09.RCC.gz"
"GSM1935960","LGWU702348-1037809WU","GSM1935960","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702348","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935960/suppl/GSM1935960_20120120_20120112-9741-2-0044_LGWU702348-1037809WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935960_20120120_20120112-9741-2-0044_LGWU702348-1037809WU_04.RCC.gz"
"GSM1935961","LGWU702366-1037813WU","GSM1935961","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702366","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935961/suppl/GSM1935961_20120120_20120112-9741-2-0044_LGWU702366-1037813WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935961_20120120_20120112-9741-2-0044_LGWU702366-1037813WU_07.RCC.gz"
"GSM1935962","LGWU702520-1037814WU","GSM1935962","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702520","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935962/suppl/GSM1935962_20120120_20120112-9741-2-0044_LGWU702520-1037814WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935962_20120120_20120112-9741-2-0044_LGWU702520-1037814WU_08.RCC.gz"
"GSM1935963","LGWU702746-1037806WU","GSM1935963","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702746","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935963/suppl/GSM1935963_20120120_20120112-9741-2-0044_LGWU702746-1037806WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935963_20120120_20120112-9741-2-0044_LGWU702746-1037806WU_01.RCC.gz"
"GSM1935964","LGWU702778-1037808WU","GSM1935964","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702778","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935964/suppl/GSM1935964_20120120_20120112-9741-2-0044_LGWU702778-1037808WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935964_20120120_20120112-9741-2-0044_LGWU702778-1037808WU_03.RCC.gz"
"GSM1935965","LGWU702823-1037811WU","GSM1935965","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702823","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935965/suppl/GSM1935965_20120120_20120112-9741-2-0044_LGWU702823-1037811WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935965_20120120_20120112-9741-2-0044_LGWU702823-1037811WU_06.RCC.gz"
"GSM1935966","LGWU703230-1037807WU","GSM1935966","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703230","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935966/suppl/GSM1935966_20120120_20120112-9741-2-0044_LGWU703230-1037807WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935966_20120120_20120112-9741-2-0044_LGWU703230-1037807WU_02.RCC.gz"
"GSM1935967","LGWU102541-1037833WU","GSM1935967","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102541","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935967/suppl/GSM1935967_20120120_20120112-9741-3-0023_LGWU102541-1037833WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935967_20120120_20120112-9741-3-0023_LGWU102541-1037833WU_12.RCC.gz"
"GSM1935968","LGWU102714-1037819WU","GSM1935968","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102714","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935968/suppl/GSM1935968_20120120_20120112-9741-3-0023_LGWU102714-1037819WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935968_20120120_20120112-9741-3-0023_LGWU102714-1037819WU_01.RCC.gz"
"GSM1935969","LGWU102716-1037822WU","GSM1935969","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102716","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935969/suppl/GSM1935969_20120120_20120112-9741-3-0023_LGWU102716-1037822WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935969_20120120_20120112-9741-3-0023_LGWU102716-1037822WU_02.RCC.gz"
"GSM1935970","LGWU102720-1037832WU","GSM1935970","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102720","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935970/suppl/GSM1935970_20120120_20120112-9741-3-0023_LGWU102720-1037832WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935970_20120120_20120112-9741-3-0023_LGWU102720-1037832WU_11.RCC.gz"
"GSM1935971","LGWU1054071-1037828WU","GSM1935971","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 105407","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935971/suppl/GSM1935971_20120120_20120112-9741-3-0023_LGWU1054071-1037828WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935971_20120120_20120112-9741-3-0023_LGWU1054071-1037828WU_08.RCC.gz"
"GSM1935972","LGWU107379-1037826WU","GSM1935972","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107379","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935972/suppl/GSM1935972_20120120_20120112-9741-3-0023_LGWU107379-1037826WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935972_20120120_20120112-9741-3-0023_LGWU107379-1037826WU_06.RCC.gz"
"GSM1935973","LGWU109199-1037830WU","GSM1935973","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109199","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935973/suppl/GSM1935973_20120120_20120112-9741-3-0023_LGWU109199-1037830WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935973_20120120_20120112-9741-3-0023_LGWU109199-1037830WU_10.RCC.gz"
"GSM1935974","LGWU109207-1037829WU","GSM1935974","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109207","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935974/suppl/GSM1935974_20120120_20120112-9741-3-0023_LGWU109207-1037829WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935974_20120120_20120112-9741-3-0023_LGWU109207-1037829WU_09.RCC.gz"
"GSM1935975","LGWU109296-1037827WU","GSM1935975","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109296","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935975/suppl/GSM1935975_20120120_20120112-9741-3-0023_LGWU109296-1037827WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935975_20120120_20120112-9741-3-0023_LGWU109296-1037827WU_07.RCC.gz"
"GSM1935976","LGWU200380-1037824WU","GSM1935976","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 200380","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935976/suppl/GSM1935976_20120120_20120112-9741-3-0023_LGWU200380-1037824WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935976_20120120_20120112-9741-3-0023_LGWU200380-1037824WU_04.RCC.gz"
"GSM1935977","LGWU201776-1037823WU","GSM1935977","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 201776","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935977/suppl/GSM1935977_20120120_20120112-9741-3-0023_LGWU201776-1037823WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935977_20120120_20120112-9741-3-0023_LGWU201776-1037823WU_03.RCC.gz"
"GSM1935978","LGWU700854-1037825WU","GSM1935978","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 700854","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935978/suppl/GSM1935978_20120120_20120112-9741-3-0023_LGWU700854-1037825WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935978_20120120_20120112-9741-3-0023_LGWU700854-1037825WU_05.RCC.gz"
"GSM1935979","LGWU102005-1037843WU","GSM1935979","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102005","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935979/suppl/GSM1935979_20120120_20120112-9741-4-0044_LGWU102005-1037843WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935979_20120120_20120112-9741-4-0044_LGWU102005-1037843WU_08.RCC.gz"
"GSM1935980","LGWU102548-1037846WU","GSM1935980","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102548","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935980/suppl/GSM1935980_20120120_20120112-9741-4-0044_LGWU102548-1037846WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935980_20120120_20120112-9741-4-0044_LGWU102548-1037846WU_10.RCC.gz"
"GSM1935981","LGWU102733-1037848WU","GSM1935981","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102733","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935981/suppl/GSM1935981_20120120_20120112-9741-4-0044_LGWU102733-1037848WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935981_20120120_20120112-9741-4-0044_LGWU102733-1037848WU_11.RCC.gz"
"GSM1935982","LGWU102747-1037849WU","GSM1935982","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102747","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935982/suppl/GSM1935982_20120120_20120112-9741-4-0044_LGWU102747-1037849WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935982_20120120_20120112-9741-4-0044_LGWU102747-1037849WU_12.RCC.gz"
"GSM1935983","LGWU102763-1037834WU","GSM1935983","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102763","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935983/suppl/GSM1935983_20120120_20120112-9741-4-0044_LGWU102763-1037834WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935983_20120120_20120112-9741-4-0044_LGWU102763-1037834WU_01.RCC.gz"
"GSM1935984","LGWU107309-1037845WU","GSM1935984","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107309","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935984/suppl/GSM1935984_20120120_20120112-9741-4-0044_LGWU107309-1037845WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935984_20120120_20120112-9741-4-0044_LGWU107309-1037845WU_09.RCC.gz"
"GSM1935985","LGWU107345-1037836WU","GSM1935985","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107345","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935985/suppl/GSM1935985_20120120_20120112-9741-4-0044_LGWU107345-1037836WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935985_20120120_20120112-9741-4-0044_LGWU107345-1037836WU_03.RCC.gz"
"GSM1935986","LGWU107359-1037835WU","GSM1935986","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107359","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935986/suppl/GSM1935986_20120120_20120112-9741-4-0044_LGWU107359-1037835WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935986_20120120_20120112-9741-4-0044_LGWU107359-1037835WU_02.RCC.gz"
"GSM1935987","LGWU108996-1037837WU","GSM1935987","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 108996","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935987/suppl/GSM1935987_20120120_20120112-9741-4-0044_LGWU108996-1037837WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935987_20120120_20120112-9741-4-0044_LGWU108996-1037837WU_04.RCC.gz"
"GSM1935988","LGWU109012-1037838WU","GSM1935988","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109012","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935988/suppl/GSM1935988_20120120_20120112-9741-4-0044_LGWU109012-1037838WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935988_20120120_20120112-9741-4-0044_LGWU109012-1037838WU_05.RCC.gz"
"GSM1935989","LGWU109063-1037839WU","GSM1935989","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109063","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935989/suppl/GSM1935989_20120120_20120112-9741-4-0044_LGWU109063-1037839WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935989_20120120_20120112-9741-4-0044_LGWU109063-1037839WU_06.RCC.gz"
"GSM1935990","LGWU109141-1037841WU","GSM1935990","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109141","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935990/suppl/GSM1935990_20120120_20120112-9741-4-0044_LGWU109141-1037841WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935990_20120120_20120112-9741-4-0044_LGWU109141-1037841WU_07.RCC.gz"
"GSM1935991","LGWU102635-1036514WU","GSM1935991","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102635","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935991/suppl/GSM1935991_20120124_20120123-9741-1-0023_LGWU102635-1036514WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935991_20120124_20120123-9741-1-0023_LGWU102635-1036514WU_08.RCC.gz"
"GSM1935992","LGWU102705-1037852WU","GSM1935992","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102705","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935992/suppl/GSM1935992_20120124_20120123-9741-1-0023_LGWU102705-1037852WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935992_20120124_20120123-9741-1-0023_LGWU102705-1037852WU_03.RCC.gz"
"GSM1935993","LGWU1054044-1037851WU","GSM1935993","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 105404","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935993/suppl/GSM1935993_20120124_20120123-9741-1-0023_LGWU1054044-1037851WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935993_20120124_20120123-9741-1-0023_LGWU1054044-1037851WU_02.RCC.gz"
"GSM1935994","LGWU107356-1036767WU","GSM1935994","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107356","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935994/suppl/GSM1935994_20120124_20120123-9741-1-0023_LGWU107356-1036767WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935994_20120124_20120123-9741-1-0023_LGWU107356-1036767WU_05.RCC.gz"
"GSM1935995","LGWU109360-1036763WU","GSM1935995","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109360","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935995/suppl/GSM1935995_20120124_20120123-9741-1-0023_LGWU109360-1036763WU_10.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935995_20120124_20120123-9741-1-0023_LGWU109360-1036763WU_10.RCC.gz"
"GSM1935996","LGWU109388-1036781WU","GSM1935996","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109388","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935996/suppl/GSM1935996_20120124_20120123-9741-1-0023_LGWU109388-1036781WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935996_20120124_20120123-9741-1-0023_LGWU109388-1036781WU_12.RCC.gz"
"GSM1935997","LGWU201001-1037020WU","GSM1935997","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 201001","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935997/suppl/GSM1935997_20120124_20120123-9741-1-0023_LGWU201001-1037020WU_09.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935997_20120124_20120123-9741-1-0023_LGWU201001-1037020WU_09.RCC.gz"
"GSM1935998","LGWU702326-1037853WU","GSM1935998","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702326","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935998/suppl/GSM1935998_20120124_20120123-9741-1-0023_LGWU702326-1037853WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935998_20120124_20120123-9741-1-0023_LGWU702326-1037853WU_04.RCC.gz"
"GSM1935999","LGWU703171-1037035WU","GSM1935999","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703171","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1935nnn/GSM1935999/suppl/GSM1935999_20120124_20120123-9741-1-0023_LGWU703171-1037035WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1935999_20120124_20120123-9741-1-0023_LGWU703171-1037035WU_06.RCC.gz"
"GSM1936000","LGWU703410-1036998WU","GSM1936000","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703410","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936000/suppl/GSM1936000_20120124_20120123-9741-1-0023_LGWU703410-1036998WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936000_20120124_20120123-9741-1-0023_LGWU703410-1036998WU_07.RCC.gz"
"GSM1936001","LGWU102001-1037062WU","GSM1936001","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102001","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936001/suppl/GSM1936001_20120124_20120123-9741-2-0044-rescan_LGWU102001-1037062WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936001_20120124_20120123-9741-2-0044-rescan_LGWU102001-1037062WU_02.RCC.gz"
"GSM1936002","LGWU103900-1036411WU","GSM1936002","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 103900","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936002/suppl/GSM1936002_20120124_20120123-9741-2-0044-rescan_LGWU103900-1036411WU_07.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936002_20120124_20120123-9741-2-0044-rescan_LGWU103900-1036411WU_07.RCC.gz"
"GSM1936003","LGWU107249-1037000WU","GSM1936003","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107249","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936003/suppl/GSM1936003_20120124_20120123-9741-2-0044-rescan_LGWU107249-1037000WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936003_20120124_20120123-9741-2-0044-rescan_LGWU107249-1037000WU_04.RCC.gz"
"GSM1936004","LGWU109327-1036486WU","GSM1936004","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 109327","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936004/suppl/GSM1936004_20120124_20120123-9741-2-0044-rescan_LGWU109327-1036486WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936004_20120124_20120123-9741-2-0044-rescan_LGWU109327-1036486WU_05.RCC.gz"
"GSM1936005","LGWU702362-1036865WU","GSM1936005","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702362","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936005/suppl/GSM1936005_20120124_20120123-9741-2-0044-rescan_LGWU702362-1036865WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936005_20120124_20120123-9741-2-0044-rescan_LGWU702362-1036865WU_03.RCC.gz"
"GSM1936006","LGWU702502-1036703WU","GSM1936006","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702502","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936006/suppl/GSM1936006_20120124_20120123-9741-2-0044-rescan_LGWU702502-1036703WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936006_20120124_20120123-9741-2-0044-rescan_LGWU702502-1036703WU_11.RCC.gz"
"GSM1936007","LGWU702727-1036455WU","GSM1936007","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702727","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936007/suppl/GSM1936007_20120124_20120123-9741-2-0044-rescan_LGWU702727-1036455WU_06.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936007_20120124_20120123-9741-2-0044-rescan_LGWU702727-1036455WU_06.RCC.gz"
"GSM1936008","LGWU702847-1036982WU","GSM1936008","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702847","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936008/suppl/GSM1936008_20120124_20120123-9741-2-0044-rescan_LGWU702847-1036982WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936008_20120124_20120123-9741-2-0044-rescan_LGWU702847-1036982WU_01.RCC.gz"
"GSM1936009","LGWU703285-1036435WU","GSM1936009","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 703285","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936009/suppl/GSM1936009_20120124_20120123-9741-2-0044-rescan_LGWU703285-1036435WU_08.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936009_20120124_20120123-9741-2-0044-rescan_LGWU703285-1036435WU_08.RCC.gz"
"GSM1936010","LGWU102578-1037720WU","GSM1936010","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 102578","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936010/suppl/GSM1936010_20120124_20120123-9741-3-0023_LGWU102578-1037720WU_12.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936010_20120124_20120123-9741-3-0023_LGWU102578-1037720WU_12.RCC.gz"
"GSM1936011","LGWU107256-1037207WU","GSM1936011","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107256","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936011/suppl/GSM1936011_20120124_20120123-9741-3-0023_LGWU107256-1037207WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936011_20120124_20120123-9741-3-0023_LGWU107256-1037207WU_04.RCC.gz"
"GSM1936012","LGWU107390-1037297WU","GSM1936012","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 107390","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936012/suppl/GSM1936012_20120124_20120123-9741-3-0023_LGWU107390-1037297WU_05.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936012_20120124_20120123-9741-3-0023_LGWU107390-1037297WU_05.RCC.gz"
"GSM1936013","LGWU702450-1037719WU","GSM1936013","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702450","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936013/suppl/GSM1936013_20120124_20120123-9741-3-0023_LGWU702450-1037719WU_11.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936013_20120124_20120123-9741-3-0023_LGWU702450-1037719WU_11.RCC.gz"
"GSM1936014","LGWU702487-1037721WU","GSM1936014","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702487","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936014/suppl/GSM1936014_20120125_20120124-9741-1-0023-halfcart_LGWU702487-1037721WU_01.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936014_20120125_20120124-9741-1-0023-halfcart_LGWU702487-1037721WU_01.RCC.gz"
"GSM1936015","LGWU702498-1037723WU","GSM1936015","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702498","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936015/suppl/GSM1936015_20120125_20120124-9741-1-0023-halfcart_LGWU702498-1037723WU_02.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936015_20120125_20120124-9741-1-0023-halfcart_LGWU702498-1037723WU_02.RCC.gz"
"GSM1936016","LGWU702508-1037726WU","GSM1936016","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702508","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936016/suppl/GSM1936016_20120125_20120124-9741-1-0023-halfcart_LGWU702508-1037726WU_03.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936016_20120125_20120124-9741-1-0023-halfcart_LGWU702508-1037726WU_03.RCC.gz"
"GSM1936017","LGWU702711-1037739WU","GSM1936017","Public on Nov 10 2015","Nov 09 2015","Nov 10 2015","RNA","1","Breast Tumor CALGB 702711","Homo sapiens","gender: female","tissue type: Breast Tumor","fixative: Formalin-Fixed Paraffin Embedded Tissue","CALGB","The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.","N/A","total RNA","http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf",NA,"See manufacturer's website http://www.nanostring.com for procedures","9606","See manufacturer's website http://www.nanostring.com for procedures.","See manufacturer's website http://www.nanostring.com for procedures.  Digital Analyzer was set to scan at 1155 FOV (fields of view)","See manufacturer's website http://www.nanostring.com.  Raw data was background subtracted and normalized to the geometric mean of the housekeepers.","GPL21114","Sherri,R,Davies","daviess@wustl.edu","3147473073","Washington University","4950 Parkview Place","Saint Louis","MO","63110","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1936nnn/GSM1936017/suppl/GSM1936017_20120125_20120124-9741-1-0023-halfcart_LGWU702711-1037739WU_04.RCC.gz","72","Formalin-Fixed Paraffin Embedded Tissue","female","Breast Tumor","GSM1936017_20120125_20120124-9741-1-0023-halfcart_LGWU702711-1037739WU_04.RCC.gz"
